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The role of dietary fat in the causation of fatty liver and its progression to non-
alcoholic steatohepatitis (NASH) is reviewed. A series of experiments to induce fatty 
liver were conducted in mice. The effects of high fat vs high carbohydrate, 
eicosapentaenoic acid (EPA) vs docosahexaenoic acid (DHA) and altered palmitic rich 
triacylglycerol structure were studied. Increasing the proportion of energy from fat, 
promoted adipose tissue fat accumulation and only slightly increased liver fat, but did 
not exacerbate hepatic damage compared to a high carbohydrate intake. Both types of 
hypercaloric diet resulted in the accumulation predominantly of palmitic and oleic acid 
in the liver. DHA decreased hepatic fat accumulation and tended to decrease liver 
damage but like EPA reduced hepatic cholesteryl oleate accumulation. Triacylglycerols 
with a high proportion of palmitic acid in the sn-2 position (lard and randomized palm 
olein) increased hepatic cholesteryl oleate compared with palm olein where the palmitic 
acid is mainly in the sn-1 and sn-3 position. Triacylglycerol from native palm olein vs 
randomized palm oil also resulted in greater accumulation of long-chain n-3 
polyunsaturated fatty acids in all lipid fractions. These finding indicate that 
triacylglycerol structure influences the fate of fatty acids in the liver. Proteins separated 
by 2-D differential-in gel-electrophoreis (DIGE) and identified by high resolution LC-
MS/MS showed significant differences in expression between hypercaloric vs eucaloric 
control groups: isoform 1 of epoxide hydrolase 2, catalase, ATP synthase subunit-alpha 
mitochondrial, ornithine carbamoyltransferase-mitochondrial (OTC), regucalcin and 
carbonic anhydrase 3. There were no differences in protein expression between high fat 
and high carbohydrate hypercaloric diets or between EPA and DHA. High 
carbohydrate/low fat hypercaloric diet down-regulated miR-199a-5p, miR-200b, miR-
324-3p, miR-21*, miR-31* and miR-451 by -66%, -76%, -37%, -33%, -57% and -9%, 
respectively compared to controls. Overfeeding with high fat hypercaloric diet down-
regulated miR-199a-5p, miR-200b, miR-324-3p, miR-21*, miR-31*, miR-345-3p and 
miR-466f by -86%, -86%, -51%, -76%, -76%, -72% and -62%, respectively compared 
to control. The expressions of miR-21* and miR-466f were lower following the high fat 
compared to the high carbohydrate/low fat diet. Perturbations in protein profiles may 
reflect the changes in liver profiles seen with dietary intervention. The findings reported 
in this thesis indicate that excessive calories intake is more important in generating fatty 
liver than whether the energy is derived from fat or carbohydrate. The findings are 
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 Non-alcoholic steatohepatitis (NASH) has emerged as a major cause of liver 
failure and liver cancer and is linked to the increased prevalence of obesity and insulin 
resistance (Marchesini et al, 1999; Farrell & Larter 2006; Qureshi & Abrams 2007; 
Cong et al, 2008; Pascale et al, 2010; Leavens & Birnbaum 2011; Wree et al, 2011). 
According to the European Association for the Study of Liver Disease (EASL), there is 
a need for non-invasive diagnosis of NASH in order to reduce the risk of developing 
fibrosis in patients (Ratziu et al, 2010). One of the aims of this research presented in the 
thesis was to identify novel biomarkers for NASH. However, few studies have 
examined the effect of varying fat composition on NASH. This thesis therefore 
investigates the hypothesis that the type and level of fat consumed influences the 
development of NASH. It is first, however, necessary to describe the relationship 
between non-alcoholic fatty liver disease (NAFLD), NASH and the related pathologies. 
 
1.1 Spectrum of NAFLD in relation to NASH 
NAFLD refers to the accumulation of fats in the liver exceeding 5% to 10% by 
weight (Neuschwander-Tetri & Caldwell 2003). NASH is the term used to describe the 
accumulation of fats in the liver and this is commonly associated with signs of 
inflammation (Neuschwander-Tetri & Caldwell 2003, Harmon et al, 2011). Most of the 
fat is present as triacylglycerols (TAG) within hepatocytes. Although fatty liver may be 
a benign state it can under some circumstances progress to NASH and then cirrhosis 
which is characterised by inflammation, oxidative stress and scarring (Angulo 2002). 
The multiple factors that lead to this progression are uncertain, but involve the 
production of pro-inflammatory cytokines, activation of stellate cells, dysregulation of 
lipolysis and lipogenesis (Postic & Girard 2008) and oxidative changes possibly 
influenced by the type of fat (Larter & Farrell 2006; Stanton et al, 2011). 
 
1.1.1 Definition of NASH 
In 1980, the term NASH was first coined to describe the biopsy results of obese 
patients with fatty liver in the absence of a history of alcohol misuse, which in some 
cases led to cirrhosis (Ludwig et al, 1980). NASH appears to be commonly associated 
with obesity, hyperlipidemia, and insulin resistance, which include diabetes and 
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metabolic syndrome (Marchesini et al, 2001; Neuschwander-Tetri and Caldwell 2003; 
Abdelmalek & Diehl 2007).  
Steatosis increases the vulnerability of the liver to NASH involving 
environmental and genetic factors that ultimately leads to end-stage liver cirrhosis 
(Leite et al, 2009). In summary, NASH is defined as a type of cryptogenic liver disease 
accompanied by the accumulation of triacylglycerols (TAGs) with signs of hepatic 
inflammation excluding the influence of viral hepatitis, autoimmune, toxicities and 
alcohol consumption of more than 20 g/day for men and  more than 10 g/day for women 
(Moore 2010).  
In 1998, the 2-hit hypothesis to explain the progression of non-alcoholic fatty 
liver disease was proposed by Day and James (Figure 1.1). This hypothesis stated that 
insulin resistance and hepatic fatty acid oxidation causes NAFLD and the progression 
from steatosis in the presence of inflammation leads to fibrogenesis (Day & James 
1998). However, the complexity of defining NASH was reviewed by Charlton (2007) 
and proposed NAFLD is likely to be more complex than the 2-hit phenomenon and 
therefore suggested at least a 3-hit phenomenon.  
Undoubtedly, the mechanisms underlying NASH are awaiting clarification due 








Figures 1. 1: The progressive development of NASH  
Normal liver function 
a) Normal digestion and absorption of dietary lipids 
 Cellular uptake of long chain fatty acids (LCFA) 
 Fat digestion and absorption 
 Re-esterification of TAG and packaged into lipoprotein  
particles (chylomicrons) 
 Hepatic assembly, export, and disposition of very low  
density lipoproteins (VLDL) 
 VLDL transports esterified TAG within the liver to  
muscle and adipose tissue 
 Regulation of β-oxidation of fatty acids in the liver 




Steatosis (Bradbury & Berk 2004) 
a) Increase accumulation of TAG by: 
 Increase synthesis of LCFA and TAG 
 Increase uptake of TAG from adipose tissue 
b) Decrease secretion of TAG from liver 
 Decrease synthesis of Apolipoprotein B-100 
 Decrease VLDL import and export 
c) Metabolism of LCFA in liver 




Non-alcoholic steatohepatitis (NASH) 
 Increased oxidative stress and lipid peroxidation 
 Increased expression of pro-inflammatory cytokine  
release; TNFα,β 
 Increase in lipopolysaccharide 
 Stellate cell activation 
 Microscopically, hepatocellular steatosis,  
ballooning degeneration, Mallory bodies, inflammation  
and fibrosis 
 
Source: Day & James (1998) and Bradbury & Berk (2004) 
 
 
1.2 The prevalence of NASH as a new epidemic of NAFLD 
In the United States, 30 % of the adult population suffers from liver steatosis 
which is defined when TAG content is more than 5.5% normal TAG content (Angulo 
2007). The prevalence is estimated to be one third of NAFLD cases which parallels the 
frequency of obesity (Caldwell et al, 2004; Gholam et al, 2007; Moore 2010), insulin 
1
st
 stage of NAFLD 
2
nd
 stage of NAFLD 
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resistance (Seppala-Lindroos et al, 2002) and metabolic syndrome (Marchesini & 
Marzocchi 2007; Moore 2010).  
Similarly in animal models, mainly rodents, experimental studies showed an 
association of obesity, insulin resistance and metabolic syndrome with hepatic steatosis 
(Coleman 1982; den Boer et al, 2004; Nanji 2004; Larter & Yeh 2008; Gaemers et al, 
2011). In humans, steatohepatitis and the development of fibrosis predispose to cirrhosis 
and have a survival of 7 to 10 years (Farrell and Larter 2006).  
 
1.2.1 Prevalence of NASH in different age groups 
In 2004, the International Obesity Task Force (IOTF) reported there was a 
prevalence of 22 million overweight children followed by 20 million overweight 
children younger than 5 years of age in the European Union.  A National Health and 
Nutrition Examination Survey (NHANES) study from 1999 to 2004 associated the 
elevated levels of circulating alanine aminotransferase (ALT) with increased waist 
circumference and insulin resistance in adolescents aged 12 to 19 years (Fernandez et al, 
2004). The elevated ALT levels increased according to age (Fraser et al, 2007). 
However, there are still complications in standardizing the measurements of children 
between age 5 and 14 years due to rapid growth in height and weight.  Therefore, 
clinical trials are required to develop different cut-off points for ALT levels as a 
benchmark for assessing children before diagnosing for NASH.  
As for adults, the prevalence of NAFLD in the UK was mainly found in the 
middle-aged (≥ 50 to < 60) and the elderly (≥ 60) (Frith et al, 2009). Although ALT 
levels have been used as a biomarker to identify patients with hepatocyte damage for the 
past 55 years (Karmen et al, 1955), it has been reported that normal ALT levels do not 
indicate the absence of NAFLD (Mofrad et al, 2003). Therefore further work needs to 
be carried out to identify biomarkers for NAFLD more accurately.   
Aging-related studies in animals showed increased prevalence of liver diseases 
in old mice aged 24-36 months (Ito et al 2007; Gregg et al, 2012). Old age in mice 
showed increased hepatic sinusoid which led to impairment in clearance of chylomicron 
remnant and disruption of microcirculation (Warren et al, 2005; Le Couteur et al, 2008). 
The thickening of the endothelium and increased hepatic sinusoid also known as 
pseudocapillatication is common in aged liver (Le Couteur et al, 2008) and may have 




1.2.2 Prevalence of NASH by gender  
The prevalence of NAFLD in female adults is commonly found to be higher 
than in males due to different metabolic behaviour such as higher visceral fat, TAG and 
LDL-cholesterol levels in women (Fernandes et al, 2010; Fracanzani et al, 2011).  
Animal studies on gene expression related to lipid metabolism in response to 
high fat diets have highlighted important gender differences after 6 months of high-fat 
feeding. Male rats had higher hepatic peroxisome proliferator-activated receptor–alpha 
(PPAR-α) and carnitine palmitoyltransferase-1 (CPT-1) expression compared to female 
rats indicating higher lipid oxidation and higher hepatic TAG (Priego et al, 2008). In 
contrast, female rats gained more weight with higher adiposity index and increased gene 
expression related to energy influx in adipose tissue (Rodriguez et al, 2004). Therefore 
female rats have a higher capacity for fat storage in adipose tissue and fat oxidation in 
muscles whereas males have a higher risk of hepatic fat accumulation.    
 
1.2.3 Prevalence of NASH by race and ethnicity 
Different racial and ethnic group studies show different susceptibility towards 
visceral adiposity, hepatic fat accumulation and insulin resistance. The prevalence of 
NASH is dependent on ethnicity whereby the frequency of NASH is highest in 
Hispanics, followed by whites and blacks (Browning et al 2004). In the Asia-Pacific 
region, NASH is highest in the Indian population compared with the Chinese and 
Malays (Chitturi et al, 2007; Amarapurkar et al, 2007). Chow et al (2007) showed that 
73% Singaporeans Chinese non-diabetic patients with histological proven NASH went 
on to develop fibrosis. 
These ethnic and racial variations may reflect differences in environmental and 
genetic susceptibility towards visceral adiposity, hepatic fat accumulation and fatty 
acids regulation (Weston et al, 2005). Therefore the differentiation between steatosis 
and NASH should take into account the ethnic and racial background towards NAFLD, 




1.3 Metabolic pathways leading to lipid accumulation 
Although the exact biochemical pathway of NASH is still unclear, there is 
strong evidence showing that the infiltration and accumulation of TAG increases the 
risk of lipid peroxidation in the liver leading to inflammation. The potential pathways of 
dietary fat contributing to NASH include the following: 
i) High fat dietary intake to the liver through chylomicrons. 
ii) Suppression of mitochondrial beta-oxidation in the liver. 
iii) High influx of non-esterified fatty acids (NEFA) from adipose tissue to 
the liver (also known as lipolysis). 
iv) Fatty acids made within the liver through de novo lipogenesis. 
v) Low secretion rate of very low-density lipoprotein (VLDL) from the 
liver.   
 
Figures 1. 2: Flow chart of the fatty acid regulatory system  
 
Adapted from various sources including Hussain et al, (2000) and Dallinga-Thie et al, 
(2010) 
 
Plasma lipids are transported in 2 forms namely NEFA and TAG (Figure 1.2). 
NEFA is derived from adipocytes and transported with plasma albumin whereas TAG 
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and cholesteryl esters are transported in the core of plasma lipoproteins. Dietary fat is 
secreted and transported by chylomicrons to the liver for storage. Dietary cholesterol is 
transported to the liver by chylomicron remnants. TAG is then released from the liver in 
the form of VLDL for utilisation or storage in extrahepatic tissues. In the conversion of 
VLDL to LDL, these lipoproteins are packed with cholesteryl esters (Spector 1984). 
The occurrence of NASH due to the accumulation of fats in the liver may be affected by 
the types and composition of fatty acids ingested.  
 
1.3.1 Delivery of dietary fat to the liver through chylomicrons 
 Chylomicrons are fat transporters (mainly TAGs) from the intestine to the liver 
and adipose tissue (Hussain et al, 2000). Ingested fats travel down the oesophagus to the 
duodenum, stimulating secretion of cholecystokinin (CCK) causing the gall bladder to 
contract and release bile into the duodenum (Glatzle et al, 2003). The bile emulsifies 
and breaks down fats allowing fats to be absorbed by the enterocytes, epithelial cells of 
intestine. Fats and cholesterols are then packaged into chylomicrons in the enterocytes. 
A chylomicron is a single monolayer of phospholipids and cholesterol that contains 
mainly TAGs with an integral protein apolipoprotein B-48 which is important for 
chylomicron synthesis. The absence or defect in apolipoprotein B-48 will cause 
disruption in formation of chylomicrons and fats will either accumulate in the intestine 
or be secreted in faeces (Lo et al, 2008). Chylomicrons are then released from the 
basolateral site of enterocytes to lacteals and travel to the lymphatic system and end up 
in the thoracic duct, then the circulatory system to the blood stream, obtaining 2 new 
integral proteins (apolipoprotein C and E). From the blood vessels, chylomicron travels 
to either the liver or adipose tissue.   
In the liver, hepatocytes have LDL receptors which bind to apolipoprotein E. 
When bound to the LDL receptors, TAG in the chylomicrons will be taken up by the 
liver. In the adipose tissue, adipocytes express enzyme lipoprotein lipases (LPL) which 
bind to apolipoprotein C. When bound to LPL, TAG will be cleaved to glycerol and 
individual fatty acids and absorbed by the adipocytes therefore decreasing the levels of 
TAG in chylomicrons. When TAGs within the chylomicron are reduced to 20%, 
apolipoprotein C will be detached forming chylomicron remnants (Cooper et al, 1997). 
Chylomicron remnants (CR) then travel to the liver and binds to the CR receptors to 
absorb the remaining TAG. The hepatic uptake of TAG from the CR is dependent on 
the type of dietary fats as shown in a study by Lambert et al, (2000). Saturated 
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chylomicrons are metabolized slower compared with polyunsaturated ones (Green et al, 
1984).  
 
1.3.2 Suppression of beta-oxidation in the liver 
The process of beta-oxidation occurs in the mitochondria or peroxisomes (van 
Roermund et al, 1998) and serves to break down fatty acids in the form of acyl-CoA to 
generate acetyl-CoA which then enters the Kreb cycle to generate ATP as an energy 
source. The rate of oxidation decreases with increasing fatty acid chain length (Leyton 
et al., 1987). Long chain fatty acids (LCFA) are actively transported from the cytoplasm 
into mitochondria by carnitine palmitoyl transferase -1 (CPT-1) for beta-oxidation to 
take place. In the mitochondria, LCFA are broken down in 4 steps; dehydration, 
hydration, oxidation and thiolysis. The result of one cycle is formation of one acetyl-
CoA and the release of 2 carbons from the end of the fatty acid chain. This cycle 
continues to shorten the fatty acid through oxidation until the entire chain of fatty acid is 
converted to acetyl CoA. The fate of acetyl-CoA transported to the Krebs cycle (citric 
acid cycle) is oxidation to CO2 and H2O which increases the formation of FADH2 and 
NADH + H
+
 (energy carriers). These carriers transfer energy, and oxidation takes place 
in the mitochondrial electron transport system to generate ATP. Besides that, acetyl-
CoA can also be transported to the liver for the production of ketone bodies. High fat 
diets can increase total peroxisomal beta-oxidation by 1.4 to 2.4 fold in rat liver (Neat et 
al, 1980).  
Suppression of mitochondrial beta-oxidation regulated by CPT-1 is associated 
with hepatic fat accumulation (Serviddio et al, 2011). The effects of mitochondrial beta-
oxidation are commonly studied in methionine choline deficient (MCD) mice. These 
mouse models show higher rates of oxidative phosphorylation and low efficiency of 
cytochrome oxidase activity. In rats, provision of MCD deficient diets result in 
decreased mitochondrial ATP synthesis that may cause steatosis and oxidative stress 
reflecting the features of NASH (Romestaing et al, 2008). Mitochondrial dysfunction 
was also associated with the over production of reactive oxygen species in hepatocytes 
causing NASH (Sato 2007).  
Mutations in mitochondrial DNA are found to cause fat accumulation and 
cellular stress in myocytes due to the activation of Jun N-terminal kinase (Lu & Archer 
2007). In the hepatocytes, the disrupted flow of electrons causes the increase formation 
of ROS and peroxynitrite generated by ROS during lipid peroxidation. Therefore, liver 
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lesions caused by mitochondrial oxidative stress due to lipid peroxidation products may 
also result in NASH.  
 
1.3.3 High influx of NEFA to the liver 
 The main source of NEFA in the liver is from the adipose tissue. Hydrolysis of 
TAG produces glycerol and NEFA. NEFA release from adipocytes is regulated by 
hormone sensitive lipase (HSL) activated by glucagon and epinephrine but inhibited by 
insulin (Emanuele et al, 2004). The muscle and liver are the major target tissues of 
NEFA bound to albumin (Larter et al, 2008). In the liver, NEFA is passively absorbed 
by hepatocytes bound to fatty acid binding protein followed by the activation process of 
NEFA converting into CoA derivatives for energy production in the mitochondria with 
CPT as the carrier (Nosadini et al, 1984).  
A metabolic labelling study using hyperlipidemic mice showed that the 
increased TAG synthesis rate contributing to excessive TAG stores in the liver was due 
to esterification of fatty acids (Donnelly et al, 2004). Furthermore, the quantification of 
hepatic TAG in NAFLD patients who were obese with fasting hypertriglyceridemia and 
hyperinsulinemia demonstrated that 59% of TAG was derived from NEFA, 26% from 
de novo lipogenesis and 15% from the diet (Donnelly et al, 2005). These quantitative 
metabolic labelling studies affirmed that the accumulation of hepatic TAG is mainly 
contributed by NEFA. The influx of NEFA to the liver leads to TAG synthesis in the 
liver.  
C57BL/6J mice have an average TAG content determined by genetic factors 
influencing the hepatic fatty acid synthesis rates and TAG secretion compared to other 
strains such as BALB/c and SWR/J mice (Lin et al, 2005). Additionally, BALB/c mice 
presented the highest increase in fasting plasma NEFA and hepatic TAG concentrations 
followed by C57BL/6J and least in SWR/J mice. Findings from the aforementioned 
study concluded that the accumulation of hepatic TAG is strain-dependent (Lin et al, 
2005). 
The rates of oxidation of fatty acids are dependent on chain length and degree of 
unsaturation. Short and medium chain saturated fatty acids are oxidised rapidly. Of the 
major fatty acids, oleic acid is oxidised more rapidly than palmitic acid. Rates of TAG 
secretion by the liver can be according to type of fatty acid (Kohout et al, 1971). Kohout 
et al, (1971) concluded that maximal rates of TAG secretion will only occur when the 
metabolic pool for NEFA reaches an appropriate concentration with oleic acid being the 
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most suitable substrate for TAG secretion followed by palmitic and linoleic acid. These 
findings are consistent with more recent in vitro, studies with HepG2 cells showing that 
oleic acid is a potent stimulator of VLDL secretion. 
 In humans, TAG is secreted as VLDL containing apolipoprotein B-100 rather 
than apolipoprotein B-48 in rodents (Brown et al, 1997). Despite the differences, the 
fractional rates of TAG turnover are similar in both mice and rats. However, humans 
may retain a larger proportion of TAG within the cell compared to rodents which have a 
higher rate of VLDL-TAG secretion (Salter et al, 1998). Long-chain n-3 
polyunsaturated fatty acids decrease TAG synthesis from the liver and decreases 
VLDL-TAG secretion from the liver but it is uncertain whether these fatty acids reduce 
fat accumulation in the liver in overfeeding models. 
   
1.3.4 Low VLDL-TAG secretion rate 
VLDL is produced by the liver to transport fats from the liver to adipose and 
other tissues. VLDL carries TAG and CE with apolipoprotein B-100 (in man) or 
apolipoprotein B-48 in rodents as the integral protein (Chen et al, 2008). Similar to the 
chylomicrons, VLDL travels into the blood vessels and obtains 2 new peripheral 
proteins (apolipoprotein C and E) from HDL. Apolipoprotein C then binds to the 
lipoprotein lipase (LPL) and cleaves TAG into glycerol and free fatty acids. When the 
TAG levels in VLDL decrease to 50%, apolipoprotein C unbinds and travels back to the 
liver (Qin et al, 2011). The increased production of TAG and decreased secretion of 
TAG exported as VLDL could be related to the mechanisms involved in TAG 
accumulation which influences NAFLD (Goldberg & Ginsberg 2006).   
Obese NAFLD subjects showed higher VLDL-TAG secretion but no difference 
in VLDL-apolipoprotein B-100 secretion rates when compared to subjects with normal 
hepatic TAG content (Fabbrini et al, 2008); ie they secreted VLDL particles that were 
enriched in TAG. The increase in VLDL-TAG is caused by the high influx of NEFA 
derived from lipolysis but the increased VLDL-TAG secretion is insufficient to 
normalize hepatic TAG content in NAFLD (Fabbrini et al, 2008). The increased rates of 
lipolysis and hepatic VLDL-TAG secretion may contribute to hypertriglyceridemia and 
may exacerbate insulin resistance which in turn would promote NAFLD (Seppala-
Lindroos et al, 2002).  
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The alterations in VLDL-TAG metabolism in adipose tissue and liver in 
NAFLD remains controversial due to other factors influencing hepatic lipoprotein 
metabolism such as gender and adiposity (Mittendorfer et al, 2003).   
 
1.4 The effects of different types of fats in the liver 
The different type of fatty acids in the liver may be a more important factor 
affecting the pathogenesis and progression of non-alcoholic fatty liver disease 
(NAFLD) compared to the quantity of fat (Barboriak et al, 1957). Dietary fats were 
reported to inhibit the release of fatty acid synthesised de novo from the liver to the 
plasma which led to the accumulation of fatty acids in the liver. In contrast, a fat-free 
diet showed significant increase in SFA and MUFA but not PUFA in both the liver and 
plasma (Nelson et al, 1987).  
Alterations in hepatic fatty acid composition and content may be important in 
the pathogenesis of NASH.  For example: obese mice have significantly higher linoleic 
acid (18:2n-6) in liver phospholipids (PL), cholesterol esters (CE) and triacylglycerols 
(TAG) (Emanuele et al, 2004) compared to the controls. Phosphatidylcholine is the 
most common PL in the diet and is absorbed by the intestine, which then appears in 
plasma lipoproteins and blood (Noga & Vance 2003; Wu & Cohen 2005). EPA and 
DHA may replace arachidonic acid (AA) in membrane phospholipids in liver and these 
changes are accompanied by alterations in cytochrome P450 enzymes (Arnold et al, 
2010). Other PL such phosphatidylethanolamine, phosphatidylserine and 
phosphatidylinositol are ingested in small amounts (Koba et al, 1994; Jacobs et al, 
2010). Dihomo-gamma-linolenic acid (DGLA; 20:3n-6) increases in PL with weight 
gain (P<0.001). However, PL arachidonic acid (AA; 20:4n-6) does not show significant 
differences with obesity status (Phinney et al, 1994). Cholesterol esters are less polar 
compared with free-cholesterol and contains high proportion of PUFA mainly of 
phosphatidylcholine.  
 
1.4.1 Effects of high fat hypercaloric feeding in the liver 
The recommendations by World Health Organization (2003) consists of 15 - 
30% of total fat whereby <10% is derived from saturated fats, 5 - 8 % from n-6 
polyunsaturated fats (PUFA) and 1 – 2% from n-3 PUFA. Animal studies have 
generally used nutritional models based on high-fat diets providing 40% to 70% energy 
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from fat to induce obesity, hyperglycemia, insulin resistance and progression of NASH 
that may lead to fibrosis (Nishikawa et al, 2007; Satyanarayana et al, 2011; Yimin et al, 
2011). 
 One well-established high-fat diet protocol designed for animal studies is the 
Lieber-DeCarli feeding regimen whereby the controls are fed 35% fat, 47% 
carbohydrate, 18% protein. However, in this liquid diet model it is to be noted that most 
of the energy is derived from carbohydrate. The regimen is an overfeeding model rather 
than a high fat diet. In an experiment, when rats were fed ad libitum with 71% energy 
fat, 11% energy carbohydrate and 18% energy protein for 3 weeks there was a 2-fold 
increase in panlobular steatosis when compared to controls fed the standard diet (Lieber 
et al, 2004). Furthermore, the rats developed abnormal mitochondria with degenerating 
cristae, mononuclear inflammation with increased hepatic TNF-α and Cyp2e1 mRNA, 
significant hepatic oxidant damage indicated by increased levels of 4-hydroxynonenal 
and increased hepatic concentrations of collagen type 1 and 1α procollagen mRNA 
(Lieber et al, 2004). As expected in controls there were less steatosis, inflammation, 
oxidative stress and lower plasma insulin concentrations. However, this high fat diet did 
not increase body weight or alter ALT activities in the serum (Lieber et al, 2004). 
 Intragastric overfeeding of mice with 85% fat for 9 weeks, increased body 
weight by 71% caused by the accumulation of visceral fat and led to hyperglycemia, 
hyperinsulinemia, hyperleptinemia, glucose intolerance and insulin resistance (Deng et 
al, 2005).  Forty-six percent of these mice developed NASH with increased plasma ALT 
by 5-6 fold and neutrophil infiltration in liver. Similarly, in human NASH, there is 
sinusoidal and pericellular fibrosis. The excess build-up of white adipose tissue 
developed higher TNF-α and leptin, reduced adiponectin mRNA expression, increased 
expression of lipogenic transcription factors (SREBP-1c, PPARγ and LXRα) and 
reduced the expression of lipolytic nuclear transcription factor, PPARα (Deng et al, 
2005).  
A study by Li et al (2005) administered a high fat diet (59% energy) to C57BL-6 
mice for 13 weeks. This aforementioned study resulted in decreased hepatic natural 
killer T (NKT) cells with sensitization of the liver to low-dose lipopolysaccharides 
(LPS) (Li et al, 2005). This study showed decreased hepatic natural killer T (NKT) cells 
with sensitization of the liver to low-dose lipopolysaccharides (LPS) (Li et al, 2005). 
The decreased levels of NKT cells decreased the expression of anti-inflammatory 
cytokines (Th-2) and increased expression of pro-inflammatory cytokines (Th-1) in the 
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liver of mice fed the 59% fat diet. ALT activities were also elevated following 
stimulation by LPS. However, levels of inflammation or fibrosis after high-fat feeding 
were not reported (Li et al, 2005). 
Similarly, based on a ‘two hit’ approach by Ito et al (2006), C57BL-6 mice fed 
with a 60 % fat with tetracycline diet resulted in increased serum ALT activities with 
development of hepatic inflammation. In addition, a 60 % by weight lard diet was used 
to trigger the 2
nd
 hit and cause steatohepatitis in fa/fa rats. Consequently, these rats 
developed oxidative stress induced NASH due to increase NADPH oxidase activity, 
lipid peroxidation and protein carbonyl formation followed by a significant reduction in 
serum adiponectin caused by the reduced activation of PPARα-mediated liver fatty acid 
pathway (Carmiel-Haggai et al, 2005). The test diet, however, was nutritionally 
imbalanced.  
 
1.4.2 Effects of polyunsaturated fatty acids (PUFA) on lipid metabolism 
There are two families of polyunsaturated fatty acids derived from linoleic and 
α-linolenic acid that give rise to the n-6 and n-3 series respectively by alternating 
desaturation and chain elongation. Linoleic acid is an essential nutrient with a wide 
variety of functions and many of its effects are mediated via arachidonic acid. The 
essentiality of α-linolenic acid hinges on its conversion to docosahexaenoic acid, which 
has an important physiological role in the retina and the brain. These polyunsaturated 
fatty acids have effects on cell signalling and gene expression which includes 
inflammatory signalling and lipid metabolism. The long-chain derivatives of α-linolenic 
acid, eicosapentaenoic acid and docosahexaenoic acid which are found in marine lipids 
have been shown to possess a variety of physiological effects that are different from 
their parent fatty acids. In particular, they have anti-inflammatory effects and stimulate 
fatty acid oxidation and decrease triglyceride synthesis in the liver.  
In n-6 PUFA family, arachidonic acid (AA) is the predominant long chain 
metabolite and it regulates cellular functions through conversion to prostaglandins, 
lipooxygenase and cyclooxygenase products (Schmitz & Ecker 2008). AA can be 
replaced by EPA but its eicosanoid metabolites are generally inactive. Linoleic acid, 
itself has a role in cholesteryl ester transport and is the preferred substrate for lecithin 
cholesteryl acyl transferase. Mice supplemented with n-6 PUFA also show increased 
expression of leptin gene transcripts in epididymal fats but do not change in mice fed n-
3 PUFA.  
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Studies have reported that hepatic transcription genes related to fat metabolism 
are directly correlated to the different types of dietary fats delivered to the liver 
(Radonjic et al, 2009; Yang et al, 2010; Do et al, 2011). EPA and DHA are ligands for 
PPAR-α, which is transcription factor regulating fat oxidation and hepatic TAG 
synthesis. 
There are reports that n-3 PUFA may have a favourable effect in animals with 
NASH. Therefore, supplementing diets with n-3 PUFA such as EPA and DHA, may 
prevent or reverse NASH either by (i) inhibition of lipogenesis due to a decrease in 
mature sterol–regulatory element-binding proteins (SREBPs) or (ii) stimulation of fatty 
acid oxidation via peroxisome proliferator-activator receptor (PPAR) alpha (Hirako et 
al, 2010).   
In a 12-month study, Tanaka et al, (2008) reported that NASH patients 
supplemented with 2700 mg/d of purified EPA resulted in enhanced ALT activities, and 
increased serum free fatty acids and plasma soluble tumour necrosis factor (TNF) 
receptor 1 and 2 levels. Although there was no change in either body weight, insulin and 
adiponectin concentrations, there was a significant decrease in oxidative stress in the 
liver. The liver biopsy showed a decrease in hepatic fibrosis, hepatocyte ballooning and 
lobular inflammation. Other studies have reported inhibition of linolenic acid 
conversion pathways (desaturation and elongation) in response to increasing dietary 
EPA and DHA intake (Emken et al., 1999; Vermunt et al., 2000). Conversion of EPA to 
DHA involves ∆5 and ∆6-desaturation chain elongation, desaturation and limited 
peroxisomal beta-oxidation (Sprecher 2000). 
However, the effects of EPA and DHA as individual fatty acids remains unclear 
and further supplementation studies are required to investigate the optimal amount of n-
3 PUFA necessary for inducing positive biological effects.  
 
1.4.3 Effects of EPA in the liver 
EPA was shown to reduce fatty droplets in hepatic cells, decrease liver weights, 
lower plasma levels of total cholesterol, free total cholesterol, phospholipids and 
triacylglycerols (Nemoto et al, 2009). EPA may have a greater serum TAG reducing 
agent compare to DHA (Gotoh et al, 2009) but the evidence is not consistent and the 
totality of evidence indicates that both EPA and DHA are equipotent. A 1000 mg 
dosage of eicosapentaenoic acid (EPA) per day per kg body weight was shown to 
decrease serum TAG by 45% after 10 days while there was no significant differences in 
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serum cholesterol when compared to mice fed palmitic acid and controls (Demoz et al, 
1992). EPA was also found to reduce levels of hepatic lipid peroxides while no change 
was observed in palmitic acid fed mice in comparison to the controls (Demoz et al, 
1992). Therefore, it was suggested that EPA may be able to prevent non-alcoholic 
steatohepatitis.  
Mice fed a high fat diet for 6 weeks followed by an EPA diet for 5 weeks 
showed reduced insulin resistance, reduced adipose inflammation, lipogenesis and 
markers of fatty acid oxidation (Kalupahana et al, 2010). In addition, 16 weeks of 
feeding saturated fats followed by supplementation with 98% of purified EPA for 12 
weeks in PPAR-null mice was shown to result in amelioration of steatosis through 
inhibition of sterol-responsive element-binding protein-1 (SREBP-1) in the absence of 
PPAR-alpha. Furthermore, fatty acid uptake was suppressed and hydrolysis of 
intrahepatic TAG was enhanced in the presence of EPA, independent of PPAR-alpha. 
Therefore, the aforementioned effects of EPA in the absence of PPAR-alpha activation 
demonstrates the potent function of EPA in decreasing lipid peroxides and ameliorating 
steatosis by reducing hepatic oxidative stress (Tanaka et al, 2010).  
A followed-up study by Sugiyama et al, (2008) showed the increased 
composition of hepatic TAG and monounsaturated fatty acids (MUFA) in mice a fed 
high fat and high sucrose diet (HFHSD) for 2 weeks was altered when EPA was 
administered to mice. In the presence of EPA, hepatic TAG content was significantly 
suppressed and MUFA composition of palmitoleic acid (C16:1) and oleic acid (C18:1) 
was lowered. Besides that, n-3 PUFA such as EPA and DHA were increased in liver 
(Kajikawa et al, 2009). 
Although EPA is used clinically used to treat hypertriglyceridemia, there is a 
lack of evidence to demonstrate that it has beneficial effect in patients with NASH. 
 
1.4.4 Effects of DHA in the liver 
In the liver, DHA may exert its anti-inflammatory effects by inhibiting cytokines 
and eicosanoid metabolism (Gonzalez-Periz et al, 2006; Beharry et al, 2007). DHA but 
not EPA was reported to reduce insulin resistance through an increase in circulating 
adiponectin (Vemuri et al, 2007). DHA on its own is highly susceptible to lipid 
peroxidation due to its volatile chemical structure with six double bonds. Peroxidation 
of DHA causes cell membrane degeneration (Song et al, 2000). 
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Dietary DHA was shown to be mainly incorporated into 
phosphatidylethanolamine and phosphatidylcholine of the liver and adipose tissue after 
4 days of feeding mice with a DHA rich diet which resulted in an improved profile of 
adipokines (Lefils et al, 2010). Recently, Sun et al, (2011) reported that DHA increased 
the expression of lipogenesis and lipolysis genes in adipose tissue, whereas in the liver 
lipogenesis genes were decreased and lipolysis genes were increased by DHA. 
Therefore, this study concluded that DHA could reduce body fat mass by regulating 
lipogenesis and lipolysis genes (Sun et al, 2011).  
The reduction of hepatic TAG content in DHA fed mice was shown to be related 
to the suppression of hepatic enzymes related to TAG synthesis (Kim et al, 2008). Also, 
mice administered with DHA for 4 weeks show reduced fatty acid synthase (FAS) and 
malic enzyme activity (Gotoh et al, 2009). Besides that, the serum adiponectin 
concentrations were raised due to the suppression of TAG synthesis (Gotoh et al, 2009).  
 
1.4.5 Effects of TAG structure in dietary fats in the liver 
The differential positional distribution of TAG in fatty acids affect lipid 
metabolism (Christensen et al, 1998; Sundram et al, 2007). It has been suggested that 
animal fats such as lard which are high in saturated fatty acids (SFA) exacerbates fatty 
liver disease (Sanders et al 2011). Lard consists of a high proportion of SFA in the sn-2 
position of TAG whereas vegetable fats such as palm oil contain the SFA in the sn-1 
and sn-3 position.   Kayden et al, (1967) demonstrated that SFA in the sn-2 position of 
TAG are well absorbed in rodents whereas randomized lard is less well absorbed. Fatty 
acids in the sn-2 position are retained in that position upon absorption and TAG 
synthesis in the intestine retains the same fatty acid as in the sn-2 monoacylglycerol 
(Small 1991).  
Lieber et al, (2008) demonstrated that medium-chain TAG (MCT) which 
consists mainly of C8-C10 saturated fatty acids is not toxic in the liver in the absence of 
long chain TAG (LCT). Indeed, MCT are used in the dietary management of liver 
disorders. LCT emulsions (derived from soybean oil) cause slow clearance from the 
bloodstream and reticuloendothelial system (Seidner et al, 1989). MCT, however, do 
not result in chylomicron formation and are transported to the liver in the hepatic portal 
vein and rapidly oxidized by the liver. The total replacement of dietary LCT with MCT 
is beneficial whereas partial replacement becomes toxic unless dietary restrictions take 
place. Partial replacement increases TNF-alpha and its mRNA but does not promote 
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hepatic fat accumulation.  However, when 70% fat is fully replaced with MCT, steatosis 
does not develop and hepatic TNF-alpha decreases. Similar results are obtained when 
all MCT are replaced with carbohydrates (Lieber et al, 2008).  
Fatty acids distribution in the liver may depend of the type of fatty acids in the 
sn-2 position of TAG (Robins et al, 1991; Schmid et al, 1997). A TAG with unsaturated 
fat in sn-2 position may lead to different effects on hepatic lipids and distribution of 
fatty acids when compared to saturated fats in the sn-2 position.  
 
 
1.5 Liver proteomes of mice fed either low fat or high fat 
hypercaloric diets 
The term proteomics was coined in 1994 by Marc Wilkins and the proteome is 
defined as a complement of proteins expressed in a cell (Wasinger et al, 1995). Proteins 
are important in the development of cells and tissues and regulate their function. 
Proteomics, using 2 dimensional – differential in gel electrophoresis (2D-DIGE) have 
been carried out to investigate changes in protein expression in response to the various 
types of dietary fat. For example, dietary fat intakes have been shown to modify 
mitochondrial proteomes in the liver such as superoxide dismutase 2 (Lee et al, 2008) 
and alter proteins in various pathways such as nitric oxide metabolism (Eccleston et al, 
2011), cellular adaptation (de Roos et al, 2009), and methionine metabolism (DiBello et 
al, 2010). The proteomics approach of these aforementioned studies using 2D-DIGE did 
not investigate the effects of different types of hypercaloric diets on the liver. In the 
study for this thesis we investigate how various dietary fats cause changes in the liver 
proteome.  
 
1.5.1 Protein expression in mouse liver associated with high fat hypercaloric 
feeding 
Liver PPAR-α and PPAR-γ play major roles in the pathogenesis of NASH by 
affecting hepatic lipogenesis and fatty acid oxidation (Issemann & Green 1990). 
Although in humans, hepatic PPAR-alpha is less abundant compared to rodents, human 
PPAR-alphas appear to have similar functional characteristics to rodents (Holden & 
Tugwood 1999). Studies in mice with defective peroxisomal fatty acid β-oxidation 
showed increased hepatic PPAR-α, cytochrome (Cyp) P450, Cyp 4a10, Cyp 4a14 
expression and elevated hydrogen peroxide (H2O2) at 4 to 5 months of age (Infante et al, 
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2002). This is followed by a drastic increase in fatty acid (FA) oxidation particularly 
long chain fatty acids. By 15 months of age, mice with defective peroxisomal fatty acid 
β-oxidation develope adenomas and carcinomas. In contrast, the activation of PPAR-α 
is known to regulate fatty acid metabolism by increasing lipolysis and clearance of 
chylomicron remnants (Sugden et al, 2002). PPAR- α also stimulates the conversion of 
fatty acid to acyl-CoA derivatives, inducing beta-oxidation, reducing TAG synthesis 
and decreasing VLDL production (Schoonjans et al, 1996). Recently, a study showed 
that hepatic steatosis was ameliorated by EPA, independent of PPAR-α by inhibiting 
sterol-responsive element-binding protein-1c (SREBP-1c) (Tanaka et al, 2010). The 
effects of n-3 polyunsaturated fatty acids in the liver will be discussed in the next sub-
chapter.  
PPAR-γ is a nuclear receptor involved in glucose and lipid homeostasis. Its 
down-regulation protects mice from hepatic steatosis induced by a high fat hypercaloric 
diet. The down-regulation of PPAR-γ cascades to the down-regulation of genes related 
to lipogenesis (SCD-1 and SREBP-1c) and β-oxidation such as PPAR- α (Moran-
Salvador et al, 2011). Other studies, although not directly looking at the effects of high 
fat hypercaloric diets, showed that there was a reduction in lipogenesis in mice fed high 
fat diets due to the down-regulation of SREBP-1c. This leads to a decreased fat 
accumulation in the liver (Sheng et al, 2011; Murase et al, 2011). SREBPs are 
transcription factors that regulate lipid homeostasis by activating enzymes required for 
endogenous non-esterified fatty acids, triacylglycerols, cholesterol and phospholipids 
synthesis (Eberle et al, 2004).  
Aside from the high fat diet, a methionine-choline deficient (MCD) diet is 
commonly administered to mice in order to investigate the underlying mechanisms of 
NASH (Rinella et al, 2008; Lee et al, 2011). MCD diets potentially exacerbate fatty 
liver but do not cause insulin resistance in mice fed high fat (45% calories) diets when 
compared to mice fed 10% calories of low fat diet (Raubenheimer et al, 2006). MCD 
diets incorporated with a high carbohydrate or sugar content may induce NASH rapidly 
in mice models (Pickens et al, 2010). In addition, MCD diets inhibit diacylglycerol 
acyltransferase-2 (DGAT-2) hence resulting in the development of hepatic steatosis, 
necroinflammation, and fibrosis in mice (Yamaguchi et al, 2008). Interestingly, a 
reduction in hepatic expression of tumour necrosis factor-alpha (TNF-α), elevates 
adiponectin and improves insulin sensitivity, does not attenuate steatosis but leads to the 
development of NASH (Yamaguchi et al 2007). The aforementioned study concluded 
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that, TNF- α, adiponectin in adipose tissue and insulin sensitivity may not be 
appropriate biomarkers for NASH (Yamaguchi et al 2007).  
TNF- α converting enzyme (TACE) was shown to be significantly expressed in 
livers of mice overfed a high fat diet (Ono et al, 2003). Palmitic acid, lipolysaccharide, 
high glucose, and high insulin were reported to be responsible for the raised TACE 
activity. The over-expression of TACE resulted in the impairment of insulin-dependent 
phosphorylation of AKT and glycogen synthase kinase 3 (GSK3) in mouse hepatocytes 
(Fiorentino et al, 2010). The up-regulation of Akt in sterol regulatory element binding 
proteins-1c (SREBP-1c) knock-out mice is associated with hypertriglyceridemia, 
hepatic triglyceride accumulation and hypoglycaemia (Ono et al, 2003). 
Previous studies on the effects of hypercaloric diets on mice liver have 
confirmed that the genetic models of NASH commonly develop hepatocellular 
adenomas and carcinomas unexpectedly (Lieber et al, 2008; Sheng et al, 2011). 
However, these models do not present a distinctive phase between steatosis and NASH. 
On the other hand, genetically modified animals may be preferred in investigating the 
mechanisms involved in the development of carcinomas in the liver rather than the 
progression of NASH from steatosis.  
For the studies in this thesis, the effects of different types of diets on the protein 
profiles of the liver will be investigated.  
 
1.5.2 The effects different types of dietary fats on protein expression in mice liver  
 The different types of dietary fats mainly saturated and polyunsaturated fats as 
described in Chapter 1.4 may directly be associated with the differential expression of 
proteins in mouse liver.   
Chronic high fat diets (70% energy as fat, 11% carbohydrate and 18% protein) 
administered to mice for 16 weeks have previously demonstrated to cause steatosis, 
altered nitric oxide metabolism and modified proteomes in liver mitochondria. The liver 
mitochondrial proteins involved were ATP synthase and pyruvate and malate 
dehydrogenase (Eccleston et al, 2011).  Another high fat model, consisting of 45% of 
energy from fat with palm oil as the main source of the fat, was shown to cause 
alterations in hepatic one-carbon metabolism. In simple terms, the hepatic one-carbon 
metabolism involves the coupling of high levels of choline and low levels of methionine 
(Rubio-Aliaga et al, 2011). 
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 The effect of fish oil on lowering the levels of hepatic enzymes related to 
steatosis such as epoxide hydrolase (Mavrommatis et al, 2010) has been used 
extensively. Long n-3 polyunsaturated fats in fish oils, mainly EPA and DHA, may 
have beneficial effects on the liver by suppressing TAG synthesis and up-regulating 
protective mechanism that decrease oxidative stress. However, high intakes of fish oil 
have well documented adverse effects and promote steatitis and the effects of EPA and 
DHA may differ when fed separately. Furthermore, many studies have failed to ensure 
that diets containing additional EPA and DHA are matched with an increased intake of 
vitamin E.  
One study showed that fish oil but not pure DHA significantly lowered hepatic 
epoxide hydrolase levels in male apolipoprotein E knockout mice when compared to 
mice fed high-oleic sunflower oil (Mavrommatis et al, 2010). It was suggested that EPA 
rather than DHA is responsible for the lowering expoxide hydrolase observed with fish 
oil feeding. On the other hand, DHA was found to be more efficient in enhancing 
lipoprotein metabolism and reducing oxidative stress in comparison with EPA 
(Mavrommatis et al, 2010). 
Mice fed a high-fat fish oil diet for 3 weeks presented significant increases in 
peroxisomal beta-oxidation and catalase activity in both liver and myocardium (De 
Craemer et al, 1994). Further investigations were carried out whereby 2% (w/w) of 
DHA administered to healthy mice showed slight but significant increases in catalase 
activity of myocardium after 3 weeks, but no change in the liver. In addition, there were 
no changes in the peroxisomes of the myocardium and liver indicating that DHA dosage 
used in the aforementioned study did not disrupt fatty acid metabolism in the liver (De 
Craemer et al, 1996).  
On the other hand, the administration of EPA has shown to be involved 
beneficially, in the development of insulin resistance and lowering of adipokine 
production, which stimulates AMP-activated protein kinase (Lorente-Cebrian et al, 
2009). Mice fed on a high fat diet (45% energy from fat) for 6 weeks, followed by a 
high EPA diet (45% energy from fat; 36 g/kg EPA) resulted in improvement of insulin 
resistance and lower plasma adiponectin. Furthermore, proteomic work in the 
aforementioned study reported an increase in markers of fatty acid oxidation and 
reduction in lipogenesis (Kalupahana et al, 2010). One key lipogenic enzyme, namely 
glycerol-3-phosphate dehydrogenase was reduced (Kalupahana et al, 2010).  
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In relation to proteomics of n-3 fatty acid composition in the liver, Demoz et al, 
(1992) showed that hepatic acyl-CoA oxidase and catalase activities increased by 50% 
and 30%, respectively, in EPA administered mice. EPA was shown to reduce levels of 
hepatic lipid peroxides while no change was observed in palmitic acid fed mice in 
comparison to the controls (Demoz et al, 1992). To this date, although fish oil is known 
for its protective effects against high fat-induced fatty liver and inflammation, the 
biological mechanisms of EPA and DHA as individual source of fatty acid are still 
being elucidated. For this thesis, the protein changes in the liver caused by the effects of 
hypercaloric diets are investigated, followed by the dietary effects of supplemental EPA 




1.6 MicroRNA (miRNA) expression in fatty liver of mice 
MicroRNAs (miRNAs) are single stranded non-coding RNAs comprising of 19 - 
25 nucleotides and play an important role in the regulation of gene expression by 
binding to complementary site of target messenger RNA causing either transcript 
degradation or translational repression (Wiklund et al, 2010). Transcript degradation 
occurs when miRNA is a perfect match with its target gene causing the transcripts to 
cleave whereas translational repression happens when there are imperfect matches 
throughout the transcripts causing it to bind at the 3’UTR (untranslated region) of target 
messenger RNAs (mRNAs). To this date, the miRNA Registry contains 5071 miRNA 
loci expressing 5922 mature miRNA from 58 species (http://microrna.sanger.ac.uk/; 
Griffiths-Jones 2008).   
It has been estimated that 30% of mammalian genes are regulated by miRNAs 
and a single miRNA can inhibit translation of more than 200 different mRNAs at one 
time by binding to the 3’UTR of target mRNAs (Bartel 2004). As a result, the inhibition 
of protein synthesis and destabilization of mRNA may be an important mechanism for 
causing disease. For example, the down-regulation of the liver-specific miRNA-122 
results in reduced rates of cholesterol synthesis and enhanced hepatic fatty acid 
metabolism in a diet-induced mouse model of obesity (Esau et al, 2006).    
The possibility of using miRNAs in understanding complicated diseases and its 
biological processes have received wide interest among researchers. It has been 
proposed that there is a need to further develop therapeutic uses of miRNAs as potential 






1.6.1 Biogenesis of miRNA 
The biogenesis of miRNA involves enzymatic processes in the following order 
(Figure 1.3): 
 miRNA transcribed by polymerase II to primary transcripts. 
 Dorsha and Pasha process primary miRNA to pre-miRNA by cleaving at 
the stem loop. 
 Pre-miRNA is transported from nucleus to cytoplasm by Exportin-5. 
 Cleavage of pre-miRNA to miRNA duplexes by Dicer. 
 The duplexes are unwinded into a single strand and incorporated into the 
RICS to bind to3’UTR or target mRNA.  
 The target mRNA is then translationally repressed or cleaved depending 
on the degree of homology.  
 
Figures 1. 3: Biogenesis of miRNA  
 
Source: Adapted from (Kim et al, 2009) 
 
It has been suggested that miRNAs in humans reside in intron of either coding 
or non-coding transcription units (Rodriguez et al, 2004). Primary-miRNAs (pri-
miRNA; 50-80 nucleotides) are products of independent genes which are transcribed by 
48 
 
RNA polymerase II (Morlando et al, 2008). The nuclear microprocessor protein 
complex containing Drosha and Pahsa cleaves pri-miRNAs into precursor-miRNAs 
(pre-miRNAs; 50-70 nucleotides). Drosha promotes intron degradation before splicing, 
which may influence maturation of mRNAs. Pre-miRNAs are then transported actively 
into the cytoplasm by RAN-GTP-dependent factor exportin-5. In the cytoplasm, Dicers 
cleave pre-miRNAs into duplexes consisting of 20 – 24 nucleotide mature miRNAs 
(Tijsterman & Plasterk 2004). The duplexes are located into the RNA-induced silencing 
complex (RISC) containing argonaute, which determines the functional strand before 
localizing the single stranded miRNA in the cytoplasm (Rand et al., 2005). Each pre-
miRNA produces a single mature miRNA. As a result, post-transcriptional gene 
repression takes place either by transcript degradation or translational inhibitions 
depending on the complementarities of target mRNA to the miRNA. Other detailed 
aspects of miRNA metabolism and control can be found in selective reviews, for 
example Kim et al, (2009).  
 
1.6.2 Implications of miRNA in gene regulation 
The developmental timing in Caenorhabditis elegans led to the first miRNAs 
being discovered, namely lin-4 and let-7. Both these miRNAs were found to repress 
translation of their respective targets, namely lin-14 and lin-41 genes (Ambros 2004). 
Since then, advanced understanding of the mechanisms of miRNA in developmental 
processes such as differentiation and apoptosis have been investigated (Alvarez-Garcia 
& Miska 2005; Cheng et al, 2005). Studies on animal viruses have used miRNA for 
RNA silencing by targeting mRNAs for gene regulation (Pfeffer et al, 2004). This has 
led to a growing interest in miRNA in relation to cancer research. For example, down-
regulation of miR-15 and -16 leads to chronic lymphatic leukaemia (Calin et al, 2002) 
and up-regulation of miR-221, -222 and -146 leads to the development of tumours (He 
et al, 2005). Undeniably, there is an increasing interest in the emerging role of miRNA 
either in gene regulation, as potential biomarkers or in therapeutics. In this study for the 
thesis, there is a focus on the miRNAs in the liver which alter in response to different 
types of hypercaloric diets.  
 
1.6.3 MiRNA expression and pathways involved in hepatic steatosis 
The understanding of miRNA in the underlying mechanisms and pathways of 
hepatic metabolism is rather limited and thus unclear. Recent studies have shown that 
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miR-122 is the most abundant miRNA (Young et al, 2010; Li et al, 2011) followed by 
miR-192 and miR-199a/b (Hou et al, 2011). These account for 52%, 16.9% and 4.9% of 
total liver miRNAs, respectively (Hou et al, 2011). More interestingly Cheung et al, 
(2008) reported that miR-122 was 63% down-regulated in livers of NASH patients and 
affected the expression levels of mRNAs encoding SREBP-1c. 
In a normal mouse, the inhibition of miR-122 was found to reduce plasma 
cholesterol levels, increase hepatic fatty acid-oxidation and decrease hepatic fatty acid 
concentration (Esau et al, 2006).  
There are some well-established cancer studies on miR-199 and miR-200 
families (Yeligar et al, 2009; Murakami et al, 2011). For example, these show that the 
up-regulation of miR-199 attenuate hypoxia-inducible factor-1alpha (HIF-1 alpha) and 
endothelin-1 (ET-1) expression directly (Yeligar et al, 2009). Administration of anti-
miR-199 showed reversed effects (Yeligar et al, 2009). HIF-1 and ET-1 are related to 
hypoxia and hepatic microcirculation, respectively, which may cause liver inflammation 
and cirrhosis. The miR-200 family is down-regulated in liver metastases and primary 
tumours by relieving inhibition of mesenchymal transcription factor Zeb1 that then 
suppresses E-cadherin (Olson et al, 2009). It is known that tumours that progress from 
adenomas to invasive carcinoma are characterized by loss of E-cadherin (Perl et al, 
1998). 
The up-regulation of miR-21 leads to significant changes in the miR-21 targets 
such as phosphatase and tensin homolog (PTEN) (Zhu et al, 2010). The up-regulation of 
miR-21 is dependent on the up-regulation of the AP-1 and ErbB/Stat3 pathway that 
plays an important role in liver carcinogenesis (Zhu et al, 2010). Another study on miR-
21 showed its up-regulation was responsible for the reduced expression of hepatic 
PTEN in the early stages of hepatocarcinogenesis in C57BL/6J mice fed choline-
deficient diet (Wang et al 2009). Additionally, the expression of miR-21 was 
significantly decreased in liver of rats fed fructose-enriched diets but showed no change 
in liver of rats fed a combined high fat and high fructose diets (Alisi et al, 2011). 
Several studies have shown miRNAs are strongly associated with liver cancer 
(Calin et al, 2004; Braconi et al, 2011) and the differentiation state of hepatocellular 
carcinoma cells (Wong et al, 2008; Liu et al, 2011). Therefore, a miRNA profile in 
relation to NASH may be generated in order to understand the pathogenesis of these 
conditions. For this thesis, we will be investigating the effects of hypercaloric diets, 
which may lead to the development of NASH. However, the limitations in miRNA 
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profiling and validation towards understanding the mechanisms on how dietary fats 
affects the liver is mainly due to the lack of biological data linking specific miRNA 
expression to respective mRNA targets. Current software such as MiRanda and 
TargetScan are available for finding list of targets regulated by miRNAs but requires 






1.7 Aims and hypotheses of the thesis 
The aim of this project was to investigate the effects of varying the level and 
type of fat on the development of fatty liver in mice and to ascertain the extent of 
changes in the liver using biochemical and histological indices of liver damage. 
Proteomic and microRNA (miRNA) studies were conducted to identify changes in 
protein expression and molecular regulation in order to look for potential markers of 
liver damage and/or to identify points of regulatory control.  
The hypotheses of this project are:  
1. Different types of hypercaloric high fat diets cause alteration in lipid 
accumulation in the liver and exacerbate NASH.  
2. Dietary n-3 PUFA such as EPA and DHA play a protective role by regulating 
synthesis and oxidation of fatty acids and alters the pattern of fat accumulation 
in the liver. 
3. Palmitic acid in the sn-2 position may be more detrimental to liver lipid 
metabolism than it is in the sn-1 and sn-3 position. 
4. Proteomics using 2-dimensional differential ingel electrophoresis can determine 
proteins that change in response to high fat diets and n-3 polyunsaturated fatty 
acids. 
5. Hypercaloric feeding of mice with either low or high fat diets result in the 








Chapter 2:  





2.1.1 Apparatus: List of suppliers 
a)  Diet preparation 
 Electric blender for 1 kg of feed - Kenwood 
 Electric blender for 10 kg of feed - The Hobart, MFG. Co. Ltd 
 Weighing scale - Oertling 
 Freeze dryer - LSL Secfroid 
 Bomb calorimeter - Gallenkamp 
 Soxhlet extractor - Sigma 
 Markham steam distillation apparatus – Sigma 
 
 
b) Animal work 
 Raised bottom wired cages – Tecniplast 
 Utemp1284 mouse cages - Tecniplast 
 Wood chips bedding – Aspen-wood chips, B and K Ltd 
 Paper roll 
 Bench-top centrifuge (Microlite Microfuge) - Thermo Electron Corporation 
 Light microscope (Microphot FX) – Nikon 
 
 
c)  Lipidomics 
 Oxygen cylindrical tank – BOC 
 Gas chromatography 6890 series – Agilent technologies 
 Water bath tank – Grant Instruments (Cambridge) Ltd 
 Centrifudge GS-6R – Beckman  
 Concentrator SF50 for Teflon tubes – Genelac  
 Concentrator 5301 for 2 ml tubes – Eppendorf 
 Vacmaster – Tecsis 
 
d)  Proteomics  
 Tissue lyser with adapter sets (TissueLyser II) – Qiagen 
 Plate-reader Synergy HT - Biotek 
 IPGphor machine, chamber, manifold, white electrode pads, electrodes, cups – 
GE Healthcare 
 EttanDaltTwelve tank 
 EttanDaltScanner 
 96-well microplates (flat bottom) - Starlabs 
 
e) Genomics 
 Nanodrop ND-1000 spectrophotometer – Thermo Scientific 
 7900 HT Fast RT-PCR System – Applied Biosystems 
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 Agilent 2100 bioanalyzer RNA 6000 NanoChip - Agilent Technologies 
 Affymetrix Hybridization Oven 640 
 Affymetrix Fluidics Station 450 
 GeneChip Scanner 3000 7G 
 Biomek FX Liquid handling robot - Beckman Coultier 
 Centrifudge with plate holders – Major Laboratory Supplier (MLS) 
 PTC-225 Peltier Thermal Cycler – Bio Rad 
 Microcentrifudge - MLS 
 
2.1.2 Lab consumables: List of suppliers 
a)  Diet preparation 
 Hexagonal 45 ml jam jars - Euro-bottles 
 Cotton threads, crucibles for bomb calorimeter - Gallenkamp 
 Extraction thimbles, Cotton wool for Soxhlet extractor -  
 Nitrogen-free paper, anti-bumping granules for Kjeldahl  method 
 
b)  Animal work 
 1 litre polypropylene bottles - Nalgene 
 Syringes (1 ml), needles (25 g x 16 mm) - Plastipak 
 StarTags Laser Sheets (3.5 x 1.25 cm) - Starlabs 
 Cryogenic tubes - Starlabs 
 Cryogenic boxes - Starlabs 
 Microcentrifudge tubes (0.5, 1.5 and 2.0 ml) - Starlabs  
 
c)  Lipidomics 
 Aminopropyl cartridges (Strata C18-E) - Sigma  
 Teflon lined screw-capped tube – Pyrex 
 2 ml screw top vials with blue silicone/PTFE screw caps – Chromacol Ltd 
 Weighing scale Precisa 125A – PAT COSHH Limited 
 
d)  Genomics 
 1.5 ml microcentrifudge tubes – Starlab 
 ABI Prism 96-Well Optical Reaction plate with barcode (code 128) – Applied 
Biosystems 
 ABI Prism 384-Well Clear Optical Reaction Plate with barcode (code 128) – 
Applied Biosystems 
 ABI Prism Optical Adhesive Covers – Applied Biosystems 
 
e) Proteomics  
 Microcentrifuge tubes (2 ml, 0.5 ml; Protein LoBind) - Eppendorf  
 Test-tubes (15 ml, 50 ml) - Greiner 
 Grinding balls, 5 mm stainless steel - VWR International 
 pH indicator paper sticks – Fisher Scientific 
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 Lint free tissue – Fisher Scientific 
 96 well digester plates (ProGest Blue Microtiter Plates) – Genomics solutions 
 Immobiline DryStrip gels 3-11NL (24cm) – GE Healthcare 
 IPG buffer 3-11 NL, Pharmalytes pH 3-10 – GE Healthcare 
 CyDye DIGE Fluor kit (5 nmol / dye) of Cy2, Cy3, Cy5 – GE Healthcare 
 Paper electrode pads – GE Healthcare 
 Loading cups – GE Healthcare 
 Paraffin oil; DryStrip cover fluid – GE Healthcare 
 2-D Quant Kit - GE Healthcare 
 2-D Clean-up kit - GE Healthcare 
 Pierce 660 protein assay kit - Thermo Scientific 
 Parafilm – VWR International 
 Pre-cast gels - GE Healthcare 
 
2.1.3 Chemicals: List of suppliers 
a)  Animal work 
 Ethanol ACS grade - Sigma 
 Formalin – Sigma 
 Isofluorane (IsoFlo) - Abott Laboratories Ltd 
 Phosphate buffered saline (PBS) – Oxoid 
 
b)  Diet preparation 
 Concentrated sulphuric acid – Fisher Scientific 
 30% hydrogen peroxide - Sigma  
 Boric acid - Sigma 
 Sodium carbonate - Sigma 
 Ammonium sulphate - Sigma 
 Kjeltabs CTC catalyst tablets (contains potassium sulphate to raise boiling point, 
copper and titanium as catalysts) - Sigma 
 Methyl orange indicator - Sigma 
  
2.1.4 Buffers and reagents 
a) Serum analyses 
 Glucose reagent - Siemens Healthcare Diagnostics Ltd 
 Alkaline phosphatase (ALP) reagent - Siemens Healthcare Diagnostics Ltd 
 Aspartate transaminase (AST) reagent - Siemens Healthcare Diagnostics Ltd 
 Alanine transaminase (ALT) reagent - Siemens Healthcare Diagnostics Ltd 
 NEFA assay kit - WAKO Chemicals 
 Cholesterol reagents -  Siemens Medical Solutions Diagnostics Ltd 
 Triacylglycerol reagents - Siemens Medical Solutions Diagnostics Ltd 
 
b) Genomics 
 TRIzol Reagent – Invitrogen 
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 Ambion RNA nuclease free water – Qiagen 
 Reverse transcription kits 
 TaqMan MicroRNA Reverse transcription kit - Applied Biosystems 
 PCR Master Mixes 
 TaqMan Universal PCR Master Mix II, No UNG – Applied Biosystems 
 TaqMan 2x Universal PCR Master Mix - Applied Biosystems 
 
c)  Proteomics 
 Bromophenol blue - PlusOne  
 7 M Urea - PlusOne    
 2 M Thiourea - PlusOne    
 4 % CHAPS - PlusOne    
 30 mM Tris - PlusOne   
 MilliQ water 
 Lysine; Mw 182.6 - Sigma   
 DIGE Destreak Rehydration solution 
 0.5 % (v/v) Pharmalyte pH 3-10  
 Acrylamide, bis solution - PlusOne   
 Mixed bed ion exchanger - Amberlite  
 Sodiumdodecylsulphate (SDS) - PlusOne 
 Glycine - PlusOne  
 Agarose – PlusOne       
 30 % Glycerol - PlusOne     
 Dithiothrietol (DTT) - PlusOne 
 Iodoacetamide - PlusOne   
 2% v/v IPG buffer - Pharmalyte 
 SDS Gel buffer Tris-Cl pH 8.8 (4x conc)  
 Hydrochlolric acid – Fisher Scientific   
 Ammonium persulfate solution (APS) - PlusOne  
 Acrylamide, Bis solution - PlusOne   
 N,N,N,N-Tetramethylethylenediamine (TEMED; 100%) - PlusOne  
 Glycerol - PlusOne   
 Reference markers - IR markers 
 Bind silane – PlusOne 
 Deep Purple stain – GE Heatlhcare 
 15% Ethanol – Fisher Scientific 
 10% Glacial acetic acid – Fisher Scientific 
 1% Citric acid – Fisher Scientific 
 6.2% Boric acid – Fisher Scientific 
 Sodium hydroxide – Fisher Scientific 
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2.1.5 Animal experiments 
C57BL/6J male mice were obtained from Charles River, UK, Manston Road, 
Margate, CT9 4LT, Kent, England.  
 
a) Diets 
 Mineral mix (AIN-93-G-MX) - MP Biomedicals 
 Vitamin mix (AIN-93-VX) - MP Biomedicals 
 Light condensed milk - Nestle 
 Sucrose - BDH Chemicals 
 Cellulose - BDH Chemicals 
 Casein - BDH Chemicals 
 Cornstarch - BDH Chemicals 
 L- Methionine - BDH Chemicals 
 Choline hydrogen tartrate - Merck   
 Lard - Sainsbury 
 DHA 500 TG SR, SF06340 - Incromega 
 EPA 500 TG SR, SF05244 - Incromega 





2.2.1 Preparation of the semi-synthetic solid food 
Diets were prepared by mixing the dry components for an hour with an electric 
blender followed by another 30 minutes when different types of fats were added to the 
dry mixture. 100 ml of water was added to every 200 g of diets and mixed for 15 
minutes to get a malleable dough consistency. The dough was shaped into 6 cm
3 
blocks 
and arranged individually on a tray lined with aluminium foil. The nutrient 
compositions of the diets incorporated with different types of fats are represented in 
Table 2.1 and 2.3. The diets were prepared separately in batches of 10 kg, differentiated 
by shapes and stored in a -40°C freezer for 12 hours. Finally, the frozen diets were 
transferred to a freeze dryer for 3 days for lyophilisation.  The freeze-dried pellets were 
stored in a 4°C cold room until needed.  
The energy content of diets was quantified using a bomb calorimeter by 
measuring the heat of chemical reactions. The fat and protein content of the diets were 
determined using the Soxhlet extraction and Kjeldahl method, respectively. The energy 
composition of the diets is presented in Table 2.2.  
 
2.2.2 Preparation of the fat-free condensed milk incorporated with fats 
Different types of fats were added to the fat-free condensed milk (Light 
condensed milk Carnation, Nestle, UK) to make up the fat to carbohydrate ratio 
relatively similar to the pellets. Condensed milk (CM) in the low fat and high fat 
hypercaloric groups were incorporated with 1% and 8% fats respectively. Energy 
compositions of the CM incorporated with fats are presented in Table 2.4. All mice 
groups abbreviated with LF, HF, HFDHA, HFEPA, HOSO, PO, IPO and LARD were 
fed on light condensed milk incorporated with 8% test fat except for LFR group (see 
Table 2.5 for detailed description of the groups).  
59 
 
Table 2. 1: The nutrient composition of mice pelleted diets containing either 2% corn 
oil (co), 18% palm oil (po), 15% palm oil with 3% docosahexaenoic acid (dha) or 15% 
palm oil with 3% eicosapentaenoic acid (epa) presented in grams and kilocalories 
Ingredients 
2% corn oil 18% palm oil 
15% palm oil 
+ 3%DHA 
15% palm oil 
+ 3%EPA 
gram kcal gram kcal gram kcal gram kcal 
Casein 19.8 79.2 19.8 79.2 19.8 79.2 19.8 79.2 
L-Methionine 0.2 0.8 0.2 0.8 0.2 0.8 0.2 0.8 
Cornstarch 58.0 208.8 42.0 151.2 42.0 151.2 42.0 151.2 
Sucrose (Icing 
Sugar) 
10.0 37.5 10.0 37.5 10.0 37.5 10.0 37.5 
Solka-floc 
(Cellulose) 
5.3 0.0 5.3 0.0 5.3 0.0 5.3 0.0 
MineralMix 
(AIN93G) 
3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 
VitaminMix 
AIN93VX 
1.0 3.9 1.0 3.9 1.0 3.9 1.0 3.9 
Choline Bititrate 0.2 0.0 0.2 0.0 0.2 0.0 0.2 0.0 
Corn oil 2.0 18.0 0.0 0.0 0.0 0.0 0.0 0.0 
Palm oil 0.0 0.0 18.0 162.0 15.0 135.0 15.0 135.0 
DHA 0.0 0.0 0.0 0.0 3.0 27.0 0.0 0.0 
EPA 0.0 0.0 0.0 0.0 0.0 0.0 3.0 27.0 
Total 100.0 351.3 100.0 437.7 100.0 437.7 100.0 437.7 
Energy composition from protein, carbohydrate and fat of the pelleted diets determined 




Table 2. 2: Energy composition from protein, carbohydrate and fat diets determined 
by Kjeldahl, bomb calorimeter and Soxhlet method respectively. 
  Low fat pellets High fat hypercaloric pellets 
Protein (g/100 g) 20.0 (22.8) 20.0 (18.3) 
Carbohydrate (g/100 g) 78.0 (83.3) 62.0 (44.7) 
Fat (g/100 g) 2.0 (5.1) 18.0 (37.0) 
Energy (kcal/100 g) 351.3 437.7 
Values in parentheses represent the % energy. Energy contents are calculated using 








Table 2. 3: The nutrient composition of mice pelleted diets containing either 18% 
high oleic sunflower oil (HOSO), 18% palm oil (PO), 18% interesterified palm oil 
(IPO) or 18% lard presented in grams and kilocalories  
  18% HOSO  18% PO  18% IPO  18% lard 
 gram kcal gram kcal gram kcal gram kcal 
Casein 19.8 79.2 19.8 79.2 19.8 79.2 19.8 79.2 
L-Methionine 0.2 0.8 0.2 0.8 0.2 0.8 0.2 0.8 
Cornstarch 42.0 151.2 42.0 151.2 42 151.2 42 151.2 
Sucrose (Icing 
Sugar) 
10.0 37.5 10.0 37.5 10.0 37.5 10.0 37.5 
Solka-
floc(Cellulose) 
5.3 0.0 5.3 0.0 5.3 0.0 5.3 0.0 
Mineral Mix 
(AIN 93G) 
3.5 3.1 3.5 3.1 3.5 3.1 3.5 3.1 
Vitamin Mix 
(AIN 93VX) 
1.0 3.9 1.0 3.9 1.0 3.9 1.0 3.9 
Choline bititrate 0.2 0.0 0.2 0.0 0.2 0.0 0.2 0.0 
Sunflower oil 18 162 0.0 0.0 0.0 0.0 0.0 0.0 
Palm oil 0.0 0.0 18 162 0.0 0.0 0.0 0.0 
Interesterified 
palm oil 
0.0 0.0 0.0 0.0 18 162 0.0 0.0 
Lard 0.0 0.0 0.0 0.0 0.0 0.0 18 162 
TOTAL 100 437.7 100 437.7 100 437.7 100 437.7 
Energy composition from protein, carbohydrate and fat of the pelleted diets determined 




Table 2. 4: Energy composition of light condensed milk (CM) incorporated with 1% 









Protein (g/100 g) 9.3 (3.4) 9.3 (13.8) 9.3 (10.9) 
Carbohydrate (g/100 g) 59.5 (21.5) 59.5 (82.9) 59.5 (65.2) 
Fat (g/100 g) 0.2 (0.07) 1.0 (3.3) 8.0 (21.1) 
Energy (kcal/100 g) 277.0 284.2 342.0 
Values in parentheses represent the % energy. Energy contents are calculated using 
Atwater factors of 4 kcal/g for protein, 3.75 kcal/g for carbohydrate and 9 kcal/g for fat. 
Light condensed milk was used in both the condensed milk incorporated with fats for all 




2.2.3 Measurement of energy composition in diets with bomb calorimeter 
a)  Principle (Miller & Payne 1959)  
The gross energy content of the diets was calculated using the ballistic bomb 
colorimeter by measuring the amount of heat released when the samples were 
completely oxidised during combustion.  The change of conductivity in the 
thermocouple attached to the bomb calorimeter is proportional to the amount of heat 
released with an assumption of no heat loss. The change in conductivity was determined 
by the deflection on the galvanometer. Sucrose was used to calibrate the galvanometer. 
The availability of energy to the body depends on the amount of energy lost in feaces 
and urine which was assumed to be 5%. Therefore, digestible energy content was 
calculated by multiplying gross energy by 0.95 and metabolisable energy was calculated 
by subtracting 0.075 x N% (kcal/g) of the diet.  
b)   Methods 
 Firstly, the calorimeter was bombed with no samples in the crucible to obtain a 
blank value. Approximately 1 g of sucrose was weighed in a crucible and 3 strands of 
cotton thread were embedded in the sample and looped to the firing wire. The bomb 
body was fitted and thermocouple inserted at the top. A pressure of constant 25 atm of 
oxygen was released gradually to the bomb calorimeter without developing excessive 
pressure. The galvanometer was zeroed and the firing button was pressed. The pressure 
gauge and galvanometer readings increased in 5 seconds after firing and the reading on 
the galvanometer was noted after 35 seconds when the peak reading was attained. Then 
the gas pressure was released and the bomb body was removed and cooled under 
running water in preparation for the next sample.  The factor of sucrose standards was 
calculated using the formula,  
Factor = 3.94 / (Deflection – Blank value) / weight 
After cooling the bomb body under running water, the body was wiped thoroughly. The 
steps were repeated for the samples in duplicates ensuring that the diets were of low 
bulk density and dry to reduce the burning rate and allow uniform combustion. After all 







2.2.4 Determination of fat content by Soxhlet method 
a)   Principle 
 Fat was extracted from dried sample with petrol ether and the dissolved fat was 
siphoned off with ether. The fat-free samples were re-weighed and the fat difference 
was calculated.  
b)  Methods 
 The Soxhlet extractor was fitted with a reflux condenser and flask. Thimbles and 
cotton wool were dried in the oven, weighed immediately to prevent absorption of 
moisture and stored in desiccators. Thimbles were labelled with a pencil. 
Approximately 3 g of dried samples were added to the thimble and weighed accurately. 
The weighed cotton wool was used as a stopper in the thimble and placed in the 
extractor. Petrol ether was added until it siphoned over and more were added. The aater 
temperature was adjusted until the ether boiled gently and the set-up was left for 12 
hours. On the next day, the thimble was removed when the extractor barrel was emptied 
and left to drain until the ether was evaporated. Samples were dried in the oven to 
constant weight and allowed to cool in desiccators. Then, g fat/ 100 g of diets were 
calculated. 
 
2.2.5 Quantification of proteins by Kjeldahl method 
a)  Principle 
The Kjeldahl method was used to measure the nitrogen levels to determine the 
protein content in the diets. The nitrogen content of varies from 15 – 18% and by 
multiplying the nitrogen content with 6.25 the protein content was determined 
(Bradstreet, 1965). The three main processes in the Kjeldahl method can be divided into 
digestion, distillation and titration. The principal of this method involves the reduction 
of nitrogen to ammonium ions using sulphuric acid and oxidation of carbon to carbon 
dioxide. The chemical decomposition of the sample was known to be completed when 
the solution turned clear. The ammonium ions were then converted into ammonia gas 
through distillation with sodium hydroxide. The amount of ammonia gas trapped was 
converted back to ammonium ions in acidic buffer and titrated against a standard 
solution of sulphuric acid, a process known as back titration. A steam distillation 
apparatus designed by Markham (1942) was used. The end of the condenser was dipped 
into boric acid, allowing the ammonia to react with the acid and the remainder was 
titrated with sodium carbonate and methyl orange pH indicator.  
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b)  Methods 
Approximately 1.5 g of sample was ground, weighed on nitrogen-free paper and 
transferred to a digestion flask containing strong sulphuric acid. For each gram of 
sample, 20 ml of concentrated sulphuric acid was added and mixed well. Then, 5 ml of 
30-35% hydrogen peroxide was added drop-wise to prevent an exothermic reaction 
which may cause an explosion. To this, 1 tablet of Kjeltabs CTC catalyst and a few anti-
bumping granules were added to speed up reaction. The reactants were mixed then 
heated until the solution was clear. The clear solution was heated for another 20 minutes 
just below the boiling point to ensure that all the ammonia was converted to ammonium 
sulphate. 
Before distillation, the sample was cooled on the rack. After cooling, 50 ml of 
distilled water was carefully added to the solution and transferred to a 100 ml 
volumetric flask. The solution was made up to a volume of 100 ml. Then, 5 ml aliquots 
were taken for distillation with the Markham apparatus. A series of 50 ml conical flasks 
filled with 10 ml indicator solution was prepared. One portion was diluted with 10 ml of 
water and used as a colour check for the end-point. Firstly, the apparatus was steamed 
out. The steam generator was connected to the steam jacket, the waste clip was closed, 
the stopper inserted and then the steam was let out for 10 – 15 minutes. The steam 
pressure was reduced by removing the Bunsen burner and cold water was added. The 
vacuum created by the cooling of the steam jacket caused the water to flush out, which 
was drained off by opening the waste clip.  
  After steaming out the apparatus, samples were ready to be distilled. The waste 
clip was closed, the stopper inserted and the steam generator was disconnected. A 
conical flask with a condenser was immersed under the indicator solution to trap 
gaseous ammonia that preceded the first drop of distillate. Then, 5 ml of sample was 
pipetted into the still and the tip of pipette was placed in the neck of the opening. Five 
millilitres of water was washed in and the stopper was replaced. After this, 10 ml of 
40% NaOH was poured into the reservoir and the stopper was lifted up slightly, 
allowing NaOH to run gently into the digest. Water was left around the stopper to form 
a seal.  
The steam generator was reconnected and distillation proceeded. Ten millilitres 
of distillate was collected after the indicator turned green by removing the tip of the 
condenser from the liquid, and distillation was continued for another 2 minutes. The 
outside of the condenser tip was washed and samples were set aside for titration. Heat 
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was removed from the steam generator and the liquid was flushed out. The reservoir and 
still were washed with distilled water and flushed out. The waste clip was opened to 
drain off excess water and the apparatus was then ready for the next sample.  
The sharpness of the titration end-point was enhanced by comparing the 
intensity of methyl orange indicator and 1% boric acid as a reference solution. A 
standard solution of ammonium sulphate containing 1 mg nitrogen/ml was prepared in 2 
ml aliquots. The acid in the biurette was standardised by titrating against ammonia in 
boric acid/indicator solution from the distillation of the standard solution. The amounts 
of nitrogen from the sample were calculated by noting the amount of acid required to 
titrate 2 mg of nitrogen. 
 
2.3 Experimental design 
2.3.1 Laboratory animals 
All procedures were carried out according to the project license guidelines under 
the UK Home Office Animals Scientific Procedures Act, 1986. The animals were 
divided into 9 groups (8 mice per group), labelled and fed with the respective diets as in 
Table 2.5. Small amounts (2% by weight) of corn oil (CO) were used in the low fat (LF) 
and low fat reference (LFR) diets in order to ensure an adequate intake of linoleic acid. 
The LFR group is a eucaloric group whereas the LF group is a hypercaloric diet. Palm 
olein (iodine value 56, PO, Archer Daniel Mills PLC, Erith, Kent) provided the sole 
source of fat in the high fat (HF) diet. EPA and DHA rich triacylglycerol concentrates 
(Croda Ltd, Hull) were substituted for 3% by weight of PO in the respective high fat 
diets. The first feeding study compared LFR, LF, HF, HFDHA and HFEPA diets. Pre-
specified comparisons were made between: low fat and high fat hypercaloric groups 
with or without EPA or DHA. In the second study, high oleic sunflower oil (HOSO, 
provided by Archer Daniel Mills, Erith Kent), which consists mainly of triolein, was 
used as a comparator. In the 2
nd
 feeding study which compared HOSO, PO, 
interesterified PO (IPO, supplied by Archer Daniel Mills, Erith Kent prepared from the 
same material as the PO) and lard (LARD, purchased from Sainsbury PLC) high fat 
diets. The experimental high fat milk was made by blending light condensed milk 
(LCM) with 8% (w/w) test fat and provided to the mice in jars separate from the 
pelleted diet; prespecified comparisons were made between. PO, IPO and LARD groups 
vs HOSO and between PO, IPO and LARD groups. Abbreviations of the groups are 




Table 2. 5: Abbreviations used for different types of groups fed different types of diets 
in this study for the thesis 
Groups     Types of diets 
Low fat reference (LFR)   2% Corn oil (CO) pellets 
Low fat (LF)  2% CO pellets + LCM incorporated with 
1% CO 
High fat (HF) 18% Palm olein (PO) pellets + LCM 
incorporated with 8% PO 
DHA (HFDHA) 15% PO, 3% Docosahexaenoic acid 
(DHA) pellets + LCM incorporated with 
5% PO, 3% DHA 
EPA (HFEPA) 15% PO, 3% Eicosapentaenoic acid (EPA) 
pellets + LCM incorporated with 5% PO, 
3% EPA 
High oleic sunflower oil (HOSO) 18% high oleic sunflower oil (HOSO) 
pellets + LCM incorporated with 8% 
HOSO 
Palm olein (PO) Similar to HF, a different name is used to 
differentiate the 1
st
 from the 2
nd
 study 
Interesterified palm olein (IPO) 18% interesterified palm olein (IPO) 
pellets + LCM incorporated with 8% IPO 
Lard (LARD) 18% lard pellets + LCM incorporated with 
8% lard 
LFR, LF and HF were used in Chapter 5, 8 and 10. HF, HFDHA and HFEPA were 
used in Chapter 6, 9 and 11. HOSO, PO and IPO were used in Chapter 7. LCM stands 
for light condensed milk 
 
 
2.3.2 Feeding methods 
 It has been shown that overfeeding of high-fat liquid diet continuously at 
different time points can lead to the progression of NASH when compared to the mice 
fed ad libitum a solid high fat hypercaloric diet (Gaemers et al, 2011). For example, 
overfed animals with high fat liquid diets show characteristics of NASH such as 
obesity, hyperinsulinemia and loss of liver glycogen (Gaemers et al, 2011). In this 
thesis, mice were overfed ad libitum with condensed milk (CM) incorporated with 
different type of fats to match the solid food.   
For the first week of study, mice were acclimatised with the pellets and had 
access to water ad libitum without the condensed milk. After the acclimatization period, 
all mice except for LFR mice were provided with condensed milk through custom made 
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feeding jars. Pellets and CM were replaced every Monday, Wednesday and Friday for 6 
weeks. Body weights, pellet intake and CM consumption were recorded 3 times a week. 
An amount of diets equivalent to approximately 15% of their bodyweight per day was 
fed to the mice (Wolfensohn et al, 2003). By monitoring the growth of mice daily, mice 
were ensured to have healthy growth rates and no weight loss. 
 
2.3.3 Dissection 
After 7 weeks, mice were fasted overnight before culling. During sampling, 
blood samples were collected via decapitation and left to drain into a 2 ml sterile tube 
using a funnel. The blood was then left to coagulate at room temperature for 60 minutes 
and then centrifuged for 15 minutes at a speed of 350 g in a cooled bench-top 
centrifuged to obtain serum. Serum was then carefully pipetted from the top layer and 
immediately transferred to another sterile cryogenic tube, snap frozen in liquid nitrogen 
and stored in -80°C.   
Liver samples and fat pads were collected and weighed.  The liver was divided 
into 6 sections on a sterile petri dish placed on ice before being snap frozen in liquid 
nitrogen. Samples for histology were placed in formalin, without freezing.  Other tissues 
such as soleus, plantaris and gastrocnemius muscles were obtained from both hind legs 
and weighed. All the collected samples were stored in -80°C freezer for further 
analyses.  
After every dissection, all surfaces and equipment were washed with 70% (v/v) 
ethanol to keep cross-contamination to a minimal level. Liver samples needed for 
histology were stored in the formalin for 48 hours and sent to the histopathology 






2.4.1 Tissue preparation 
 Livers were sectioned using the cryostat, a microtome inside a freezer at a 
constant temperature of -20 °C and set to cut at 7 µm. The liver specimen was 
embedded in Optimal Cutting Temperature (OCT) compound on a cylindrical block 
until it becomes frozen. The sections were then picked up on a glass slide (Hendley-
Essex, microscope slides PTFE coated) ready for staining.  
 
2.4.2 Fixing and hydration 
Frozen sections were fixed in 4% paraformaldehyde (PFA) and rinsed in cold 
phosphate buffered saline (PBS). In the staining step, liver sections on the glass slide 
were covered with hematoxylin for 2 minutes and then rinsed under running water until 
the water turned clear for 2 minutes. Next, slides were dipped into blueing solution and 
allowed to stand in running water for another 2 minutes. Slides were immersed into 
80% ethanol for 2 minutes followed by 5 minutes in eosin. This was followed by the 
dehydration step whereby slides were dipped 5 times in 80% ethanol to rinse out excess 
eosin, followed by 2 minutes in 95% ethanol and another 2 minutes in 95% ethanol, 2 
minutes in 100% ethanol twice followed by 3 minutes in xylene for three times. Lastly, 
the slides with fixed, stained and dehydrated liver section was dotted with mounting gel 
(Permount) and covered with coverslips. Observations under the microscope showed 
nuclei which was stained dark blue (hematoxylin) and the cytoplasm was stained pink 
(eosin). 
 
2.4.3 Statistical analyses 
Histological evaluations were carried out by scoring the change observed in 
steatosis, inflammation and reticulin condensation in the liver. Analyses were 
preformed single-blinded by a recognised histopathologist in King’s College London, 
Denmark Hill. Histopathological scores for steatosis, inflammation and reticulin 
condensation are presented in counts and percentage within group with P values 





2.5 Serum analysis 
Serum analysis (glucose, alkaline phosphatase, aspartate aminotransferase, 
alanine transaminase, non-esterified fatty acids, cholesterol and triacylglycerols) were 
carried out by a clinical chemist, Dr. Tracy Dew at KingsPath King’s College London 
Hospital in Denmark Hill using laboratory diagnostics procedures. The parameters were 
determined by measuring the change of absorbance using the clinical analyser ADVIA 
1650 (Bayer Diagnostics, Newbury, UK). 
 
2.5.1 Determination of glucose 
Glucose measurements are used as part of a panel of biomarkers for the 
diagnosis and management of diabetes mellitus which is also a common risk factor for 
non-alcoholic steatohepatitis (NASH).  
In the sample, glucose was phosphorylated by the transfer of phosphate from 
adenosine triphophosphate (ATP) via the action of hexokinase. Glucose-6-phosphate 
formed in this reaction was oxidised by glucose-6-phosphate dehydrogenase. This was 
accompanied by the reduction of NAD
+
 to NADH which resulted in the increase of 
absorbance at 340 nm which was proportional to the glucose concentration in the 
sample. The increase in absorbance was converted to glucose concentration by reference 
to a previously determined calibrator and reagent blank. The effects of any interfering 




2.5.2 Determination of alkaline phosphatase (ALP)  
The enzyme alkaline phosphatase (ALP) is an indicator of bone formation and is 
raised in association with increased bone turnover. The production of hepatic ALP is 
also increased in cholestasis by bile induction due to liver injury and thus a raised ALP 
may also act as a marker for hepatotoxicity. Para-nitrophenyl phosphate (PNPP) is an 
artificial substrate for ALP. ALP hydrolyses PNPP to form free phosphate and para-
nitrophenol which is highly coloured (yellow). The reaction is monitored kinetically at 
410 nm, the rate of increase in absorbance being directly proportional to ALP activity in 
the sample and expressed as IU/L by means of a conversion factor. 4-
aminomethylpropanol (AMP) buffer maintains the required alkaline pH and acts as a 
phoshate acceptor, thus driving the reaction. Magnesium and zinc ions are present as 
ALP co-factors (Tietz et al, 1983). 
 
2.5.3 Determination of aspartate aminotransferase (AST)  
Aspartate transaminase (AST) is an intracellular (mitochondrial) enzyme present 
in most tissues, notably in the liver parenchymal cells, cardiac muscle and skeletal 
muscle. Raised levels of AST are associated with cell necrosis or increased cell leakage. 
AST is therefore markedly raised in hepatic inflammation or tissue damage and skeletal 
muscle damage and may be moderately raised in myocardial infarction. Reasonably, 
AST acts as a sensitive indicator of hepatitis, liver necrosis or liver transplant rejection 
and a relatively late indicator of myocardial infarction. The reaction is initiated by the 
addition of the substrate (2-oxoglutarate - contained in reagent 2) to the sample/co-
enzyme (reagent 1) mixture. 
                                                                               
L-aspartate + 2-oxoglutarate                                    oxaloacetate + L-glutamate 
 
Oxaloacetate + NADH                                                        malate + NAD+ 
 
The rate of NADH consumption by the 2nd (linked) reaction is monitored at 340 
nm and is directly proportional to the AST activity in the sample. Pre-incubation of the 
sample with the co-enzyme reagent removes any endogenous NADH by the conversion 
of oxaloacetate to malate by malate dehydrogenase which was added to the reagent 






2.5.4 Determination of alanine transaminase (ALT) 
Alanine transaminase (ALT) is an intracellular (cytosolic) enzyme present in 
most tissues but notably in the liver parenchymal cells and skeletal muscle. Raised 
levels of ALT are associated with cell necrosis or increased cell leakage.  ALT is 
therefore markedly raised in hepatic inflammation or tissue damage and skeletal muscle 
damage. ALT is thus a sensitive indicator of hepatitis, liver necrosis or liver transplant 
rejection. It is more specific for liver damage than AST (which is present to a much 
larger extent than ALT in cardiac muscle), and also more sensitive, being a cytosolic 
rather than mitochondrial enzyme. The reaction is initiated by the addition of the 
substrate (2-oxoglutarate - contained in reagent 2) to the sample/co-enzyme (reagent 1) 
mixture. 
                                                                
                   L-alanine  +  2-oxoglutarate                                pyruvate  +  L-glutamate 
                                                   
            Pyruvate  +  NADH                                                       lactate  +   NAD+ 
 
The rate of NADH consumption by the 2nd (linked) reaction is monitored at 340 
nm and is directly proportional to the ALT activity in the sample. Pre-incubation of the 
sample with the co-enzyme reagent before the first measurement is taken to remove any 
endogenous NADH by the conversion of pyruvate to lactate by lactate dehydrogenase 






2.5.5 Determination of serum non-esterified fatty acids (NEFA) 
NEFA in the blood is bound to albumin and is used as an important energy 
source of peripheral tissues. The amount of NEFA in serum depends on a balance 
between intake by the liver and peripheral tissues, and the release from adipose tissue. 
Serum NEFA levels are decreased by physical exercise, and increased by starvation, 
cold, fear or smoking and plays a key role in diabetes mellitus and insulin resistance. An 
increase in serum NEFA concentration is a risk marker of diabetes mellitus type 2 
developments. In this assay NEFA in the sample was converted to acyl-coenzyme A, 
AMP and pyrophosphoric acid (PPi) by the action of acyl-coenzyme A synthetase 
(ACS), under coexistence with coenzyme A (CoA) and ATP. Obtained acyl-coenzyme 
A is oxidised and yields 2, 3-trans-enoyl-CoA and hydrogen peroxide by the action of 
acyl-coenzyme A oxidase (ACOD). In the presence of peroxide, the hydrogen peroxide 
formed yields a blue purple pigment by quantitative oxidation condensation with 3-
methyl-N-ethyl-N-ß-hydroxyethyl-aniline (MEHA) and 4-amino-antipyrine (4-AA). 
Non-esterified fatty acids concentration is obtained by measuring absorbance of the blue 
purple colour (Okabe et al, 1980). 
 
RCOOH + ATP + CoA                                   Acyl-CoA + AMP + PPi 
 
Acyl-CoA + O2                                                               2, 3-trans-Enoyl-CoA + H2O2 
 
 
2.5.6 Determination of serum cholesterol  
Serum cholesterol was determined by an enzymatic method using cholesterol 
esterase, oxidase and peroxidase in a chemiluminescent reaction to produce a red 






2.5.7 Determination of serum triacylglycerols (TAG)   
The Siemens Advia method for the measurement of TAG is an enzymatic assay. 
TAGs are converted to glycerol and free fatty acids by lipase. The glycerol is then 
converted to glycerol-3-phosphate by glycerol kinase followed by its conversion by 
glycerol-3-phosphate-oxidase to hydrogen peroxide. A coloured complex is formed 
from hydrogen peroxide, 4-aminophenazone and 4-chlorophenol under the catalytic 
influence of peroxidase. The absorbance of the complex is measured as an endpoint 
reaction at 505/694 nm. 
 
2.5.8 Statistical analyses 
Serum analyses were analysed using statistical software packages SPSS version 
19. One-way analysis of variance (ANOVA) analyses followed by Tukey’s multiple 
comparison tests were performed as required by the data. Results of food intake, body 
weights, organ weights and serum analyses were presented in mean with 95% 
confidence interval. Chi-square test was carried out for the histology scores. Fatty acid 
composition and concentrations of adipose tissue, non-esterified fatty acids, 
triacylglycerols, cholesteryl esters and phospholipids were presented in mean ± standard 
deviation and one way ANOVA with Tukey’s multiple range test was used. P values 







2.6.1 Extraction of lipids from liver samples (Folch method) 
a)  Principle 
The protocol was carried out using Folch method (Folch, Lees & Stanley 1957) 
to extract lipids from liver tissues containing relatively low proportion of lipid 
compared to the proportion of water using chloroform-methanol (2:1 volume/volume) 
which acts as solvent. C-17 lipid standards were added to aid quantification. The Folch 
procedure also involved a wash with 0.9 % sodium chloride to remove protein 
contaminants.  
b)  Methods 
2 ml of chloroform: methanol (2:1 by volume) was added to the weighed liver 
sample (approximately 100 mg) and homogenized with the internal standards in a 
Teflon lined screw-capped tube. After homogenizing the liver samples, the whole 
mixture was vortexed for 15 to 20 minutes at room temperature. The homogenate was 
then centrifuged to precipitate the solids. Next, the supernatant was collected by 
filtering out the solid upper phase and washed with 0.4 ml of 0.9 % of sodium chloride 
solution. Then the mixture was vortexed and centrifuged at low speeds, 350 g to 
separate the two phases. The upper layer was removed and the lower chloroform phase, 
containing the lipids, was evaporated under vacuum in a rotary evaporator. The dried 
residues were reconstituted in 0.5 ml chloroform and applied to solid phase extraction 
(SPE) cartridge in preparation for lipid class separation  (Folch et al., 1957).  
 
2.6.2 Lipid class separation using solid phase extraction (SPE) 
a)  Principle 
 Lipid class were separated on amino SPE cartridges using the techniques 
described by Kaluzny et al, (1985). This method allowed for the initial separation of 
neutral lipids, phospholipids and free fatty acids. The set up of the experiment is shown 
in Figure 2.1. A second stage was then used to separate triacylglycerols and cholesterol 
sterols. By adding appropriate internal standards containing C-15 or C-17 fatty acids the 





Figure 2. 1: The separation of lipid classes using solid phase extraction  
 
 
b)  Methods  
Firstly, the aminopropyl cartridges were pre-washed twice with 2 ml hexane 
before use. Then, liver samples were applied to the columns and pulled through the 
chamber connected to the controllable vacuum port. Next, the dry lipid extracts were 
dissolved in 0.5 ml chloroform before being transferred to the columns.  
In the columns, 4 ml of chloroform: propan-2-ol (2:1) was added and fraction A 
(TAG, cholesterol esters and cholesterol) was collected. Then, 4 ml of 2 % acetic acid in 
diethyl ether was added and fraction B (non-esterified fatty acids) was collected. 
Consequently, 4 ml of methanol was added to collect fraction C (phospholipids). Then, 
fraction A (collected in the first separation) was dried and re-dissolved in 0.2 ml of 
hexane. After that, a new column was placed beneath the existing column and 4 ml of 
hexane was added to collect fraction D (cholesterol esters). Next, 6 ml of 1 % diethyl 
ether and 10 % dichloromethane in hexane were added and fraction E (TAG) was 
extracted. Lastly, the solvents in the screw cap tubes were capped and evaporated using 
the rotary evaporator.   
 
2.6.3 Methylation of lipids in the liver 
a)  Principle (Lepage & Roy 1986) 
 A low concentration of hydrochloric acid in methanol was used to minimise the 
formation of artifacts in this acid catalysed esterification reaction. Isomeric fatty acids 
were separated on a 60 m polar capillary column. 
b) Methods 
A solution of toluene:methanol, 20:80 (v/v) was made up in a glass beaker. 
Approximately 100 mg of liver sample was weighed and transferred to a glass tube with 
SPE aminopropyl 
cartridges 






a Teflon cap. Then, 2 ml of methanol:toulene solution was added to each sample. In a 
fume cupboard, 0.2 ml of acetyl chloride was added drop-wise with a glass dropper 
taking extra caution as the production of HCL causes an exothermic reaction. The glass 
tube was then sealed and heated for 2 hours at 60 ºC under water bath conditions. After 
2 hours, the tubes were allowed to cool for an hour.  
While waiting, anhydrous K2CO3 was powdered with a mortar and pestle and 6 
g of  K2CO3 were added to 100 ml distilled water to make solution of 6 % K2CO3 (aq). 
When the tubes were completely cooled, 5 ml of K2CO3 solution were added to the 
samples. Then the mixtures were vortexed and centrifuged at 5 ºC, 1500 g and 5 
minutes. At this stage, 2 clear visible layers were observed and the upper phase was 
transferred to a clean glass vial with a glass pipette for gas chromatography (Agilent 
7890/6890) analysis injected under split mode (50:1) using a 25 m BP60x SGE column 
0.22 mm (SGE, Australia) with hydrogen as a carrier gas with a constant flow rate of 1 
ml/min, injection temperature 250 ºC and detector temperature 280 ºC.  
The gas chromatography was programmed to remain at 180 ºC for 14 minutes 
and then ramped at 15 ºC/min to 220 ºC and held for 10 minutes.  The injection volume 
was 2 μL. Fatty acid methyl esters were identified by reference to the retention times of 
standards of known composition obtained from Sigma (Standards 189-1, 189-2, 189-3) 
and a secondary reference standard of MaxEPA (Seven seas Ltd, Hull, UK) for long 
chain n-3 fatty acids.  
 
2.6.4 Determination of total fatty acids in adipose tissue 
The fatty acid composition of adipose tissue was determined by direct 
methylation similar to methods in 2.6.3 (c) using 10 mg of adipose tissue. The fatty acid 
methyl esters were separated on an Agilent 7890/6890 gas chromatograph similar to 





Two-dimensional differential in-gel electrophoresis (2-D DIGE) was carried out 
to determine proteins altered in response to different diets for protein expression 
profiling. Following the lipidomics study, there were 3 distinct sets of comparisons: (1) 
LFR vs LF and HF groups, (2) HF vs HFDHA and HFEPA groups and (3) HOSO vs 
PO, IPO and LARD groups. Proteins samples were labelled with fluorescent dyes 
allowing one to differentiate between samples. The protein samples were first separated 
according to their isoelectric point (pI) and further separated according to their 
molecular mass also known as the 2
nd
 dimension. The combination of these 2 
parameters separate different proteins on a single gel, as many as several thousands. 
To achieve this equal amount of protein from paired samples (control and 
treated) were labelled with Cy3 (a red dye) and Cy5 (a blue dye) DIGE fluorescent 
dyes, respectively. Pooled internal standards were included in each gel by mixing all the 
samples in one vial and labelling it with Cy2 (a yellow dye). By using the pooled 
internal standard in each gel, every protein on the gel was compared internally to the 
same standard. This aided matching between gels (Alban et al, 2003). CyDye 
differential gel electrophoresis enables a direct comparison between 3 samples in 1 gel 
and therefore reduces the gel to gel variation (Tonge et al, 2001). All 3 dyes were 
charge and mass matched and spectrally resolved (Alban et al, 2003). In other words, 
regardless of which CyDye the samples are labelled with, the same protein migrates to 
the same position.  
After labelling, treated, control samples and internal standard were mixed and 
applied to the IPG gel strip. The proteins migrate along the IPG strip with the electric 
field and stay at their own pI position with no net charge. The pH value on the gel strip 
changes gradually along the strip which enhances the resolving power and loading 
capacity in the 1
st
 dimension. Moreover, the isoelectric focusing step is only suitable for 
separating proteins with pI values between 3 and 10. Proteins with out-of-range (ie <pH 
3 or >pH 10) values will be poorly separated by the IPG strips. Therefore it was 
important to ensure that the labelled samples are kept at a pH of 8.5. 
  Next, protein samples were separated by their molecular mass in the 2
nd
 
dimension of SDS polyacrylamide gel electrophoresis. SDS is an anionic detergent that 
denatures proteins and imparts a net negative charge to all proteins. The migration of 
proteins depends on their molecular mass and with an applied electric field the proteins 
move from the cathode to anode at different speeds. In order to minimise variations in 
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gel casting, commercially pre-cast DIGE gels (a low fluorescent 12.5% polyacrylamide 
gel) were used to achieve highly reproducible results.  
For spot-picking, the gels were cast and separation of 250 µg proteins were 
visualised by Coomassie blue instead of silver stain. Although Coomassie blue stain 
(Neuhoff et al., 1988) is 50 times less sensitive compared to the silver stain 
(Heukeshoven & Denrick 1985), Coomassie stain is more compatible for subsequent 
peptide mass fingerprinting by mass spectrometry (Gharahdaghi et al, 1999).  
Gels were scanned with an Ettan DIGE imager showing protein spots which 
were separated according to its isoelectric point and molecular weight. Single and 
overlaid images were obtained from ImageQuant software and subjected to DeCyder 
software for further statistical analyses. From the complex analysis of multiple gels, 
proteins of interest were picked automatically using the Ettan Spot Picker and each 
protein spot was identified by mass spectrometry. A diagrammatic summary of the 




Figure 2. 2: A diagrammatic summary of the whole process of 2-D DIGE protein 
expression profiling. 
 
Source: Applied Biosystems. In this study for the thesis, crossing gel analysis and 




2.7.1 Sample preparation  
Liver tissues were prepared in a planned randomization pattern (control; treated; 
treated; control) to decrease biasness. They were weighed four at a time to prevent the 
thawing of tissue which may degrade the protein in the sample. Approximately 100 mg 
of liver tissues were weighed individually in a sterile 2 ml tube and 2 x lysis buffer 
(containing DTT and IPG buffer; Table 2.6) was added immediately to the tube with 2 
mill balls. Samples were processed in batches of 20 to prevent clustering of protein 
homogenates from a single treatment group.  
The ratio of liver weight to volume of 2x lysis buffer was set at 1:10 hence 
approximately 1 ml of buffer was added to 100 mg sample. Liver tissues were 
simultaneously disrupted using the tissue lyser for 30 seconds at 30 kilo-Hertz (Figure 
2.3). The adapter sets were pre-cooled to 4°C before use to ensure that the samples were 
not affected by the heat generated during grinding. After homogenization, the samples 
were centrifuged at maximum speed for 15 minutes at 4°C and 15000 g to separate the 
protein homogenates from the insoluble material. Then, 100 to 150 µL of clear blue 
supernatant was transferred to a clean eppendorf tube in aliquots of 25 µL. Samples 
were stored in a -80ºC freezer, ready for the clean-up procedure.   
 
Figure 2. 3: Liver tissue was homogenised in protein extraction buffer for 30 seconds 
at 30 kilo-Hertz in pre-cooled adapter racks 
 
The hybridization oven for microarray chips in Section 2.8.2. Microarray chips were 
placed into the GeneChip Hybridization Oven 640 and the trays were loaded into the 









2.7.2 Protein quantification before clean-up 
a) Principles 
For total protein quantification, the assay was performed with 2-D Quant Kit 
(GE Healthcare), which is designed to quantify precipitating proteins by excluding 
interfering substances in the solution due to the specific binding of copper ions to the 
protein. Therefore, precipitating proteins were re-suspended in a copper-containing 
solution, leaving the unbound copper to be measured with a colorimetric agent. This 
generated a linear graph with a negative gradient showing the inverse relationship 
between the colour density and protein concentration.  
b) Methods 
The first protein quantification was to ensure that the protein concentrations 
were within the range of 1-100 μg of protein in 1-100 μL of homogenate, which is 
important for the next step of clean- up samples. On average, 10 µg of sample, 
containing approximately 100 µg of protein was cleaned up in batches of 12.The 
procedure for protein quantification was carried out according to the protocol provided 
by GE Healthcare.  
For this assay, 500 µL of precipitant was added to each tube, vortexed and 
incubated for 3 minutes at room temperature. This was followed by the addition of 500 
µL of co-precipitant to each tube and mixed briefly. The tubes were then centrifuged at 
10,000 g for 5 minutes for sedimentation of proteins. A small pellet was visible and the 
supernatant was decanted. These steps were repeated rapidly to avoid re-suspension of 
the pellet. Next, the tubes were repositioned carefully in the microcentrifuge with the 
cap-hinge and pellet facing outwards to bring the remaining liquid to the bottom of the 
tube. A micropipette was used to remove the remaining supernatant until there was no 
visible liquid in the tube.  
In the next stage of the assay, 100 µL of copper solution and 400 µL of distilled 
water were added to each tube and vortexed briefly to dissolve the precipitated protein. 
Then, 1 ml of working colour reagent was added to each tube and vortexed immediately 
to ensure instantaneous mixing. Tubes were incubated at room temperature for 20 
minutes. Then, 5 µL of samples including the BSA standards were transferred to a 96-
well plate and transferred to a plate reader set at absorbance 480 nm, using water as a 
reference. The absorbance of the assay solution decreased with increasing protein 
concentration. A standard curve was generated by plotting a graph of absorbance 
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against quantity of protein. This standard curve was used to determine the protein 
concentration of the samples (Table 2.6). 
 
Table 2. 6: Example of standard curve of BSA concentrations in serial dilutions with 
2D-Quant kit 
BSA standard (µL) Protein (µg) Absorbance at 480 nm 
0 0 0.347 
5 10 0.316 
10 20 0.295 
15 30 0.251 
20 40 0.231 
25 50 0.212 
 
 
2.7.3 Protein clean-up 
a)  Principles 
 The 2-D Clean-up kit is designed to quantitate precipitated proteins while 
filtering out the interfering substances such as detergents, salts, lipids, phenolics and 
nucleic acids in the solution. Pelleted proteins were re-suspended in labelling buffer 
which is compatible with 1
st
 dimension isoelectric focusing (IEF).  
b) Methods 
The standard procedure for the clean up process (2-D Clean-up Kit) was 
followed. First, 100 µl of protein sample was transferred to a 1.5 ml microcentrifuge 
tube and 300 µl of precipitant was added to the mixture, vortexed and incubated in ice 
for 15 minutes. This was followed by the addition of 300 µl of co-precipitant and 
vortexed briefly. The tubes in a microcentrifuge were centrifuged at 12,000 g for 5 
minutes and a small pellet was visible after centrifugation. The supernatant was 
removed without disturbing the pellet. Tubes were repositioned with the cap-hinge and 
pellet facing outwards and centrifuged to bring the remaining liquid to the bottom of the 
tube. The remaining supernatant was removed with a micropipette. 
A 40 µl volume of co-precipitant was layered on top of the pellet and the tube 
was left in ice for 5 minutes. Again, the tube was reposition carefully as before and 
centrifuged for 5 minutes. Next, 25 µl of distilled water was pipetted on top of each 
pellet and vortexed for 10 seconds. The pellet was dispersed but not dissolved in the 
water. Then, 1 ml of pre-chilled wash buffer and 5 µl of wash additive were added and 
vortexed until the pellet was fully dispersed. The tubes were incubated at -20°C for 30 
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minutes, vortexed for 30 seconds every 10 minutes. At this stage, the tubes were stored 
at -20°C for up to 1 week with minimal protein degradation.  
After incubation, the tubes were centrifuged in a microcentrifuge at 12,000 g for 
5 minutes. The supernatant was removed and discarded. The visible white pellet was 
allowed to air dry for 5 minutes, without over-drying to prevent the pellet from 
becoming difficult to re-suspend. The pellets were then re-suspended in 5 µl of labelling 
buffer until completely dissolved (Table 2.7). The pellets were then quantified and the 
concentration of protein was determined more accurately after the clean-up process.  
 
Table 2. 7: Buffers prepared for DIGE sample preparation 
Solutions for sample preparation 
Bromophenol blue solution (BPB) 
1.00 % (w/v) Bromophenol blue 
0.06 % (w/v) Tris 
2 x Lysis buffer 
7.00 M Urea 
2.00 M Thiourea 
4.00 % (w/v) CHAPS 
0.04 % (w/v) BPB Solution 
2.00 % (w/v) DTT 
2.00 % (w/v) IPG Buffer ph 3-10 
Labelling buffer 
7.00 M Urea 
2.00 M Thiourea 
4.00 % (w/v) CHAPS 
0.04 % (w/v) BPB Solution 
30.00 nM Tris 
 
 
2.7.4 Protein quantification after clean-up 
a) Principles 
 The Pierce assay was used in the 2
nd
 protein quantification because it is a faster 
method compared to the 2-D Quant kit which is laborious. This Pierce assay is versatile 
and works with a wider range of detergents and reducing agents. Hence it is suitable for 
quantifying proteins in labelling buffer. The assay is based on the binding of dye metal 
complexes to proteins in an acidic solution. The measurable absorbance of 660 nm 
results from the binding of the reddish dye-metal complex (colour of the Pierce assay) 
turning green depending on the volume of the bound proteins. Proteins were quantified 
based on the basis of the absorbance obtained from a BSA standard protein dilutions 
assayed alongside the cleaned-up samples in a 96-well microplate.    
83 
 
b)  Methods 
First, 20 μl of each sample was transferred to a clean eppendorf tube. Samples 
were vortexed and centrifuged followed by the microplate procedure as mentioned in 
the protocol. Then, 5μl of each BSA standards with concentrations of 0.125, 0.250, 
0.500, 0.750, 1.000, 1.500 and 2.000 μg/μl were pipetted into the microplate wells in 
duplicate (Table 2.8). Consequently, 5μl of 1:20 dilutions of samples were pipetted into 
the labelled microplate wells followed by the addition of 150 μl of Protein Assay 
reagent into each well.  
 
Table 2. 8: Example of standard curve of BSA concentrations in serial dilutions with 
the Pierce assay 










A standard curve of absorbance at 660 nm against BSA standards and sample 
concentrations in μg/ml was plotted to determine the protein concentrations. From the 
standard curve, the protein concentrations were calculated and the volume of protein 
required for 50 µg of protein was calculated for protein labelling. The procedures were 
carried according to the protocol provided with the kit. 
 
2.7.5 Protein labelling using CyDye 
Before labelling, the samples were adjusted with 100 mM NaOH if necessary to 
a pH of 8.5 using pH indicator paper. Five microlitres of every CyDye dyes were 
reconstituted with 99.8% anhydrous dimethylformamide (DMF) to a concentration of 5 
nmol/µL. The stock solutions of Cy2 (deep yellow), Cy3 (deep red) and Cy5 (deep 
blue) were stable at -20 °C for 3 months. 
 The working solution was prepared from the stock solution by allowing the 
CyDye in the -20°C freezer to warm for 5 minutes at room temperature. Then, 2 parts 
dye to 3 parts DMF were mixed in a new vial, vortexed vigorously and centrifuged for 
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30 seconds at 12,000 g. The final concentration of each CyDye was 400 pmol/µL and 
ready for labelling. 
 A volume of sample equivalent to 50 µg protein was transferred to a 
microcentrifuge tube and 1 µL of diluted CyDye was added to it. The samples and dye 
were mixed and centrifuged for 10 seconds and left on ice for 30 minutes in the dark. 
After 30 minutes, 1 µL of 10 mmol/L lysine was added to stop the reaction. Again, 
samples were mixed, centrifuged and left on ice for 10 minutes in the dark.  
For the internal standards, the amount of protein required was calculated, 
depending on the number of gels in the experiment. For the comparison of LFR, LF, 
HF, HFDHA and HFEPA groups there were 20 gels in total and therefore a total of 40 
samples were pooled as the internal standard. The final concentrations of dye-labelled 
samples and internal standards were 400 pmol per 50 µg protein. The dye-labelled 
samples and standards can be stored for 3 months in -80°C in the dark.  
 
2.7.6 First dimension separation - Isoelectric focusing (IEF)  
i)  Pre-rehydration of IPG strips 
Twenty four centimetres long Immobiline DryStrips and rehydration solution 
were used for cup loading of samples in an Immobiline DryStrip Reswelling Tray. 
Rehydration of IPG strips were carried out 6 hours before sample application. The re-
swelling tray was levelled horizontally on the bench. Then, 450 µL of rehydration 
solution (Table 2.9) was pipetted into each groove of the re-swelling tray as a streak. 
The cover film on the IPG strip was removed and the strip was placed gel surface down. 
Air bubbles were removed by lifting the IPG strip carefully using forceps with bent tips 
and lowered carefully again. Then, 3 ml of DryStrip cover fluid was pipetted onto the 
IPG strip starting from the ends towards the centre.  The sliding lid was closed and the 
whole tray was left over night (at least 6 hours) at room temperature.  
ii)  Isoelectric focusing (1st dimension separation) 
The principal of isoelectric focusing allows the migration of proteins towards the 
anode and cathode along a pH gradient to meet their isoelectric point (pI) where the net 
charges are zero. The focusing effect takes place to avoid gain of charge when a protein 
diffuses away from its pI by migrating the protein back to its pI. From the 1
st
 dimension 
separation, the pI of the proteins can be estimated with a calibration curve using protein 
markers. This method was used for preparative applications to purify the proteins in the 
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sample, ready for the 2nd dimension separation. The quality of 2-D separation can be 
determined by the pattern on graph of voltage against current 
Samples were mixed with rehydration buffer and underwent rehydration loading 
overnight on 24 cm Immobiline DryStrips. After rehydration loading, the strips were 
transferred to a Ettan IPGphor Cup Loading Manifold (GE Healthcare) connected to the 
Ettan IPGphor Isoelectric Focusing System using the Ettan IPGphor II Control Software 
(version 1.01, Amersham Biosciences) following the manufacturer’s instructions. More 
detailed steps on isoelectric focusing are provided in the GE protocol including the 
refocusing steps which were carried out before loading the samples onto the gels. 
iii)  Strip equilibration 
 The equilibration solution (Table 2.9) was prepared and the stock solution was 
aliquoted and stored at -20°C for further use. Then, 200 ml of equilibration buffer was 
thawed at room temperature. After this, 1 g of DTT and 2.5 g of iodoacetamide was 
weighed out separately. 
 After the IEF, the proteins on the IPG strips were refocused for 15 minutes 
before equilibration. The electrodes, loading cups and electrode pads were removed 
from the Manifold and the dry cover fluid was poured. Then, 1 g of DTT was added to 
100 ml equilibration buffer, mixed thoroughly and poured into the manifold. The 
manifold was placed on an orbital shaker for 15 minutes.  Next, 2.5 g of iodoacetamide 
was added to 100 ml equilibration buffer and the steps were repeated. Steps were taken 
to ensure strips were ensured not to stay longer than 15 minute in both equilibration 





Table 2. 9: Buffers for the rehydration of Immobiline DryStrips strips 
IPG Strip Rehydration 
Rehydration solution 
99.50 % (v/v) DeStreak solution 
0.50 % (v/v) Pharmalyte pH 3-10 
Equilibration buffer 
6.00 M                        Urea  
2.00 % (v/v)                        SDS  
50.00 M Tris-Cl pH 8.8 
0.02 % (v/v) BPB Solution 
30.00 % (v/v)                        Glycerol  
 
 
2.7.7 Second dimension separation - 2-dimensional difference gel electrophoresis 
(2D- DIGE) 
i) Preparation for SDS running buffer and agarose sealing solution 
SDS running buffer was prepared in advance by dissolving 0.25 mol/L Tris, 1.92 
mol/L glycine and 1% SDS in MilliQ water to a final volume of 1 L using a magnetic 
stirrer. The SDS running buffer (10x concentrations) was stored at 4°C and later diluted 
before use. Besides that, agarose sealing solution was also prepared by mixing 0.5 g of 
0.5% agarose, 200 µL 0.02% bromephenol blue and 10 ml of SDS running buffer (10 x 
concentrations) in MilliQ water to a final volume of 100 ml. Stock solution was 
aliquoted in to 15 ml centrifuge tubes and stored at room temperature.  
ii) Procedure for 2
nd
 dimension 
 For the Ettan DALTtwelve tank, the valve of tank was set to circulate and 950 
ml running buffer (10x concentrations) was poured into the lower buffer tank. The tank 
was filled with 9.5 L of MilliQ water, set to 22°C and pump was set to ‘ON’ to  allow 
the concentrated running buffer to mix in the tank.  
The immobilized pH-gradient (IPG)-strips were transferred onto the 2
nd
 
dimension slab-gels and sealed with 0.5% (w/v) agarose solution. The gels were then 
slid into the slots of Ettan DALTtwelve System's electrophoresis tank followed by the 
2
nd
 dimension separation. The electrophoresis run was set according to the 
recommended run conditions: 1 Watt/gel for 1 hour followed by 17 Watt/gel for 5 
hours. 
 
2.7.8 Gel imaging 
After the second dimension, the gels were removed from the tank and the 
surfaces were cleaned with water and wiped with lint-free tissue. The excess water on 
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the glass plates was removed with a glass plate squeegee and left to air dry to prevent 
streakiness on the surface. 
The glass plates were scanned using the Ettan DIGE Imager with the imager 
control software which has a pre-set exposure and emission filter for each CyDye. A 
quick test scan was carried out randomly on a selected gel to determine the exposure 
times for each CyDye and the exposure areas were adjusted so that none of the areas on 
the gel presented protein spots that were over-saturated by referring to the pixel values. 
Target signals were achieved in pixel values ranging between 30,000 to 55,000 counts 
with exposure time for Cy2, Cy3 and Cy5 at 0.8, 0.3 and 0.5 seconds, respectively. All 
gels were scanned using the same exposure time and the images obtained were analysed 
using Ettan DIGE Imager. 
After scanning, gels were cropped according to the region of interest using 
Image Quant Software.  
 
2.7.9 Data analysis for proteomics 
Data obtained from the scanned images were analysed using the DeCyder 2-D 
Differential Analysis Software with the DeCyder™ Extended Data Analysis Extension 
(GE Healthcare). The gel images were automatically loaded on to the batch processor 
and the area of interest was set to full image. The spot exclusion filter was set as 
follows: Slope > 1; Area > 100; Peak height < 100 or > 50,000 and Volume < 100. 
Images were matched using Differential In-Gel Analyses (DIA). Among all the 
images, the one with the average number of spots was assigned as the Master gel. All 
other gels were matched to the Master gel using the Biological Variation Analysis 
(BVA) module. Each gel image was then assigned to a group and given a sample ID. 
After batch-processing, the gels were matched using the land marking option in the 
BVA module. Then, 10 clearly separated landmarks were used to match all gels to 
enhance the inter-gel matching accuracy. Thereafter, standard spot maps from each gel 
were matched using the Match function, followed by statistical analysis of protein 
abundance between samples using BVA module. One-way analysis of variance 
(ANOVA) analyses followed by Tukey’s multiple comparison tests was carried out to 
retain spots with P Values < 0.05. 
Spots of interest were selected and sent for further analyses to the Cambridge 
Proteomics Centre for identification by liquid chromatography tandem mass 
spectrometry (LC/MS-MS).  
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2.7.10 Preparative gels for spot-picking 
i) Preparing cassettes with bind silane 
The glass plates were cleaned with 5% Decon 90 solution overnight to remove 
any debris, gel pieces or keratin contamination. They were then rinsed with MilliQ 
water and wiped with lint-free tissue. Alternatively, water marks were avoided by 
letting the glass plates to air dry. Two self-adhesive internal reference marker stickers 
were applied on the short glass plate as shown in Figure 2.4. The spot picker camera 
identifies the internal reference markers. 
 
Figure 2. 4: Positioning of the internal reference (IR) markers on the glass plate to 











The bind-silane working solution was used for binding the gel to the glass plates 
and was made up of 8 ml of ethanol, 200 µL of acetic acid, 10 µL of bind-silane and 1.8 
ml of MilliQ water. Then, 4 ml of the bind-silane solution was pipetted onto the plate 
and distributed equally over the plate with a lint-free tissue. The plates were covered to 
avoid dust contamination and left to dry for an hour. After 1 hour, the plates were 
polished with lint-free tissue and moistened with 2 ml of MilliQ water. Then, gels were 
cast on the same day using the Ettan DALTtwelve gel caster which can cast up to 14 
gels. Instructions for gel casting can be referred to the protocol provided by GE  
ii) Gel casting 
 The SDS gel buffer Tris-Cl pH 8.8 was prepared by dissolving 1.5 mol/L Tris-
base and 0.4% SDS into 800 ml of MilliQ-water. The pH of the Tris buffer was adjusted 
to pH 8.8 with 4 mol/L hydrochloric acid. Then the buffer was made up to a final 
volume of 1 L and stored at 4°C. This was followed by the preparation of 10% 
ammonium persulfate (APS) solution. The APS solution was prepared fresh before use. 
3.5 cm 3.5 cm 




 The 12.5% homogenous monomer gel casting solution was prepared fresh, de-
gassed for 15 minutes while stirring and pre-cooled at 4°C. 175 ml of acrylamide, bis 
solution, was deionized with 3 g of mixed bed ion exchanger for 10 minutes and filtered 
before use. Then deionized acrylamide bis solution, Tris-HCL pH 8.8 and 100 % 
TEMED were dissolved in MilliQ-water. Lastly, 10% APS was added to the solution 
right before pouring into the gel caster. 
 For the displacing solution, Tris-Cl pH 8.8, 50 % glycerol and 0.02 % 
bromophenol blue solution were mixed and dissolved in MilliQ-water. After preparing 
all solutions required, the gel caster was assembled according to the manufacturer’s 
protocol. Clear low fluorescent glass plates were placed alternately with separator sheets 
into the tilted caster resting on the supported legs. The gel caster was sealed in place and 
tightened evenly without applying too much pressure and the sealing gasket was 
compressed to prevent leakage.  The caster was tip to the front and levelled horizontally 
on the bench. 
Four ml of APS was added to the monomer gel casting solution and mixed 
gently to avoid air bubbles. The gel solution was poured directly into the gel caster 
immediately until it reached 3 cm below the upper edges of the casting cassettes and air-
bubbles trapped in between the glass plates were removed. Displacing solution was 
poured to fill the V-chamber and the sloped bottom of the caster which will gave rise to 
the gel solution in the cassettes edges being 1cm below the upper edges whereby a thin 
blue layer was visible at the bottom of the cassettes. Then, 0.1% SDS overlay solution 
was sprayed over the casted gels immediately and covered with cling film to prevent 
loss of moisture from the gel. The gel caster was left at room temperature overnight to 
allow polymerisation and gel setting. The gels were either used immediately or stored in 
1x SDS running buffer at 4° until required. 
iii) Protein samples for preparative gels 
 For preparative gels, a total of 250 µg of pooled internal standard was used 
whereby 50 µg was labelled with Cy5 and 200 µg remains unlabelled. Under these 
measurements, optimum results were obtained when matching preparative gels to 
analytical DIGE gels. First and second dimension run were performed as described in 
Section 2.10.6 and 2.10.7 with the exception that the low fluorescent gel cassettes were 
carefully separated allowing preparative gels to bind to the short glass plates. The gels 
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were rinsed in deionised water and stained with Deep Purple fluorescent stain following 
the protocol provided.  
 Briefly, the gels were fixed in pre-fixing solution for 45 minutes and left in 
fixing solution overnight. The next day, gels were placed in pre-buffering solution for 
40 minutes and then replaced after 20 minutes followed by staining solution. After 1.5 
hours, the gels were placed in washing solution for 15 minutes twice and soaked in acid 
solution for 10 minutes. Steps were carried out in re-sealable polyethylene bag covered 
with aluminium foil to prevent light on the orbital shaker. All post staining buffers and 
solutions are presented in Table 2.10. The post stained gels were scanned on an Ettan 
DIGE Imager as described in Section 2.10.8. The spot-maps were analysed and spots of 
interest were picked for protein identification.   
 
Table 2. 10: Solutions for post staining of preparative DIGE gels 
Post stain buffers and solutions 
Prefixing 
15.00 % (v/v) Ethanol 
10.00 % (v/v) Glacial Acetic acid 
Fixing/ acidification 
15.00 % (v/v) Ethanol 
1.00 % (v/v) Citric acid 
Prebuffering 
6.20 % (w/v) Boric acid 
3.80 % (w/v) Sodium hydroxide 
Staining 
0.50 % (v/v) Deep purple 
6.20 % (w/v) Boric acid 
3.80 % (w/v) Sodium hydroxide 
Washing 15.00 % (v/v) Ethanol 
All buffers were prepared in deionised water 
 
 
2.7.11 Spot picking 
Proteins of interest in Chapter 3 were picked with an automated robotic, namely 
the Ettan Spot Picker together with the Instrument Control Software. Firstly, spots of 
interest were detected on preparative gels based on its x and y coordinates in reference 
to the 2 marker spots (Figure 2.6). Then a 1.4 mm picker head was chosen for 1 mm 
gels and the robot’s camera was calibrated according to the manufacturer’s protocol. 
Briefly, a sheet of white paper was placed on the gel tray in the picker station and a 
camera calibration foot was placed on the picker head with a defined spot in the centre 
of the paper sheet. The picker head was directed to the recorded x and y coordinates and 
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then returned to its original position. The calibration was verified to be successful when 
picker head returned to the calibration foot 3 times consecutively. 
After calibration 2 plate holders were placed in the tray filled with ultrapure 
water to 5 mm below the upper edges. A preparative gel was placed in the tray with the 
acidic corner close to the home position of picker head and fixed in place with plate 
holders. Then, 96 well digester plates with small holes in the bottom were placed into 
standard 96 well micro plates in the racks next to the gel tray. This was to prevent 
leakage when dispensing solution from the digester plates and avoid contamination of 
samples.  
The height of picker head versus the horizontal position (z-coordinate) of the 
preparative gel was set and the picker head was moved towards a location outside the 
picking area for trial. The picker head was lowered until it touched the glass backing 
and further adjusted until a small gap of 1 to 2 mm was seen between the holder and 
picker head. This optimal position allows for precise excision of gel plugs without 
causing damage to the glass plates and therefore saved as gel z-coordinate. The 
horizontal location, x and y-coordinate of digester plates was adjusted if necessary.  
The picking parameters were set according to the manufacturer’s instructions 
and solutions for picking (ultrapure water and 20% ethanol) were prepared and used to 
prime the system before picking protein spots of interest. The pick list was uploaded 
and the software gave information on the volume of buffer required to pick all the spots. 
After priming, the system was set up and the picker head was positioned according to 
the micro-plates and rinse station. Once the picker head was placed appropriately in the 
rinse station, the picker head was manoeuvred according to the picking parameters. The 
gel plugs excised from the preparative gel were then transferred to 96 well micro plates 
and subjected to LC MS/MS analysis.  
 
2.7.12 Mass spectrometry 
All LC-MS/MS experiments were performed using an Eksigent NanoLC-1D 
Plus (Eksigent Technologies, Dublin, CA) HPLC system and Linear Trap Quadrupole 
(LTQ) Orbitrap mass spectrometer (ThermoFisher, Waltham, MA). Separation of 
peptides was performed by Dr. Mike Deery, using reverse-phase chromatography at a 
flow rate of 300 nL/min and a LC-Packings (Dionex, Sunnyvale, CA) PepMap 100 
column (C18, 75 µM i.d. x 150 mm, 3 µM particle size). Peptides were loaded onto a 
pre-column (Dionex Acclaim PepMap 100 C18, 5 µ particle size, 100A, 300 µM i.d x 
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5mm) from the auto-sampler with 0.1% formic acid for 5 minutes at a flow rate of 10 
µL/min. After this period, the ten port valve was switched to allow elution of peptides 
from the pre-column onto the analytical column. Solvent A was water + 0.1% formic 
acid and solvent B was acetonitrile + 0.1% formic acid. The gradient employed was 5-
50% B in 40 minutes.  The LC eluant was sprayed into the mass spectrometer by means 
of a New Objective nanospray source. All m/z values of eluting ions were measured in 
the Orbitrap mass analyzer, set at a resolution of 7500.  Peptide ions with charge states 
of +2 and +3 were then isolated and fragmented in the LTQ linear ion trap by collision-
induced dissociation and MS/MS spectra were acquired. The LTQ was to improve 
capacity, trapping efficiency and scan speed.  
Post-run, the data was processed using Bioworks Browser (version 3.3.1 SP1, 
ThermoFisher).  Briefly, all MS/MS data were converted to dta (text) files using the 
Sequest Batch Search tool (within Bioworks).  The dta files were converted to a single 
mgf file using a SSH script in the SSH Secure Shell Client program (Version 3.2.9 
Build 283, SSH Communications Corp.). These combined files were then submitted to 
the Mascot search algorithm (Matrix Science, London UK) and searched against the 
NCBI mouse database, using a fixed modification of carbamidomethyl and a variable 
modification of oxidation. All LC-MS/MS experiments were carried out by Dr. Mike 
Deery and his colleagues at the Cambridge Proteomics Centre, UK. Proteins in Chapter 
3 were picked by the robot and only proteins that were abundant in Chapter 7 were 
picked by hand.  
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2.8 MiRNA expression in mice fed different types of dietary fats 
2.8.1 Procedures of total RNA extraction 
Frozen mouse liver samples (approximately 100 mg each) were submerged in 1 
ml of TRIzol Reagent (Invitrogen Life Technologies, Paisley, UK) in a 2 ml 
microcentrifudge tube with 2 mill balls and homogenised for 60 seconds using an 
electrical tissue lyser (Qiagen). Five hundred µl of homogenate was transferred to clean 
2 ml microcentrifuge tube and centrifuged at 12000 g for 10 minutes at 4°C in order to 
remove cell debris or unhomogenised particles from samples. The supernatant was 
transferred to a fresh tube and incubated for 5 minutes at room temperature.   
After incubation, 100 µl of chloroform (0.2 ml of chloroform per 1 ml of TRIzol 
Reagent) was added, shaken vigorously by hand for 15 seconds and incubated for 3 
minutes at room temperature. The solution was centrifuged at 12000 g for 15 minutes at 
4°C and the aqueous and organic phases were observed. Then, 200 µl of aqueous phase 
was transferred to a fresh 0.6 ml microcentrifuge tube and 250 µl of 100% isopropanol 
(0.5 of isopropanol per 1 ml of Trizol used for initial homogenization) was added to 
precipitate RNA. The isopropanol mixture was incubated for 10 minutes at room 
temperature and centrifuged at 12000 g for 10 minutes at 4°C to pellet the precipitated 
RNA.   
After formation of the RNA pellet, the supernatant was removed and the RNA 
pellet was washed with 500 µl of 75% ethanol (1 ml of ethanol per 1 ml of Trizol used 
for initial homogenization), centrifuged again at 7500 g for 5 minutes at 4°C and dried 
in the fume hood at room temperature for 30 minutes. The air-dried RNA pellet was 
dissolved in 40 μl of RNase-free water (Ambion) and the extracted RNA was 
resuspended in the RNase-free water. The dissolved RNA samples were aliquoted in 5 




2.8.2 Measurement of RNA quantity and purity 
Quantitation of RNA was performed using NanoDrop
®
 ND-1000 
Spectrophotometer with the selected module of “Nucleic Acid” according to the 
manufacturer’s instructions. The NanoDrop® ND-1000 Spectrophotometer (Figure 2.5) 
provided not only RNA concentration i.e., calculated from absorbance at 260 nm, but 
also purity by observing the ratio of sample absorbance at 260 nm and 280 nm, 
respectively. The maximum absorbance of nucleic acid and proteins are 260 nm and 280 
nm respectively. 
In this method, 1 µl of extracted RNA sample was pippetted onto the lower 
measurement pedestal of the Nanodrop. The upper measurement pedestal was closed 
and the spectral measurement was then performed according to the operating software 
provided. The software automatically estimated the concentration (ng/µl) of nucleic 
acids and the ratio of absorbance 260 nm and 280 nm. The 260 nm/280 nm ratio 
indicates the purity of RNA which should be approximately 1.9-2.1.  Low absorbance 
ratio of 260/280 means low concentration of nucleic acid. The sample’s absorbance was 
obtained according to the following formula: Absorbance = -log (Intensity sample/ 
Intensity blank). 
 
Figure 2. 5: The NanoDrop
®
 ND-1000 Spectrophotometer used to measure RNA 
concentration and also purity of RNA by observing the ratio of sample absorbance at 







2.8.3 Measurement of quality of RNA  
RNA quality was assessed using Agilent 2100 bioanalyzer RNA 6000 
NanoChip. The concept of RNA quality assessment is based on miniaturized platform 
technologies. RNA samples were driven electrophoretically. RNA was microfabricated 
and separated according to their size by molecular sieving, and then detected by laser 
induced fluorescence detection.  
Results were analysed by Agilent 2100 Bioanalyzer software which 
automatically generates a ribosomal ratio of 28S/18S ratio and RNA integrity number 
(RIN) as the presentation of RNA quality. The 28S/18S ratio of 2 is considered to 
indicate good quality. When RNA degradation occurs, the rRNA ratio will decrease. 
With the RNA integrity number (RIN), it has a systemic number from 1 to 10 to present 
the quality of RNA.  For example, a RIN of 1 indicates the substantial degradation of 
RNA, whereas a RIN of 10 indicates the best RNA quality. The quality of RNA was 
also visually determined via electropherogram and gel-like image output was generated 
(Figure 2.6).  
The procedures for estimating RNA quality included 3 steps of preparation.  
After an initial measurement of RNA concentration, the concentrations of samples were 
adjusted within 25-500 ng/µl to assess RNA quality using the bioanalyzer in 3 steps: 
(i)  Gel preparation   
550 µl of RNA 6000 Nano gel matrix was placed into a spin filter and 
centrifuged at 1500 g for 10 minutes.  After centrifugation, 65 µl filtered gel was 
aliquoted into 0.5 ml RNase-free microcentrifuge tubes.  
(ii) Preparation of gel-dye mix  
RNA 6000 Nano dye concentrate was left at room temperature for 30 minutes 
and vortexed for 10 seconds and spun down. 1 µl of dye was added into 65 µl of 
prepared filtered gel and mixed. The gel mixture was spun down at 13000 g for 
10 minutes at room temperature.  
(iii) Loading of Gel-dye mix, RNA 6000 Nano Marker, ladder and samples onto chip  
Before loading the RNA 6000 Nano marker, ladder and samples, a new RNA 
chip was placed on the Chip Priming Station and 9 µl of gel-dye mix was loaded 
into the well with “G” marked.  After closing the Chip Priming Station, pressing 
the plunger and releasing the clip, 9 µl of gel-dye mix in each of 2 additional 
gel-dye wells was loaded again.  After loading the gel-dye mix, 5 µl of RNA 
6000 Nano Marker (for each well) was pipetted into the Ladder well and into 
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each of 12 sample wells. Then, 1µl of ladder and 1µl in each of 12 samples wells 
was then loaded into the wells. After the completion of gel-dye mix, marker, 
ladder and samples loading, the chip was placed on the adapter and vortexed at 
280 g for 1 minute.  After vortexing, the chip was put in the bioanalyzer for 
assessment of RNA integrity. 
 
Figure 2. 6: Visual determination via electropherogram and gel-like output generated 
from the bioanalyzer for quality check 
 
e25 e36   
              
Image e25 represents good quality RNA whereas e26 represents RNA degradation. The 
2 distinct peaks in e25 represent the 18S and 28S ribosomal. Ribosomal ratio of 
28S/18S of 2 is considered to indicate good quality; and the ratio decreases if RNA 
quality is low. 
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2.9 Affymetrix miRNA Arrays 
MiRNAs are short, single-stranded RNAs that regulate gene expression by 
partial complementary base pairing to specific mRNAs. MiRNAs are non-coding RNAs 
which is becoming an important component in investigating biological processes such 
as transcriptional gene silencing and translational repression.  
The Affymetrix miRNA array consists of the most comprehensive miRNA assay 
system covering 71 organisms on a single array which includes human, mouse, rat, 
canine, monkey and additional 922 human small nuclear RNAs (snoRNAs and 
scaRNAs). SnoRNA and scaRNA are short non-translated RNAs that play a role in 
processing of ribosomal RNAs. In addition the Affymetrix array includes 4 copies of 
each miRNA probe distributed on the array. For each snoRNA and scaRNA, there are 
11-probes. All 46,228 probe sets representing 6703 miRNA sequences are perfect match 
probes which mean the probes are complementary to the nucleic acid sequences of the 
miRNAs. The arrays are biotin labelled (FlashTag Biotin HSR) using a Genisphere 
RNA labelling kit. Sequences are from Sanger miRNA (V.11) or Ensembl databases 
and snoRNABase. 
RNAs were subjected to a brief poly-A tailing reaction which is essential for 
translation and mRNA stability. The FlashTag Biotin HSR kit labels all RNA samples 
including low molecular weight RNA for analysis by Affymetrix GeneChip miRNA 
Arrays. The following step is the ligation of the biotinylated signal molecule to the 
target RNA samples at the 3’ end of the RNA. The ultrasensitive biotin labelling of the 
FlashTag Biotin HSR is due to Genisphere proprietary 3DNA dendrimer which is a 
branched structure of single and double-stranded DNA conjugated with numerous 
labels.  
 
2.9.1 Labelling of RNA   
In every experimental group, 6 samples of total RNA from individual mice were 
pooled in equal concentrations making up a total of 5000 ng of RNA and volumes were 
adjusted to 35 µl with Nuclease-Free water (Table 2.11). The labelling procedure 
started with poly (A) tailing followed by a ligation step as described:  
(i) Poly (A) Tailing 
From the pooled sample, 8 µl of RNA was transferred to ice and 2 µl of RNA 
Spike Control Oligos were added before returning samples to ice. Adenosine-5'-
triphosphate (ATP) mix was diluted in 1 mM Tris according to the protocol 
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provided by the manufacturer. A master mix of 9 µl of 10x reaction buffer, 9 µl 
of 25 mM MnCl2, 6 µl of diluted ATP mix and 6 µl of poly(A) polymerase 
(PAP) enzyme was prepared. Then, 5 µl of master mix was added to 10 µl 
RNA/Spike Control Oligos for a volume of 15 µl. Samples were 
microcentrifuged and incubated in a 37°C heat block for 15 minutes. 
(ii) Ligation 
Fifteen microlitres of tailed RNA was microcentrifuged and placed on ice. Then, 
4 µl of 5x FlashTag Biotin Ligation mix was added followed by 2 µl of T4 DNA 
ligase. The samples were mixed gently, microcentrifuged and incubated at 25°C 
for 30 minutes. Next the reaction was stopped by adding 2.5 µl of HSR Stop 
solution, mixed and microcentrifuged. A total volume of 23.5 µl of biotin-
labelled sample may be stored on ice for up to 6 hours or at -20°C for up to 2 
weeks prior to hybridization on Affymetrix GeneChip miRNA arrays.  
 
Table 2. 11: Samples pooled from the RNA extraction for microarray analysis 
Samples 
Absorbance ratio (260/280) RNA concentrations (ng/µl) 
1  2 1 2 Average 
Pool LFR 2.10 2.07 142.03 143.71 142.87 
Pool LF 2.10 2.10 136.62 137.02 136.82 
Pool HF 2.10 2.07 153.26 153.46 153.36 
Pool HFDHA 2.08 2.10 139.81 138.94 139.38 




2.9.2 Affymetrix GeneChip miRNA array procedure 
a) Preparation of ovens, arrays and sample registration files 
The Affymetrix Hybridization Oven 640 was set to 48°C. The arrays were 
unwrapped and placed on the bench top to warm to room temperature for 15 minutes. 
Each array was labelled. Then, a 200 µl unfiltered pipette tip was inserted into the upper 
right septum to allow for proper venting when the hybridization cocktail was injected. 
miRNA array library file package was installed and downloaded into the Affymetrix 
GeneChip Command Console (AGCC) software using the Command Console Library 
File importer tool. Samples and array information were uploaded into AGCC.  
b) Hybridization 
Eukaryotic Hybridization Controls were thawed completely for hybridization 
and then heated for 5 minutes at 65°C.  A master mix of hybridization cocktail was 
prepared consisting of 50 µl 2x hybridization mix, 15 µl 27.5% formamide, 10 µl 
DMSO, 5 µl 20x eukaryotic hybridization controls and 1.7 µl control oligonucleotide 
B2. At this point, the total volume was 123.2 µl, which was incubated at 99°C for 5 
minutes and then 45°C for 5 minutes. Thereafter, 100 µl of samples were aspirated and 
injected into the microarray chip. The pipette tip was removed from the upper right 
septum of the array. Both septa were covered with 1.5 inch Tough-Spots to minimize 
evaporation to prevent leaks. The microarray chips were then placed into the GeneChip 
Hybridization Oven 640 and the trays were loaded into the hybridization oven for 
incubation at 48°C for 16 hours.   
c) Washing and staining 
After 16 hours of hybridization, the arrays were removed from the oven and the 
Tough-spots were removed from the arrays. The hybridization cocktail was extracted 
from each microarray chip and transferred to a new tube. Each microarray chip was 
filled completely with Array Holding Buffer and allowed to equilibrate to room 
temperature before washing and staining. Vials were placed into sample holders on the 
fluidics station according to the manufacturer’s protocol. The Fluidics Station 450 was 
washed and stained using fluidics script FS450_0003. The arrays were checked for air 
bubbles and it was ensured that there was no dust on the glass surface before scanning.  
d) Scanning 
All instructions for using the GeneChip Scanner 3000 7G and scanner arrays 
were referred to Affymetrix Command Console Software User Manual (pg 141). Figure 
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2.7 shows the scanned image of the hybridized probe microarray, which is similar for 
all 5 microarray chips. 
 
Figure 2. 7: Image of hybridized probe microarray with probes complementary to 
miRNA information of interest  
 
Every grid represents miRNA expression levels in fluorescence intensity, green intensity 
indicates down-regulated whereas red intensity indicates up-regulated miRNA 
expression in the treated group. Yellow indicates no change in miRNA expression.  
 
e) Data analysis 
Data summarization, normalization and quality control were analysed using the 
miRNA QC Tool software (version 1.1.1.0). The workflow used in miRNA QC Tool: 
Detection   : Background detection 
Background adjustment :  RMA Global Background Correction 
Normalization   : Quantile 
Summarization  : Median Polish 
Each probe on the array was assayed for detection based on the Wilcoxon Rank-Sum 
test of the miRNA probe set signals, compared to the distribution signals from the 
background of Guanine-Cytosice (GC) content matched anti-genomic probes. P ≤ 0.06 
was considered to be detected above background hence a true detection and the P-value 
was generated using Fisher test. Therefore, with P-value > 0.06 were considered 
undetected due to the weak sample signal which was not able to discriminate from the 
background probes.   
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 Normalization of data reduced the variability after employing background 
corrections (RMA Global) and summarization (Median Polish). Most normalization 
methods assume similar distribution of intensities between the 2 groups and the number 
of over expressed miRNAs is similar to the number of under expressed miRNAs. 
Quantile normalization was thus used to compare the probe intensities across 
microarray chips and ensured that the distributions of log intensities were comparable 
(Bolstad et al, 2003). Median polish is a summarization method that ignores outlier 
probe-level intensities (Biostatistics 2003). 
An overview of data distribution as represented by the MA plot with green 
intensity ratio (M) plotted against the average intensity (A) is shown in Figure 2.8. The 
MA plot shows the normalization of data generated from the 2 microarray chips ensures 
minimal technical biasness and to ensure hybridization efficiency. In general 
assumption, most miRNAs will not alter in expression and the majority of plots will 
thus be concentrated at 0 whereby Log (1) is 0. ‘M’ represents the log difference in 
intensities between the 2 chips and ‘A’ represents average intensities. The formula for 
M and A is as follows: M=log2R- log2G; A= ½ x (log2R + log2G). 
 
Figure 2. 8: An overview of data distribution represented by MA plot with green 
intensity ratio (M) plotted against the average intensity (A). 
 
M on the y-axis represents green intensity ratio; A on the x-axis represents average 
intensities. Formula for M=log2R- log2G; A= ½ x (log2R + log2G). 
 
From the list of miRNA generated from the microarray, only mouse miRNA 
were further analysed. Only miRNAs that were up regulated with relative intensities of 
>1.5 or down regulated with relative intensities of <0.5 were considered in the miRNA 
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selection for real-time RT-qPCR.  Although there were no replicates of microarrays for 
statistical analysis, the selected miRNAs were validated with quantitative real-time RT-
qPCR. Preliminary scrutiny of the data was carried out to indentify micro-RNAs 
suitable for verification by RT-qPCR. Subsequently it was revealed that the initial 
ranking of miRNAs were inaccurate.  This was then corrected, and the data verified 
independently.  The supposition that the array data displayed in this thesis is accurate is 
supported by the following observation: there was extremely good concordance of data 
when the array and RT-qPCR data were compared for the LFR versus HF study. 
 
2.10 Quantitative real-time RT-qPCR miRNAs expression analysis 
 The miRNA microarray results were confirmed using real time RT-qPCR on 
independently derived RNAs from individual mice (n=6/group) for all 5 diet groups 
(i.e., LFR, LF, HF, HFDHA and HFEPA; Chapters 8). Total RNA was isolated as 
described in Table 2.16 and RT-qPCR was performed according to the manufacturer’s 
protocol. On each 96-well plate, a small RNA assay for each cDNA sample, 
endogenous control and no template controls to evaluate background signal were 
allocated. At the beginning of the PCR reaction, products were allowed to amplify at a 
constant, exponential rate by ensuring that it did not compete with the primer binding. 
Excessive reagents and low enough concentrations of template and product were 
applied to prevent competition with primer as described in the manufacturer’s protocol. 
Individual primers for each miRNAs were predesigned and validated using Applied 
Biosystems TaqMan by providing Applied Biosystems with the miRNA target 
sequence. Primers from the Applied Biosystems TaqMan assay are stem-loop structured 
because the miRNAs are short.  
 In this thesis, TaqMan (Applied Biosystems) was used for the detection of PCR 
products which generates fluorescence signal through the coupling of fluorogenic dye 
molecules and a quencher moiety to the same or different oligonucleotide substrates.   
 
2.10.1 Sample preparation and RT-qPCR procedures 
 A two-step RT-PCR was carried out using TaqMan Small RNA assays. For the 
reverse transcription (RT) step, cDNA was reverse transcribed from RNA samples 
using a small RNA-specific, stem-loop RT primer from the TaqMan Small RNA Assays 
and reagents from TaqMan MicroRNA Reverse Transcription Kit. In the tube, the RT 
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master mix was prepared on ice using TaqMan MicroRNA reverse transcriptase kit 
(thawed) and allowing for 20% in excess volume to compensate for losses during 
pipetting. The components of RT master mix are indicated in Table 2.12: 
 
Table 2. 12: Components of reverse transcriptase (RT) master mix 
Component Master mix volume per 15 µL reaction 
100 mM dNTPs (with dTTP) 0.15 µL 
MultiScribe Reverse transcriptase, 50 U/µL 1.00 µL 
10x reverse transcription buffer 1.50 µL 
RNase inhibitor, 20 U/µL 0.19 µL 
Nuclease-free water 4.16 µL 
Total volume 7.00 µL 
Each 15 µL reaction consists of 7 µL master mix, 3 µL of 5x RT primer and 5 µL RNA 
sample 
 
The master mix solution was mixed gently, centrifuged and placed on ice ready 
for the RNA reaction. Each 15 µL RT reaction was combined with RT master mix with 
total RNA in the ratio of 7 µL RT master mix : 5µL total RNA (1 to 10 ng per reaction). 
Then, 12 µL of RT master mix containing total RNA was transferred to a 96-well 
reaction plate. Afterwards, 3 µL of 5x RT primer from each assay set was added into the 
corresponding well. The solution in the plates was sealed, mixed thoroughly and 
centrifuged to bring all solutions to the bottom of the wells. After 5 minutes of 
incubation on ice, samples were ready to be loaded onto the PTC-225 Peltier Thermal 
Cycler. The thermal cycler was set to 4 steps: (i) 30 minutes at16°C, (ii) 30 minutes at 
42°C, (iii) 5 minutes at 85°C and (iv) hold until unloaded at 4°C. Finally, the RT run 
was performed. Immediately after the RT run, the PCR amplification step was 
continued. 
For the PCR step, PCR products were amplified from cDNA using TaqMan 
Small RNA Assay and TaqMan Universal PCR Master Mix II. Then, 20 µL per reaction 
of qPCR reaction mix was prepared allowing for 20% excess to compensate for the 
volume loss during pipetting. After this, 1.5 ml microcentrifudge tube for each sample 





Table 2. 13: Components required for polymerase chain reaction (PCR) step 
Component 
Volume per 20 µL reaction 
Single reaction Three replicates 
TaqMan Small RNA Assay (20x) 1.00 µL 3.60 µL 
Product from RT reaction
a
 1.33 µL 4.80 µL 
TaqMan Universal PCR Master Mix II (2x) 10.00 µL 36.00 µL 
Nuclease free water 7.67 µL 27.61 µL 
Total volume 20.00 µL 72.01 µL 
a
 The maximum amount of RT product that can be added to the reaction. Primer was 
diluted to a minimum of 1:15 in the final qPCR reaction. Components of master mixes 
are listed in Table 2.13. Replicate volumes include 20% excess to compensate for 
volume loss during pipetting 
 
 
The microcentrifudge tube was capped and inverted several times to mix and 
then centrifuged briefly. 20 µL of the complete qPCR reaction mix, including assay and 
RT products was transferred into each of 4 wells on a 384-well plate using the Biomek 
FX Liquid handling robot (Figure 2.9). The plate was sealed, centrifuged and loaded 
onto the 7900 HT Fast RT-PCR System. The parameters on the real-time PCR were set 
for 40 cycles according to the following parameters: 
Run mode: Standard 
Sample volume: 20 µL 
Thermal cycling conditions stated in Table 2.14 
PCR efficiency was determined by referring to the real-time PCR plots whereby 





Figure 2. 9: Biomek FX Liquid handling robot used to transfer 20 µL of the complete 
qPCR reaction mix, including assay and RT products into each of the 4 wells on a 












Hold Hold Denature Anneal/extend 
Temperature 50 C 95 C 95 C 60 C 
Time 2 minutes 10 minutes 15 seconds 60 seconds 
  
During PCR, the 5’ nuclease assay process takes place whereby TaqMan minor grove 
binder (MGB) probe anneals to a complementary sequence between the forward and 
reverse primer sites. The TaqMan MGB probe contains a reporter dye linked to the 5` 
end of the probe, MGB at the 3’end of the probe and a non-fluorescent quencher at the 
3’end of the probe. Probes that were intact suppress the reporter fluorescence by 
Forster-type energy transfer. Then probes that were hybridized to the target were 
cleaved by DNA polymerase which separates the reporter dye and the quencher dye. 
The separation between the reporter dye and the quencher dye increased the 
fluorescence by the reporter. The fluorescence signal increases when target sequence is 
complementary to the probe and therefore non-specific amplification is undetected. The 









2.10.2 Determining the Cycle threshold (Ct) by relative quantification 
The amplification plot of the endogenous control used in this study is sno-234. 
The amplification plot is a graph of fluorescence signal against cycle number (Figure 
2.10). As seen in the graph, there is little change in fluorescence in initial cycles of PCR 
and this defines the baseline of the amplification plot. In this study, a fixed threshold 
was set at 0.388, represented by the green horizontal line across the graph. The increase 
above the baseline indicates the accumulated PCR product. Ct is determined by the 
middle part of the exponential phase, normally between 25 and 35 cycles. Ct is the cycle 
number whereby the fluorescence signal reaches threshold level above background and 
this value is calculated by default using the ABI TaqMan program. The higher the initial 
sample volume, the sooner the accumulated sample is detected as a significant increase 
in fluorescence hence a lower Ct value. As seen in Figure 2.10, the Ct values are 
reproducible due to the threshold set at the exponential phase of the PCR. At the 
exponential phase there is a linear relation between the log difference in fluorescence 
and cycle number. Each non-limiting reaction was run in quadruplicate. For every 4 
samples, 2 mean Ct values were generated with 1 median Ct. For example, D30 is a 
contaminated sample but because median Ct was used in the calculations instead of the 
average Ct the outlier did not affect overall median Ct values. The difference between 
the normal and contaminated sample were 25.869 and 23.555 respectively. MiRNA 
expressions were quantified using the comparative CT method referred to as 2
- CT 
method. Briefly, the median Ct of the endogenous control (snoRNA-234) was 
subtracted from each sample to obtain ∆Ct. This was followed by the subtraction of ∆Ct 
of each sample with the average ∆Ct of the control group. The relative quantification 
presented the changes of the selected miRNAs relative to an endogenous control 
(snoRNA-234) and ∆Ct of the control group. Tables for median Ct values and its 




Table 2. 15: Individual RNA samples extracted from mice fed low fat reference 
(LFR), low fat (LF), high fat hypercaloric (HF), high fat hypercaloric DHA 
(HFDHA) or high fat EPA hypercaloric (HFEPA) ready for real-time qPCR 
 























 1 2 
LFR 
TABS 302 7.8 2.05 2.06 64.59 6.46 1.55 0.77 1.73 
TABS 303 4.6 2.1 2.08 191.74 19.17 0.52 0.26 2.24 
TABS 305 6.7 2.11 2.11 195.49 19.55 0.51 0.26 2.24 
TABS 306 6.3 2.11 2.1 276.90 27.69 0.36 0.18 2.32 
TABS 307 6.8 2.09 2.09 208.52 20.85 0.48 0.24 2.26 
TABS 308 7.3 2.11 2.09 224.47 22.45 0.45 0.22 2.28 
LF 
TABS 309 6.9 2.08 2.09 350.92 3.51 2.85 1.42 1.08 
TABS 310 6.5 2.08 2.09 244.94 24.49 0.41 0.20 2.30 
TABS 312 4.5 2.08 2.08 377.75 3.78 2.65 1.32 1.18 
TABS 313 7 2.11 2.13 214.63 21.46 0.47 0.23 2.27 
TABS 314 6.5 2.14 2.14 291.34 29.13 0.34 0.17 2.33 
TABS 316 7.6 2.08 2.08 232.37 23.24 0.43 0.22 2.28 
HF 
TABS 317 6 2.08 2.08 321.88 3.22 3.11 1.55 0.95 
TABS 320 4.5 2.08 2.08 325.38 3.25 3.07 1.54 0.96 
TABS 321 7.3 2.12 2.13 374.74 3.75 2.67 1.33 1.17 
TABS 322 6.6 2.14 2.14 262.89 26.29 0.38 0.19 2.31 
TABS 323 6.9 2.12 2.12 238.66 23.87 0.42 0.21 2.29 
TABS 324 7.9 2.13 2.13 333.27 3.33 3.00 1.50 1.00 
HFDHA 
TABS 326 5.3 2.12 2.1 306.71 3.07 3.26 1.63 0.87 
TABS 327 5.5 2.1 2.11 530.38 5.30 1.89 0.94 1.56 
TABS 328 5.8 2.09 2.09 430.86 4.31 2.32 1.16 1.34 
TABS 330 7.2 2.08 2.09 360.07 3.60 2.78 1.39 1.11 
TABS 331 7.1 2.13 2.14 266.37 26.64 0.38 0.19 2.31 
TABS 332 6.4 2.13 2.12 212.89 21.29 0.47 0.23 2.27 
HFEPA 
TABS 333 7.3 2.1 2.11 674.37 6.74 1.48 0.74 1.76 
TABS 334 6.1 2.13 2.13 301.47 3.01 3.32 1.66 0.84 
TABS 335 7.6 2.08 2.08 458.80 4.59 2.18 1.09 1.41 
TABS 337 6.9 2.09 2.08 436.31 4.36 2.29 1.15 1.35 
TABS 338 6.2 2.09 2.1 308.20 3.08 3.24 1.62 0.88 
TABS 340 6.3 2.12 2.13 352.27 3.52 2.84 1.42 1.08 
RIN stands for RNA integrity number generated by Agilent for its bioanalyzer. 
Absorbance ratio (260/280) was obtained using Nanodrop. LFR (mice fed with 2% corn 
oil); LF (mice fed with 2% corn oil with condensed milk); HF (mice fed with 18% palm 
oil with condensed milk); HFDHA (mice fed with diet containing docosahexaenoic 




Figure 2. 10: Snapshot of the amplification plot of snoRNA-234, endogenous control 
generated from RT-qPCR  
 
The amplification plot shows the fluorescence signal against cycle number. Baseline of 
graph shows there’s little change in fluorescence in initial cycles of PCR. The fixed 
threshold is represented by green line parallel to x-axis. Ct values are determined at the 














Chapter 3:  
Preliminary study investigating the effects of an 
























Non-alcoholic steatohepatitis (NASH) refers to the accumulation of fats in the 
liver with signs of inflammation and fibrosis which may lead to permanent liver 
scarring also known as cirrhosis (Neuschwander-Tetri 2005; Brunt 2005). Fatty liver 
can be induced experimentally by suppressing hepatic fatty liver oxidation under 
excessive fat intake (Cong et al, 2008). Although NASH is a highly prevalent disorder 
associated with insulin resistance, type 2 diabetes mellitus and obesity (Brunt 2009; 
Tiniakos et al, 2010; Ferreira et al, 2011), little is known about the effect of dietary fat 
composition on NASH. 
Prospective studies in animals (Yamaguchi et al, 2007) and cells (Reid et al, 
2008) showed that the accumulation of triacylglycerols (TAG) in the liver is driven by a 
high influx of non-esterified fatty acids (NEFA) into the liver. Fatty liver can be 
induced experimentally by suppressing hepatic fatty liver oxidation under excessive fat 
and carbohydrate intake. The elevated NEFA concentrations in the liver due to the 
uncontrollable and continuous stimulation of lipogenesis increases VLDL production 
(Minehira et al, 2008; Bijland et al, 2010). The inability to secrete VLDL from the liver 
contributes to hepatic steatosis (Bjorkegren et al, 2002), although there are other 
mechanisms as well (Section 1.3). 
The objective of this study was to investigate the effects of a previously 
described obesogenic diet containing lard on the liver (Samuelsson et al, 2008) and to 
analyse the lipidomic profiles of fatty liver. Additionally, this study also aimed to 
undertake liver proteomic analyses comparing controls and obesogenic mice. 
Differences in liver histology between the controls and obesogenic mice were also 
compared. It was envisaged that after this study, the model would be used for studying 
the effects of dietary interventions, such as the modifying effects of low fat and 




3.2.1 Animal models and materials 
Female C57BL/6J mice were obtained from Charles River, UK and housed 
singly in raised bottom wired cages. Pelleted diets were obtained from Special Dietary 
Services. The obesogenic group mice in addition to the obesogenic pellets were allowed 
ad libitum access to full fat condensed milk (Carnation, Nestle). Table 3.1 shows the 
nutritional composition of the pelleted diets and the condensed milk fed to controls and 
the obesogenic group. The notation ‘obesogenic diet’ and ‘obesigenic group’ will be 
used in this chapter interchangably, which is the same notation used by the original 
authors for the same diet.  
 
Table 3. 1: Nutrient composition of diets for controls and obesogenic group mice 
 Controls Obesogenic group 
 Low fat chow Obesogenic chow Condensed milk* 
Protein (g/100 g) 15 (20%) 23 (22%) 8 (10%) 
Carbohydrate (g/100 g) 57 (71%) 38 (34%) 55 (67%) 
Fat (g/100 g) 3 (9%) 20 (44%) 8 (23%) 
Energy (kcal/100 g) 301 414 310 
Values in parentheses represent the % energy. Energy contents are calculated using 
Atwater factors of 4 kcal/g for protein, 3.75 kcal/g for carbohydrate and 9 kcal/g for fat. 
Lard was used as the test fat.* indicates the full fat variety was used. 
 
 
3.2.2 Experimental design for pilot study 
 Female C57BL/6J mice approximately 100 days old were fed either the control 
or the obesogenic diet. After 6 weeks animals were killed, the liver frozen in liquid 
nitrogen and stored at -80°C until analysis. There were 10 mice in each group. The 
animals were caged in groups of five per cage and allowed ad libitum access to food and 
drink. Food intake was not measured. This study was carried out by Samuelsson et al, 
(2008) and for this thesis archival liver was obtained from the original first and last 
authors namely Dr. Anne Samuelsson and Dr. Paul Taylor, King’s College London.  
 
3.2.3 Analysis of tissue for histology and lipidomics 
Histology using H&E stain was carried out on individual liver tissues and scored 
for steatosis, inflammation and reticulin condensation by Professor Bernard Portmann, 
112 
 




Using methods as described in Chapter 2, fatty acids were extracted from liver 
(Folch et al, 1957) and fractionated into non-esterified fatty acids (NEFA), 
triacylglycerols (TAG), cholesterol esters (CE) and phospholipids (PL) by solid phase 
extraction (Kaluzny et al, 1985). C-17 internal standards were added to quantify the 
fatty acids present in each fraction. All 4 fractions were methylated and loaded onto the 
gas chromatography to obtain individual fatty acid profile (Lepage & Roy 1986).   
 
3.2.5 Analysis of tissue for proteomics 
In this study, 2D-DIGE was used to determine protein expression (up-regulated 
or down-regulated) in the obesogenic and control group.  
Before protein extraction, preliminary preparations involving tissue grinding and 
homogenization were performed. A sample grinding kit (Ettan, Amersham Biosciences) 
consisting of tubes with grinding resin and pestles were used to disrupt the liver tissues. 
Liver tissues were prepared in a planned randomization pattern (control; treated; treated; 
control) to decrease bias and weighed four at a time to prevent the thawing of tissue 
which may degrade the protein in the sample. Samples from each group (n=8/group) 
were pooled in pairs randomly.  
The homogenized samples were then quantified using 2D-Quant kit (GE 
Healthcare) to measure the amount of precipitated proteins and also to ensure that the 
protein concentrations were within the range of 1-100 µL of protein in 1-100 µL of 
homogenate. Next, samples were cleaned up using the 2D- Clean up kit and quantified 
again with the Pierce assay to obtain 50 µg of protein from each sample for labelling. 
Before labelling, the pH of the protein after clean-up was tested and the pH was 
8.0. Therefore, to increase the alkalinity of the protein, labelling buffer was added to 
each sample giving a pH of 8.5. After that, 50 μg of each sample was labelled with 400 
pmol of dye (Cy2, Cy3 and Cy3). Next the labelled samples were applied to the IPG gel 
strips for 1
st
 dimension run whereby the proteins migrate along the IPG strips with the 
electric field and stay at their own pI position with no net charge. After the 1
st
 
dimension run, the IPG strips were transferred to the gel glass plates for separation by 
molecular mass in the 2
nd
 dimension of SDS polyacrylamide gel electrophoresis in the 
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Ettan DALTtwelve tank set at 1 Watt/gel for 1 hour followed by 17 Watt/gel for 5 
hours. A more detailed procedure can be referred to the GE Healthcare protocol. 
After scanning the analytical gels (n = 4), preparative gels for spot picking were 
cast. The proteins of interest selected for picking were matched at Auto Level 1 and 
were confirmed to have a significant value of P<0.05 with Student’s T-test and at least 
± 1.5 average ratio. The proteins of interest were picked using a robotic Gel Picker (GE 
healthcare) into a 96 well plate and then sealed for further analysis with LC-MS/MS. 
The gel plugs in the sealed plate was send to the Cambridge Proteomics Centre 
(Cambridge, UK) for protein identification using LC-MS/MS.  
 
3.2.6 Statistical analysis 
 For lipidomics, data were analysed using SPSS version 18.0 by Independent 
Student’s T-test. There were 9 mice in the control group and 10 mice in the obesogenic 
group. In histology, Chi-squared test was used to compare the differences in the 
frequency of certain distributions. For proteomics, Student’s t-test was carried out using 
DeCyder between the controls and the obesogenic group. Significance was indicated 







 The staining of liver sections from the controls and obesogenic mice using 
hematoxylin and eosin are presented in Figure 3.1 and the histological findings for the 
livers are presented in Table 3.2. A greater number of mice with liver steatosis and 
reticulin condensation were found in the obesoegnic group with P<0.001 and P=0.002 
respectively. Five out of 10 mice from the obesogenic group showed signs of steatosis 
at the top end of the scores compared to the controls where the majority of the mice 
livers were graded at the lower end of the scores. None of the mice from the control 
group showed signs of reticulin condensation compared to 70% of mice from the 
obesogenic group, which developed level 1 condensation in the reticulin. Furthermore, 
30% of mice in the obesogenic group developed inflammation at level 2 compared to 
none in the controls. Overall, it appeared that histological conditions of non-alcoholic 
fatty liver disease were more severe in the obesogenic group in comparison to the 
controls. 
 
3.3.2 Fatty acid concentrations and composition of hepatic non-esterified fatty 
acids 
The accumulation of stearic acid (16:0) in the obesogenic group was 
significantly lower when compared with the controls (P<0.001) as shown in Table 3.3. 
Stearic acid was highest in the controls with 45% of the total NEFA fatty acids. Fatty 
acid composition of oleic acid (18:1n-9) contributed the highest proportion of 
monounsaturated fats (MUFA) in the obesogenic mice group (42%) and was 
significantly higher than controls (P<0.001). The proportion of linoleic acid (18:2n-6) 
was significantly higher (P=0.048) in the obesogenic group compared to the controls 
and there was no statistical significance in linolenic acid (18:3n-3). AA (20:4n-6) levels 
were significantly higher (P=0.011) in the obesogenic group when compared with the 
controls. In addition, EPA (20:5n-3) was significantly lower (P<0.001) in the 
obesogenic group (0.1%) compared to the controls (0.5%). In contrast, DHA was 
significantly higher in mice from the obesogenic group (2%) compared to controls with 
0.8% (P=0.001). Besides that, adrenic acid (22:4n-6) was significantly lower in 
obesogenic mice compared with the controls (P=0.028). The total concentration (mg/g) 




3.3.3 Fatty acid concentrations and composition of hepatic triacylglycerols 
 The proportion of hepatic palmitic acid in obesogenic mice (29%) was 
significantly lower than the controls (26%; P<0.001) as shown in Table 3.4. Similar to 
NEFA fractions, the proportion of stearic acid in the obesogenic mice were half the 
proportion in the controls (P<0.001). Oleic acid showed the highest proportion in 
hepatic TAG concentrations and was significantly higher in the obesogenic (45%) group 
when compared with the controls (30%). Linoleic acid was significantly lower in 
obesogenic mice when compared to the controls with 11% and 14%, respectively 
(P=0.010). In addition, the proportion of linolenic acid was lower in obesogenic mice 
compared with the controls (P=0.033). Levels of EPA were significantly lower in 
obesogenic mice compared to the controls (P<0.001). In contrast, DHA was highest in 
obesogenic group with 3% followed by 1% in controls (P<0.001). AHA levels were 3 
times lower in obesogenic group compared to controls (P<0.001). These findings were 
similar to NEFA composition. In concentrations terms, obesogenic mice accumulated 
the highest (52 mg/g) hepatic TAG when compared with 8 mg/g in controls.  
 
3.3.4 Fatty acid concentrations and composition of hepatic cholesteryl esters 
As seen in Table 3.5, cholesteryl palmitate and palmitoleate were similar in both 
controls and obesogenic groups. However, cholesteryl stearate in controls accounted for 
a 2-fold increase in proportion to that found in the obesogenic group with significance 
at P<0.001. Cholesteryl oleate showed a 30% increase in the obesogenic mice group 
when compared with the controls. There was proportionately less cholesterol linoleate 
(18:2n-6) in animals fed with obesogenic diet when compared to controls (P<0.001). 
Both groups have similar proportions of AA (20:4n-6) derived from cholesterol 
linoleate (18:2n-6) which did not differ significantly. However, both controls and 
obesogenic groups have similar proportions of DHA.  Similar to findings in NEFA and 
TAG concentrations, the obesogenic mice accumulated more fats when compared with 
the controls (P<0.001) (Table 3.5).  
 
3.3.5 Fatty acid concentrations and composition of hepatic phospholipids 
The data in Table 3.6 shows that the proportion of palmitic acid (16:0) was 
significantly lower in obesogenic mice when compared to the controls (P<0.001). 
However, the proportion of palmitoleic acid was similar in both groups. In the 
obesogenic group, the proportion of stearic acid was 40% lower than the control group 
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(P<0.001). Oleic acid was significantly higher in the obesogenic group (8%) when 
compared with controls (6%: P=0.019). Obesogenic mice showed linoleic acid with a 
mean proportion of 6% and is significantly higher compared with controls (4%; 
P=0.010). In contrast, linolenic acid was higher in the obesogenic group (0.9%) when 
compared to 2.2% in the controls (P=0.002). As for the composition of AA (20:4n-6), 
obesogenic mice showed significantly higher levels by 2-fold in comparison to controls. 
EPA was similar in both groups but DHA was significantly higher in the obesogenic 
group (19%) when compared to the controls with 3.5% (P<0.001). In contrast to the 
findings in NEFA, TAG and CE fractions, PL concentrations expressed in mg/g was 
lower in the obesogenic mice when compared to the controls with P=0.001.  
 
3.3.6 Protein expression in obesogenic mice using 2D-DIGE 
 A total of 2061 matching protein spots were detected on the master gel 
interfaces (n=4 gels) and 201 proteins were differentially expressed. Out of the 201 
proteins, 18 proteins were confirmed to have a significant value of P<0.05 with 
Student’s T-test and at least a 1.5 fold change (Figure 3.2). Of the 18 proteins, 5 were 
up-regulated and 13 were down-regulated (Table 3.7). Twelve of the 18 significantly 
expressed proteins were identified using LC-MS/MS. These 12 proteins were picked on 
the basis of high abundance and 3D peaks that were not overlapping (Figure 3.3) with 
significant difference of P<0.05 and average ratio of at least ≥ ±1.5.  The other 3 
proteins with protein ID numbered 1563, 1845 and 1854 were selected for reference to 
confirm the results obtained from LC-MS/MS. These 3 proteins were picked by 
referring to the reference gel on SWISS 2D-PAGE. In total, 15 proteins were selected 
for identification with LC-MS/MS (Figure 3.4). 
As shown in Table 3.8, data revealed 5 Type II keratin subunit proteins and 10 
other known proteins. However, there were no matches when comparing the results 
obtained from LC-MS/MS with the tentative protein spots identified by matching the 
preparative gel with the reference gel on SWISS 2D-PAGE. There are multiple reasons 
to why the proteins were not matched, one of which may be an error occurring during 
spot picking, whereby protein spots of interest were missed-picked by the robot. 
Furthermore, contamination by human keratin during gel handling would have caused 
apparent, ie, artificial changes in keratin abundance, whilst murine keratin 
contamination would have arisen from ongoing laboratory projects. Undoubtedly, one 
assumes that LC-MS/MS is the gold standard.  
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 There are 6 categories of intermediate filament and Type 1 and Type 2 keratin 
subunit proteins are the most diverse, comprising of acidic and basic proteins 
respectively. Type II keratins are the basic counterpart of Type I keratins and Type II 
keratins bind to form acidic and basic heterodimers to make a keratin filament (Stewart 
1990). Results from LC-MS/MS showed that keratin 4, 10, 6A, 73 and 75 were 
identified together with glutathione s-transferase omega 1 (GSTO1), quinoid 
dihydropteridine reductase (QDPR) and sepiapterin reductase (SPR). All proteins 
expressed differentially were up-regulated except for keratins type II and 6A, GSTO1 
and QDPR which were down-regulated. 
 The abundance of keratin protein was of particular concern, especially as they 
were not identified in subsequent studies (Chapter 7). The failure to see changes in 
keratin in response to hypercaloric feeding in subsequent studies may have been due to 
a greater familiarisation of analytical techniques and the application of more refined 
methodology. Furthermore, we determined whether the keratins identified by LC-
MS/MS would actually appear in the gels. However, there was marked discordance in 
the location of the keratins as identified by LC-MS/MS vs those located using the 
SWISSprot database. For example spot number 1812 had a pI of 4.72 and a molecular 
weight of 18.7 kDa by SWISSprot analyses. However, by LC-MS/MS the same spot 
number had a pI of 8.97 and a molecular weight of 66 kDa.  
 In summary, the analytical components of the data appeared to be marked by 
contamination. 
 
3.3.7 Study limitations 
This study was based on archival material and thus, there were no access to 
information on the liver weights of all the mice. Although, the composition of the 
condensed milk intake can be obtained there were no information on the amount 
ingested. Similarly, there was no information on the intakes of the pelleted diets. The 





Figure 3. 1: Hematoxylin and eosin staining of liver sections from mice fed either 







Representative micrograph shows the portal vein also known as Zone 1 is where the 
supply of oxygenated blood from hepatic arteries is highest. The hepatic vein represents 
Zone 3 where the oxygenation is poor. The white spaces between the cells represent the 
amount of fats in the liver.  
  






Table 3. 2: Histopathology scores for steatosis, inflammation, ballooning and 





 P value 
0 1 2 3 4 
Control 
(n=9) 
Count 4 4 1 0 0 
P<0.001 
% within  group 44% 44% 11% 0% 0% 
Obesogenic 
(n=10) 
Count 0 0 1 4 5 





 P value 
0 1 2 3 4 
Control 
(n=9) 
Count 1 8 0 0 0 
P=0.111 
% within  group 11% 89% 0% 0% 0% 
Obesogenic 
(n=10) 
Count 0 7 3 0 0 





 P value 
0 1 2 3 4 
Control 
(n=9) 
Count 2 7 0 0 0 
P=0.082 
% within  group 22% 78% 0% 0% 0% 
Obesogenic 
(n=10) 
Count 2 5 3 0 0% 





 P value 
0 1 2 3 4 
Control 
(n=9) 
Count 9 0 0 0 0 
P=0.002 
% within  group 100% 0% 0% 0% 0% 
Obesogenic 
(n=10) 
Count 3 7 0 0 0 
% within  group 30% 70% 0% 0% 0% 
Values are expressed in counts and percentages. Chi-square test was used for statistical 
analysis between groups. The liver scores from 0 to 4 indicate: 
       a Steatosis: 0 = absent or occasional vacuoles; 1 = 5-25%; 2 = 25-50%; 3 = 50-
75% 
          b Inflammation- 0 = absent; 1 = occasional cells; 2 = sparse cells; 3 = frequent 
cells 
     c Ballooning: 0 = absent; 1 = occasional cells; 2 = sparse cells; 3 = frequent cells 







Table 3. 3: Total fatty acid concentrations (mg/g) of hepatic non-esterified fatty acids 
(NEFA) of C57BL/6J female mice fed either standard chow or an obesogenic diet 






16:0 29.3 ± 9.9 26.3 ± 1.0 P=0.347 
16:1 4.7 ± 7.6 3.4 ± 0.6 P=0.615 
18:0 44.9 ± 9.2 12.0 ± 2.6 P<0.001 
18:1n-9 9.8 ± 5.0 42.2 ± 3.2 P<0.001 
18:2n-6 7.0 ± 4.2 10.1 ± 1.8 P=0.048 
18:3n-3 0.5 ± 0.3 0.5 ± 0.1 P=0.735 
20:3n-6 0.4 ± 0.2 0.3 ± 0.1 P=0.395 
20:4n-6 1.1 ± 0.9 2.0 ± 0.3 P=0.011 
20:5n-3 0.5 ± 0.3 0.1 ± 0.1 P<0.001 
22:4n-6 0.6 ± 0.5 0.2 ± 0.1 P=0.028 
22:5n-6 0.3 ± 0.2 0.4 ± 0.2 P=0.204 
22:5n-3 0.2 ± 0.2 0.3 ± 0.2 P=0.106 
22:6n-3 0.8 ± 0.8 2.1 ± 0.6 P=0.001 
mg/g 5.5 ± 1.8 13.7 ± 3.1 P<0.001 
Values are expressed as mean ± standard deviation. Student’s T-test was used; P values 
<0.05 indicates significant difference when compared to the controls 
 
 
Table 3. 4: Total fatty acid concentrations (mg/g) and individual fatty acid 
composition (weight %) of hepatic triacylglycerols (TAG) of C57BL/6J female mice 
fed either standard chow or an obesogenic diet 






16:0 29.1 ± 1.1 25.5 ± 1.0 P<0.001 
16:1 3.8 ± 0.3 3.8 ± 0.6 P=0.889 
18:0 13.7 ± 3.6 7.3 ± 1.3 P<0.001 
18:1n-9 30.4 ± 4.0 44.8 ± 3.2 P<0.001 
18:2n-6 13.7 ± 2.3 10.8 ± 2.0 P=0.010 
18:3n-3 0.8 ± 0.2 0.6 ± 0.1 P=0.033 
20:3n-6 1.7 ± 1.9 0.4 ± 0.1 P=0.045 
20:4n-6 1.9 ± 0.7 2.6 ± 0.3 P=0.005 
20:5n-3 1.1 ± 0.7 0.1 ± 0.1 P<0.001 
22:4n-6 1.7 ± 0.9 0.3 ± 0.2 P<0.001 
22:5n-6 0.9 ± 0.5 0.5 ± 0.2 P=0.031 
22:5n-3 0.3 ± 0.2 0.3 ± 0.2 P=0.591 
22:6n-3 0.9 ± 0.4 3.0 ± 0.7 P<0.001 
mg/g 8.1 ± 2.4 51.7 ± 21.9 P<0.001 
Values are expressed as mean ± standard deviation. Student’s T-test was used; P values 
<0.05 indicates significant difference when compared to the controls 
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Table 3. 5: Total fatty acid concentrations (mg/g) and individual fatty acid 
composition (weight %) of cholesterol esters (CE) of C57BL/6J female mice fed either 
standard chow or an obesogenic diet 






16:0 27.0 ± 1.4 26.3 ± 3.3 P=0.535 
16:1 4.0 ± 0.4 4.4 ± 1.5 P=0.456 
18:0 8.3 ± 2.3 4.2 ± 1.4 P<0.001 
18:1n-9 38.0 ± 2.4 49.5 ± 4.0 P<0.001 
18:2n-6 17.1 ± 1.5 10.2 ± 4.1 P<0.001 
18:3n-3 0.5 ± 0.5 0.6 ± 0.2 P=0.739 
20:3n-6 0.1 ± 0.3 0.3 ± 0.1 P=0.037 
20:4n-6 2.3 ± 1.8 1.6 ± 0.6 P=0.272 
20:5n-3 0.0 ± 0.0 0.1 ± 0.0 P<0.001 
22:4n-6 0.8 ± 0.6 0.3 ± 0.2 P=0.021 
22:5n-6 0.5 ± 0.4 0.4 ± 0.2 P=0.763 
22:5n-3 0.2 ± 0.2 0.3 ± 0.2 P=0.774 
22:6n-3 1.1 ± 0.6 1.9 ± 0.9 P=0.054 
mg/g 3.3 ± 1.4 24.2 ± 9.7 P<0.001 
Values are expressed as mean ± standard deviation. Student’s T-test was used; P values 
<0.05 indicates significant difference when compared to the controls 
 
Table 3. 6: Total fatty acid concentrations (mg/g) and individual fatty acid 
composition (weight %) of hepatic phospholipids (PL) of C57BL/6J female mice fed 
either standard chow or an obesogenic diet 






16:0 40.8 ± 7.8 27.0 ± 2.3 P<0.001 
16:1 0.6 ± 0.7 1.0 ± 0.5 P=0.189 
18:0 33.5 ± 6.1 19.8 ± 2.7 P<0.001 
18:1n-9 6.1 ± 1.0 8.4 ± 2.4 P=0.019 
18:2n-6 3.7 ± 2.0 5.7 ± 0.8 P=0.010 
18:3n-3 2.2 ± 1.1 0.9 ± 0.2 P=0.002 
20:3n-6 0.4 ± 0.5 0.4 ± 0.4 P=0.701 
20:4n-6 6.1 ± 5.5 14.8 ± 5.4 P=0.003 
20:5n-3 0.2 ± 0.2 0.2 ± 0.3 P=0.888 
22:4n-6 1.2 ± 0.6 0.4 ± 0.1 P=0.001 
22:5n-6 1.5 ± 0.8 2.0 ± 0.8 P=0.233 
22:5n-3 0.3 ± 0.6 0.4 ± 0.1 P=0.658 
22:6n-3 3.5 ± 3.8 19.0 ± 1.1 P<0.001 
mg/g 27.5 ± 13.3 10.8 ± 2.3 P=0.001 
Values are expressed as mean ± standard deviation. Student’s T-test was used; P values 




Figure 3. 2: Flow chart of the selection of differential proteins in 2D-DIGE 
  
In the master gel, 2061protein spots were detected and matched at 
Auto Level 1 which indicates a good match (n = 4 gels) 
210 protein spots were differentially expressed with 
P<0.05 and structurally the protein peaks were not 
overlapping 
For comparison between the controls and obesogenic group, 18 proteins 
were detected to have P<0.05 (Student’s T-test) and ≥ ± 1.5 average ratio 
A total of 11 proteins were picked for LC MS/MS  
An additional of 4 proteins of high abundance on the silver stained gel 
were picked on by referring to the 2D-DIGE image of mouse liver shown 
in SWISS 2D-PAGE to check for accuracy in spot matching 
All 15 proteins that were picked for LC-MS/MS were then compared to the 




Figure 3. 3: 3-D representative images of proteins of interest which were 
differentially expressed in mice fed control or obesogenic diets  
Spot 1723                                                            Spot 1812                  
       
 
Spot 1854                                                           Spot 2025 
 
Images were generated by DeCyder version 6.5 and location of the spots on the gels is 
indicated by the purple ring around the peak. Within the box, the left peak image 
represents spots from control mice and the right represents the obesogenic mice. 
 




Proteins selected for picking are annotated in the red box with numbers and noted by its 
contour line around the spot. Spot 1993, 1003 and 2025 were partially or wholly 
cropped out of the gel due to unknown circumstances. Gel images were clear  on screen 
and were used to compare with the  reference gel on SWISS 2D-PAGE.  All protein 
spots were confirmed to have a significant value of P<0.05 with Student’s T-test and at 
least ± 1.5 average ratio except for  
PI 
MW (kDa) 










Table 3. 7: Proteins identified to be differentially expressed with statistical 















35 NF NF NF NF 0.040 -1.81 
508 P24270 7.72 59664 Catalase 0.026 1.57 
563 P24549 7.91 54337 Retinal dehydrogenase 0.001 1.81 
684 P11679 5.70 54434 
Keratin, type II cytoskeletal 
8 
0.001 -1.84 
1012 NF NF NF NF 0.039 -2.09 
1205 Q64374 5.16 33407 Regucalcin 0.022 -1.6 
1566 NF NF NF NF 0.026 -1.56 
1645 NF NF NF NF 0.021 -4.4 
1723 NF NF NF NF 0.007 1.59 
1778 P11352 6.74 22179 Glutathione peroxidise 1 0.025 -1.52 
1781 NF NF NF NF 0.003 -1.83 
1784 O08079 6.26 26252 Peroxiredoxin 0.037 -2.14 




1812 P02762 4.72 18696 Major urinary protein 6 0.002 -4.75 
1847 P11589 4.86 18710 Major urinary protein 2 0.038 -2.22 
1993 P97450 5.40 8945 
ATP synthase-coupling 
factor 6, mitochondrial 
0.003 1.53 
2003 P10639 4.80 11544 Thioredoxin 0.015 2.02 
2025 P12787 5.01 12436 Cytchrome C oxidase 0.009 -2.08 
Statistical test was carried out using Student’s T-test. P-value with <0.05 indicates a 
significant difference between the groups. Average ratios with negative values indicate 
down-regulation of the protein in the experimental group and vice-versa.’NF‘ indicates 
that the protein spots were not found and, thus not matched to the reference gel on 
SWISS 2D-PAGE. The values for pI and MW were obtained from EXPASY.
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508 P02535 Keratin 10 (Type I) * 4.91 52824 480 13.5 
563 P04104 
Type II keratin subunit 
protein * 
8.97 65696 103 3.8 
684 P04104 
Type II keratin subunit 
protein* 
8.97 65696 207 3.8 
1563 P04104 
Type II keratin subunit 
protein 
8.97 65696 143 3.7 
1723 Q6NXH9 Keratin 73* 8.36 59502 131 4.3 








7.67 25782 389 33.6 
1812 P04104 
Type II keratin subunit 
protein* 
8.97 65696 282 5.7 
1845 Q6NXH9 Keratin 73 8.36 59502 171 4.3 
1847 P04104 
Type II keratin subunit 
protein* 
8.97 65696 225 5.7 
1854 Q8BGZ7 
Keratin type II 
cytoskeletal 75 
5.01 57978 167 5.4 
1993 Q91XH5 Sepiapterin reductase* 5.58 28208 199 23.0 
2003 P07744 Keratin 4* 9.08 44725 133 8.0 
2025 P50446 Keratin 6A* 8.04 59641 326 8.3 
All of the proteins identified were differentially expressed by at least 50% in the 
obesogenic group compared with the controls except for 1563, 1784, 1845 and 1854. 
These 4 proteins were identified to show the relevance of spot matching with the 
reference gel on SWISS 2D-PAGE. ’NF‘indicates that the protein spots were not found 
and, thus not matched to the reference gel on SWISS 2D-PAGE. * indicates the proteins 
that were altered in the comparison of LFR vs LF or LFR vs HF groups.
 
Protein score 
indicates how well the matching regions of polypeptides clusters are matched whereas 
the % coverage indicates how each of the polypeptides clusters match the protein. 
Proteins with the highest scores and % coverage were selected 




3.4.1 Methodological considerations 
 Liver samples were obtained from those female mice used by Samuelsson et al, 
(2008) to develop methodological skills for lipidomics and proteomics. In the 
aforementioned study, the female mice were fed a palatable obesogenic diet (16% lard, 
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33% sugar), were hyperphagic and showed heavier body weights compared to the 
controls fed standard chow (3% fat, 7% sugar). The obesogenic mice also showed signs 
of hypertension, cardiovascular and metabolic dysfunction, loss of skeletal muscle 
mass, increased fasting insulin and elevated plasma glucose (Samuelsson et al, 2008). 
However, no data was obtained for either whole liver weight or food intakes. 
For future studies in this thesis, it was proposed to obtain whole liver weight for 
the calculation of total lipids in the liver. The palatability of the semi-synthetic pelleted 
diets and milk intake will also be tested to ensure that the mice develop consistent 
growth patterns throughout the study (Chapter 4).  The consumption of pellet and milk 
intakes will also be weighed for determining the energy intakes of each mouse caged 
individually and to measure the amount of fats ingested.     
 
3.4.2 Lipid profile of obesogenic fed mice in comparison to controls and its 
histology 
The overall lipid profile of non-esterified fatty acids (NEFA), triacylglycerols 
(TAG) and cholesterol esters (CE) in the obesogenic group showed a significant 
increase in the levels of fatty acids when compared with the controls with P<0.05 and 
this was also observed in the liver histology. Although mice in obesogenic group did not 
develop severe NASH, obesogenic diet markedly increased hepatic lipid accumulation 
mainly in NEFA, TAG and CE fractions. The TAG fraction showed a 6-fold increase 
with increases in oleic acid, arachidonic acid (AA) and docosahexaenoic acid (DHA) 
which was similar to the fatty acid profile in the NEFA fraction. There was a 7-fold 
increase in cholesterol esters with major increases in cholesteryl oleate, cholesteryl 
palmitate and cholesteryl linoleate. In the phospholipid fraction of the liver, there were 
large increases in the proportion of DHA and AA in the obesogenic group which may 
imply that there was increased synthesis of these fatty acids from linolenic and linoleic 
acids, respectively. The increased proportion of these long-chain polyunsaturated fatty 
acids may render the liver more prone to damage and metabolic disruption because of 
their higher susceptibility to oxidation (Hostetler et al, 2006). 
Histological examination of the livers revealed that in the obesogenic mice there 
were features of mild steatosis but not severe non-alcoholic steatohepatitis (NASH). 
Notably, there was increased granularity of the hepatocyte cytoplasm with coarse 
amphophilic bodies resembling small Mallory bodies. Ninety percent of the mice from 
the obesogenic group presented signs of steatosis at the upper end of the scores 
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indicative of progression to steatohepatitis. These features were absent in the control 
animals.  
 
3.4.3 Differential protein expression in mice fed obesogenic diets compared with 
controls identified by LC-MS/MS 
Keratins are cytoskeletal proteins expressed in epithelial cells that represent the 
major subgroup of all intermediate filament proteins which are expressed as either type 
I or type II intermediate filament proteins (Moll et al, 1982). The functions of keratins 
are to modulate mechanical cell strength, cell signalling, cell differentiation and 
apoptosis (Kirfel et al, 2003; Snider et al, 2011). Alterations; both up- and down-
regulation of keratins are commonly found in hepatocytes with ballooning, Mallory 
bodies and inflammation (Ludwig et al, 1980; Brunt 2004). The ballooned hepatocytes 
containing Mallory bodies are characteristics of NASH (Zatloukal et al, 2004), thus 
suggesting that keratin may influence or reflect the levels of inflammation and oxidative 
stress caused by obesogenic feeding.   
However for this PhD, there was substantial contamination of the sample with 
keratins. The data in Table 3.7 are probably invalid.  
Quinoid dihydropteridine reductase (QDPR) is related to ferric reductase activity 
and at the mRNA level, QDPR is found to be up-regulated in liver during iron deficient 
growth conditions and down-regulated in condition when iron is excessive (Lee et al, 
2000). In the aforementioned study, pigs were used as experimental animals and no 
studies on hepatic dysfunction related to QDPR have been carried out in mice. In this 
study for the thesis, using a mouse model, QDPR was 90% down-regulated in the 
obesogenic group when compared with the controls.  
In future work, it is proposed that a comprehensive analysis of the proteins 
expressed in the liver will be carried out and the causal factors for the mismatch 
between the SWISS 2D-PAGE reference gel and LC-MS/MS will be determined. 
Further, technical development in this method will be improvised in order to pick 






Methodological development and optimization of 



















4.1 Experiment 1: Introduction  
 Animals have a preference for hypercaloric foods as a natural behaviour for the 
regulation of body temperature and energy storage, thus consuming more calories than 
needed (Takeda et al, 2001). The palatability of such diets is dependent on factors such 
as flavour (Ishii et al, 2003; Forestell & LoLordo 2003) and texture (Kadohisa et al, 
2005). In a previous study by Samuelsson et al, (2008), mice were fed with a 
hypercaloric diet (average 16% fat, 33% sugar) comprising of both the pellets and 
condensed milk. The controls were fed standard chow containing on average 3% fat and 
7% sugar, which included the pellets without the condensed milk. Table 3.1 shows the 
break-down of both the fat and sugar energy composition derived from the pellet and 
milk.  The condensed milk was provided to the mice in a jar for easy consumption. It 
was also highly palatable.  
The obesogenic diet was fed to maternal mice in one study as a novel model for 
developmental programming to investigate metabolic and cardiovascular function on 
the offspring (Samuelsson et al, 2008). The aforementioned study reported that the 
maternal mice fed on the obesogenic diet were hyperphagic, increased their body 
weights and abdominal fat pads. These maternal mice also developed hypertension and 
endothelial dysfunction. Consequently, the offsprings exposed to the influence of 
maternal programming developed similar problems as the dams (Samuelsson et al, 
2008). The livers of these maternal mice were used in the preliminary study as 
described in Chapter 3. The term obesogenic is used in the study by Samuelsson et al, 
(2008) to differentiate the hypercaloric groups subsequently used for the thesis 
(Chapters 5, 11). In fact, both the obesogenic and hypercaloric diets are similar except 
for the different types of fats used, namely lard and palm oil, respectively.  
In Chapter 3, we showed that the obesogenic diet used by Samuelsson et al, 
(2008) caused liver inflammation and mild steatosis in mice compared to the controls. 
Unfortunately, we were unable to calculate the energy intake of the mice and the 
composition of fat intakes derived from the obesogenic and control diets. Therefore, to 
obtain a more accurate measure of energy and fat intakes of mice fed obesogenic diets, 
we prepared our own hypercaloric semi-synthetic pelleted diets prepared in the food 
laboratory and then measured the energy intake derived from the pellets and condensed 
milk separately. We hypothesised that the mice would consume equal amounts of 
pelleted diets and condensed milk as measured over one week. 
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4.1.1 Animal models and materials 
 28 days old juvenile male C57BL/6J mice were obtained from Charles River, 
UK and house in Utemp1284 standard cages (Techniplast, UK) enriched with nesting 
materials such as paper strips, a cardboard roll and wood shavings. The nesting 
materials were necessary for activity (van de Weerd et al., 1997) and environmental 
enrichment (Olsson & Dahlborn 2002). The platform of the cage was layered with wood 
chips. Light condensed milk incorporated with 8% (w/w) palm oil was contained in jars. 
A detailed list of materials is contained in Chapter 2.  
 
4.1.2 Methods 
A total of 8 mice were divided into 2 groups (ie, n = 4 per group) and mice were 
fed on either the standard chow or 18% (w/w) palm oil pellets plus condensed milk 
enriched with 8% (w/w) palm oil. Mice fed with the palm oil plus condensed milk diet 
were called the hypercaloric group and mice fed on the standard chow were the 
controls. Mice were acclimatized for 3 days on standard chow followed by one week of 
feeding with either hypercaloric pellets plus condensed milk or standard chow. Diets 
used for these studies are described in Table 2.1 and. 2.2. The ears of the mice were 
crimped for identification when measuring individual food intake.  
Mice were weighed and randomized into 2 cages to either the control or 
hypercaloric group. All diets and water were fed ad libitum. The nutrient compositions 
of the semi-synthetic pelleted diet and condensed milk incorporated with palm oil are 
presented in Table 2.1 and 2.2. Body weights, food and condensed milk intake of mice 
were weighed daily for 7 days. The moisture absorbance of pellet and condensed milk 
was also tested. Mice were fasted overnight before culling. Liver and fat pads were 
collected and snap frozen in liquid nitrogen. Weights of soleus, plantaris and 
gastrocnemius muscles were recorded. 
 
4.1.3 Results  
During the acclimatization period, body weights and feed intake of mice were 
recorded. It was observed that there was moderate contamination of the condensed milk 
with wood chips which made the measurement of the food intake laborious. There was 
no overt change in weight (ie, an indication of hydration) of the food pellets or 
condensed milk when left for 24 hours (data not presented for brevity). 
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Figure 4.1 showed that mice from both groups gained body weight gradually 
throughout when fed on the control and hypercaloric diets. Mice fed the hypercaloric 
diet showed similar body weights when compared to the controls. There were no 
significant difference in weights of liver, adipose tissue and the total hind limb muscles 
(Table 4.1). The total weights of hind limb muscles included soleus, plantaris and 
gastrocnemius muscles. 
 The energy intakes of mice in the hypercaloric group were mainly derived from 
condensed milk (Table 4.2). The calculated total energy intake in mice fed the control 
and hypercaloric diet was relatively comparable (Figure 4.2). The mean energy intake 
of the hypercaloric group was 58 kcal/week compared to 41 kcal/week in the control 
group (Figure 4.3). Mice in the hypercaloric group consumed a significantly higher 
proportion of the total condensed milk compared to the pellets (Figure 4.4). 
 
Figure 4. 1: Mean body weights of mice fed either a control or a hypercaloric diet 























Body weights are presented in mean ± standard deviation. Day 1-7, Acclimatization 





Table 4. 1: Organ weights (g) soleus:plantaris ratio and total hind limb muscles of 
mice after 6 days of feeding 
Organs (g) Groups n Mean 
95% Confidence 
Interval Bounds P Value 
Lower Upper 
Liver 
Controls 4 0.692 0.529 0.856 
P=0.613 
Hypercaloric 4 0.732 0.562 0.901 
Adipose tissues 
Controls 4 0.164 0.120 0.207 
P=0.071 
Hypercaloric 4 0.290 0.111 0.469 
Soleus 
Controls 4 0.006 0.005 0.007 
P=0.705 
Hypercaloric 4 0.006 0.004 0.007 
Plantaris 
Controls 4 0.010 0.009 0.011 
P=0.097 
Hypercaloric 4 0.012 0.009 0.014 
Gastrocnemius 
Controls 4 0.083 0.072 0.094 
P=1.000 
Hypercaloric 4 0.083 0.073 0.093 
Soleus:Plantaris 
ratio 
Controls 4 0.600 0.488 0.713 
P=0.179 
Hypercaloric 4 0.505 0.341 0.669 
Total hind limbs 
muscles 
Controls 4 0.099 0.087 0.112 
P=0.827 
Hypercaloric 4 0.101 0.088 0.113 
Values are expressed as mean with 95% CI. Independent Student’s t-test was used. 
Total hind limb muscles refer to the sum of soleus, plantaris and gastrocnemius muscle 
weights are combined left and right 
 
 
Table 4. 2: The energy intake of mice over 6 days in control group fed standard chow 
and from hypercaloric animals  
 Control Hypercaloric  
Time (Day) Feed consumed (g) Feed consumed (g) 
Condensed milk 
consumed (g) 
1 14.0 0.4 23.8 
2 12.1 1.2 14.7 
3 12.2 0.6 17.5 
4 12.1 0.7 21.6 
5 12.1 1.0 17.5 
6 12.2 1.3 12.0 






Figure 4. 2: Energy intakes of the mice over 6 days during the feeding period with 































Mean energy intake is presented without standard deviation because there was only one 
cage per group (n = 4 per group). 
 
 




































Figure 4. 4: The total mean energy intake of mice over 6 days in control or 































 Both the control and hypercaloric diets supported growth over a short period of 
feeding and there were no differences in lean tissue as represented by the muscle 
weights. There were no statistically differences in body, liver and adipose tissue weights 
which may be due to the short period of feeding. Consumption of the hypercaloric diet 
resulted in an increased energy intake by 40% mainly contributed by the palm oil 
enriched condensed milk.  
The findings for this PhD indicate that it will be necessary to modify the fatty 
acid composition of the condensed milk as well as the pelleted diet in order to test the 
hypothesis that different dietary fatty acids influence NASH. This is because when 
condensed milk is added alongside the pelleted feed in the hypercaloric diet, the mice 
showed a significantly higher preference towards the condensed milk. By incorporating 





4.2 Experiment 2: Introduction 
 Experiment 2 was to further confirm the finding in Experiment 1 in this section 
that the full fat variety of condensed milk was responsible for the increased food intake 
rather than the composition of the pelleted diet. Therefore, I aimed to test the hypothesis 
that the acclimatization to the pelleted diet prior to the introduction of condensed milk 
would result in increased pellet consumption when condensed milk is introduced. In 
Experiment 2, I will be comparing the energy intake in mice fed standard chow with 
and without condensed milk. In addition, I will also compare the energy intake between 
the mice fed a low fat pelleted diet (2% corn oil) with condensed milk and mice fed a 
hypercaloric pelleted diet (18% palm oil) with condensed milk. I also reduced wood 
chips and paper contamination in the milk jar to increase the accuracy of measuring 
food intake. 
 
4.2.1 Animals and materials 
 C57BL/6J male mice were housed in raised bottom wired cages containing 
cardboard rolls and an aluminium tin to contain the milk jar. 
 
4.2.2 Methods 
 A total of 16 C57BL/6J mice were acclimatized without condensed milk for one 
week. Mice were then allocated to either one of the following 4 groups: standard chow, 
standard chow with access to condensed milk, low fat pellet (2% corn oil) or 
hypercaloric pellet (18% palm oil) with access to condensed milk.  The condensed milk 
used in this study is the full fat variety instead of the light condensed milk. The groups 
were identified as (1) Controls (2) Controls with condensed milk (3) Low fat (4) 
hypercaloric groups. Full details of the diets and their detailed composition are found in 
Chapter 2 and Table 2.1, 2.2 and 2.4. Weights of mice, pellet and condensed milk 
intake were recorded every day for 3 weeks. In order to avoid contamination of 
condensed milk in the jar, mice were placed in raised wire-bottomed cages. After 3 
weeks, feeding jars were removed and mice were fasted overnight before culling. Liver 
tissues were collected and muscle weights were recorded similar to procedures in 




4.2.3   Results 
The weights of adipose tissue in the controls with condensed milk group were 
significantly higher compared to the controls and low fat group (P=0.005). Interestingly, 
the adipose tissue weight in the controls with condensed milk group was 2 fold higher 
compared with the hypercaloric group. There were no significant changes in the weights 
of liver, soleus, plantaris, gantrocnemius and total hind limb weights (Table 4.3). 
Animals fed the pelleted diet (either control or hypercaloric) with condensed 
milk ad-libitum showed increased energy intakes and growth rates that did not differ 
significantly (Figure 4.5). The increased energy intake of these groups was mainly a 
consequence of increased condensed milk consumption (Figure 4.6), which is high in 
sugar/carbohydrate. In the present study no contamination of the condensed milk 
occurred due to the use of raised cages. There was less contamination in the milk jars 
which increased reliability of feed intake measurement. Other observations included 
mice building a nest in the aluminium tin by removing scraps of paper from the 
cardboard roll. This nesting behaviour was consistent throughout the whole experiment; 




Table 4. 3: Organ weights (g), soleus:plantaris ratio and total hind limb muscles of 
mice in  the controls, controls with condensed milk, low fat and hypercaloric groups 
Organs 
(g) 





e Lower Upper 
Liver 
Controls 4 0.662 0.574 0.749 
0.177 
Controls with condensed milk 4 0.723 0.616 0.829 
Low fat 4 0.622 0.507 0.736 
Hypercaloric 4 0.720 0.586 0.854 
Adipose 
tissue 
Controls 4 0.152 
a
 0.052 0.252 
0.005 
Controls with condensed milk 4 0.481
 b
 0.255 0.707 
Low fat 4 0.101
 a
 0.077 0.125 
Hypercaloric 4 0.280
 a,b
 0.038 0.598 
Soleus 
Controls 4 0.015 0.009 0.021 
0.396 
Controls with condensed milk 4 0.014 0.009 0.019 
Low fat 4 0.010 0.001 0.019 
Hypercaloric 4 0.011 0.003 0.018 
Plantaris 
Controls 4 0.015 0.007 0.022 
0.344 
Controls with condensed milk 4 0.016 0.011 0.021 
Low fat 4 0.013 0.010 0.017 
Hypercaloric 4 0.017 0.016 0.019 
Gastrocn
emius 
Controls 4 0.090 0.055 0.124 
0.206 
Controls with condensed milk 4 0.103 0.096 0.110 
Low fat 4 0.097 0.087 0.107 




Controls 4 1.110 0.413 1.808 
0.406 
Controls with condensed milk 4 0.882 0.603 1.160 
Low fat 4 0.841 0.034 1.715 




Controls 4 0.119 0.087 0.150 
0.198 
Controls with condensed milk 4 0.133 0.125 0.140 
Low fat 4 0.121 0.107 0.134 
Hypercaloric 4 0.138 0.113 0.163 
Values are expressed as mean with 95% CI. One way analysis of variance (ANOVA) 
and Tukey’s multiple range test was used. Values with different superscripts indicate 




Figure 4. 5: Body weights of mice in controls, controls with condensed milk, low fat 























 Time line: Day 1-7, without milk; Day 7-21, Feeding period; Day 21-22, Fasted 




Figure 4. 6: Energy intake in week 2 and 3 of mice in controls, controls with 
condensed milk, low fat and hypercaloric groups from acclimatization period to 
feeding and fasted state 
Energy intake (kcal/week)
0 20 40 60
Controls











The results in Experiment 2 show the consumption of condensed milk by mice 
was significantly higher compared to the pelleted diet despite acclimatizing the mice 
with pelleted diets. The acclimatization of mice on only the pelleted diets did not 
increase pelleted diet intake when condensed milk was added to the diet in week 2. This 
was observed in all 3 groups; controls with condensed milk, low fat and the 
hypercaloric group whereby condensed milk was provided in the diet. The results of 
Experiment 2 indicated that it is necessary to modify the fat composition of the 
condensed milk as well as the pelleted diet in order to investigate the effects of dietary 
fats in the diets of mice.  In the subsequent main studies, test fats of known 
concentrations will be incorporated to light condensed milk which has 0% fat to match 
the fat content in the pellets. By increasing the fat content in the light condensed milk, 
the fat content will be more proportionate to the carbohydrate/sugar content in the light 
condensed milk thus, comparable to the ratio of fat to carbohydrate/sugar in the semi-
synthetic hypercaloric diet. Therefore, all condensed milk mentioned in Chapter 5 to 8 
are light condensed milk incorporated with different types of fats. Detailed composition 
of all the diets are contained in Chapter 2 in Table 2.1, 2.2 and 2.4. 
In 2 weeks of feeding period, the weight of adipose tissue showed a 50% 
increase in mice fed the control with condensed milk compared to the mice fed the 
hypercaloric diet which contains 18% (w/w) palm oil. However, the weight of adipose 
tissue in the hypercaloric group was not significantly different when compared to the 
low fat and control group. In simple terms, it can be suggested that the fatty acid 
concentration in the adipose tissue of the hypercaloric group is higher than the controls 
which mimics the diets provided to the respective group. This expected observation 
suggested that the fatty acid profile of the adipose tissue in the study for the thesis may 
reflect the fatty acid profile of the dietary fats provided. In the subsequent main studies 
(Chapter 5 and 6), fatty acid profiles of adipose tissue will be investigated to compare 
with the dietary fat intakes.   
Lastly, raised bottom cages with cardboard roll will be used to prevent mice 
from gnawing on bedding. Jars containing condensed milk will be placed in an 
aluminium container to allow accurate measure of condensed milk spillage. The food 
intake measurements were as accurate as possible, to generate a reliable and more 





The effects of overfeeding with diets high or low 
in fat on the pattern of fatty acid accumulation in 





Fat accumulation in the liver occurs when hepatic fatty acid oxidation is 
suppressed and/or there is excessive delivery of triacylglycerol (TAG) to the liver from 
chylomicrons (Yasunaga et al, 2007) or an excessive flux of non-esterified fatty acids 
(NEFA) from adipose tissue (Larter et al, 2009; Stanton et al, 2011) resulting in hepatic 
TAG synthesis. Overfeeding in humans (Klein et al, 1998; Grau & Bonet 2009) and 
animals (Gaemers et al 2011; Chapter 3) is associated with the development of fatty 
liver and the progression to non-alcoholic steatohepatitis (NASH) and can be achieved 
by overfeeding a diet high in fat and sugar. 
Although liver biopsy is the gold standard measure for the diagnosis of liver 
disease (Brunt & Tiniakos 2010), there are limitations associated with morbidity 
associated with the biopsy procedure (Myers et al, 2008). Therefore, a less invasive 
method is required to distinguish steatosis from NASH to avoid permanent liver 
damage. The effectiveness of histological scoring systems (Brunt et al, 1999; Merat et 
al, 2008) and analyses of serum liver enzymes (Mathiesen et al, 1999; Sorrentino et al, 
2004) related to NASH are well-established but unreliable in diagnosis of early-stage 
NASH. Furthermore, there is a need to identify whether there are differences in the 
pattern of fatty acid accumulation in the various liver lipid fractions which are NEFA, 
TAG, cholesteryl esters and phospholipids.  
In the fed state, excess carbohydrate is converted to fatty acids (mainly palmitic 
and oleic acids) in the liver and stored as TAG in adipose tissue. TAG can also be 
derived from chylomicrons and chylomicrons containing saturated fatty acids (SFA) 
may be metabolized slower than PUFA (Green et al, 1984). However, this may depend 
on the chain length of the fatty acids (Leyton et al, 1987) and their physical properties 
(Berry, 2009).  In the fed state, insulin inhibits hormone sensitive lipase (HSL) in 
adipose tissue which in turn inhibits the supply of NEFA from the adipose tissue to the 
liver (Reid et al., 2008). This may be a potential protective mechanism by the action of 
HSL to prevent further accumulation of fat in the liver.  
In the fasting state, TAG in adipose tissue is hydrolyzed and mobilized into 
plasma causing an influx of NEFA to the liver. In the liver, NEFA has two main fates, 
either beta-oxidation takes place to generate energy including the formation of ketone 
bodies which can be used as an energy source for extrahepatic tissues including the 
brain (Heijboer et al, 2005) or, if oxidation is suppressed, re-esterification from TAG 
(Postic & Girard 2008). The liver is the primary site for cholesterol metabolism and is 
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interlinked with TAG metabolism. Both TAG and cholesteryl esters (CE) accumulate 
within the hepatocyte and their accumulation normally results in the formation and 
secretion of lipoproteins. Very low density lipoproteins (VLDL) are predominantly rich 
in TAG but also contain some CE (Redgrave 1970).  Inhibition of cholesterol synthesis 
by HMGCoA reductase inhibitors decreases VLDL secretion, whereas in vitro studies 
suggest that oleic acid promotes VLDL formation and secretion. The normal process is 
for fat synthesised within the liver to be exported as VLDL for use by muscle or storage 
in adipose tissue. In mammals, the accumulation of fat within the liver generally reflects 
and imbalance between TAG synthesis and secretion; for example in acute starvation. 
One of the pathological features of associated with fatty liver is the ballooning of 
hepatocytes which is believed to be a consequence of an imbalance between 
phosphatidylcholine and phosphotidylethanolamine, and is associated with 
inflammation (Li et al, 2006).  
Excess energy from carbohydrate stimulates de novo lipogenesis in the liver 
whereas excess energy from fat may lead to direct accumulation of lipid within the liver 
even though it suppresses de novo lipogenesis. Fat accumulation in the liver cause 
insulin resistance (Ning et al, 2011) and, therefore, the normal suppression of lipolysis 
following food intake may not occur and the increased flux of NEFA would further 
drive increased TAG accumulation. It is currently uncertain whether the suppression of 
hepatic TAG synthesis would reduce hepatic fat accumulation on a high fat diet. 
Eicosapentaenoic acid (20:5n-3, EPA) and docosahexaenoic acid (22:6n-3, DHA) are 
known to suppress hepatic TAG synthesis. It is uncertain whether they have favourable 
effects in the context of a hypercaloric diet on fat accumulation within the liver. 
It was hypothesised that a hypercaloric diet consisting of ad libitum access to 
condensed milk (CM) and a high saturated and monounsaturated fat diet would 
exacerbate fat accumulation in the liver compared to one low in fat/high in sugar and 
that EPA and DHA would reverse this effect. To test this hypothesis mice were 
randomly allocated to five diets (n=8 per group); a low fat reference (LFR) and 4 
hypercaloric diets  where the animals had access to pelleted diet and condensed milk 
that were low in fat (LF group) or high in fat (HF) with or without additional EPA 





1. Does the addition of fat to a hypercaloric diet alter the pattern of lipid 
accumulation in the liver? 
2. Do EPA and DHA alter the pattern of fat accumulation in the liver? 
 
Aims and objectives 
To conduct a parallel designed feeding trial of 7 weeks duration in mice and to 
assess the pattern of fatty acids accumulation in the liver lipid fractions. 
 
5.2 Methods 
5.2.1    Animal models and materials 
Male C57BL/6J 28-day-old mice obtained from Charles River, UK were housed 
singly in raised bottom wired cages and acclimatised for one week. They were then 
randomly allocated into 5 treatment groups (n=8): low fat reference (LFR), low fat 
hypercaloric (LF) or high fat (HF) or high fat with EPA or DHA (HFEPA and HFDHA 
respectively). The animals were fed on pelleted diet for 1 week and then on pelleted diet 
+ condensed milk except of the eucaloric group, who received pelleted diet only. 
Growth rates and food intakes were monitored and after 7 weeks, food was withdrawn 
in the evening, the animal euthanized the following morning and blood and tissue 
collected. Blood samples were collected via cardiac puncture under anaesthesia and 
whole blood was processed to obtain serum after cervical dislocation. Liver, epididymal 
fat pads, soleus, plantaris and gastrocnemius muscles were collected, blotted dry and 
weights were recorded. All tissues were sectioned into separate vials before being 
rapidly frozen in liquid nitrogen and stored at -70°C until analysis. 
 
5.2.2    Diets 
Semi-synthetic pelleted diets were prepared as described Chapter 2 and the 
freeze dried pellets were stored at 4°C. In order to meet essential fatty acids 
requirements in the low fat groups, the diet contained 2% by weight corn oil. The high 
fat pelleted diets contained 18% fat by weight palm olein or 15% palm olein + 3% EPA 
triacylglycerol concentrate or 15% palm oil + 3% DHA triacylglycerol concentrate. 
Animals allocated to the low fat hypercaloric diet received a condensed milk containing 
1% fat prepared by blending low fat condensed milk (Carnation Light) with corn oil 
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(99:1). The animals on the high fat hypercaloric diet received a blend 92:8 by volume of 
low fat condensed milk and test oil (ie, palm olein, or palm olein + EPA or palm olein + 
DHA).  
 
5.2.3    Analysis of tissue 
Samples of liver were taken for histology (haematoxylin and eosin staining) and 
scored for steatosis, inflammation and reticulin condensation, by Prof. B Portmann 
(KCL). Serum was analysed for insulin, glucose, cholesterol, triglycerides, NEFA and 
liver enzymes ALT, AST and ALP by routine methods. Lipids were extracted from liver 
(Folch et al, 1957) and fractionated into non-esterified fatty acid (NEFA), 
triacylglycerol (TAG), cholesteryl ester (CE) and phospholipid (PL) fractions in the 
presence of C17 containing internal standards to facilitate quantitation. These fractions 
were reacted with HCL in methanol: toluene to form methyl esters which were analysed 
by capillary gas chromatography as described in Chapter 2. Epididymal fat pads were 
directly methylated without any separation into lipid class as they consist almost 
entirely of TAG.  
 
5.2.4    Statistical analysis 
Repeated measure ANOVA was used to compare growth values and dietary 
intake. Other data were analysed using one way analysis of variance (ANOVA). 
Tukey’s multiple range tests was used to make comparisons between diets. Dunnet’s 
test was used to compare energy intakes of mice from LFR group to all other groups. 







5.3.1    Food intake 
Energy intake from solid food declined when there was access to condensed 
milk in both LF and HF group but remained relatively constant in the LFR group 
(Figure 5.1 and Appendix 5.1). Total energy intake was 17 kcal/d higher on the HF 
than the LF group which in turn was greater than the LFR.  The higher energy density 
of the HF condensed milk was mainly responsible for this difference in energy intake. 
The average intakes of energy with 95% CI were 80 kcal/week (74, 86) on the LFR, 94 
kcal/week (88, 99) on LF, 105 kcal/week (99, 110) on the HF, 109 kcal/week (98, 119) 
on HFDHA and 106 kcal/week (100,111) on HFEPA group. Energy intakes from solid 
food and condensed milk are shown in Appendix 5.2 and 5.3 respectively. The 
contribution to energy intake from solid food declined markedly on introduction of 
condensed milk so that the condensed milk was providing about 90% of the energy 
intake. 
 
Figure 5. 1: Total energy intake (kcal/week) from the consumption of all sources 
during run-in and over 6 weeks of feeding period in low fat reference (LFR), low fat 



























Mean values ± SD, 8 animals/group. Repeated measures ANOVA shows significant 
difference between diets P<0.0001. LFR diet is significantly different from all other 
diets (Dunnett's test P<0.05). There are no significant differences between high fat 
diets. The energy intake on the LF diet is 13 kcal/day (95% CI 5, 21) lower than on the 




5.3.2    Body and organ weights  
Generally the animals appeared to remain in good health throughout the study as 
shown in the growth rates of the animals (Figure 5.2 and Appendix 5.4). At the end of 
the study body weights increased in the LF and HF groups, respectively (both P<0.001) 
compared with the LFR group. The weight gain was only 3.6 g greater in the HF group 
compared to the LF group even though the additional energy intake 546 kcal over the 6 
week feeding period would be predicted to result in an increase in weight of about 54.6 
g (assuming each additional 10 kcal results in a 1 g weight gain) (Appendix 5.5). 
Epididymal fat pad weights were correspondingly higher in the HF group compared to 
the LF group but the liver weights did not differ. The weight gain in the LF group 
compared to the LFR group was 4.6 g whereas the additional energy intake of 160 kcal 
would predict an increase weight by 16 g. These findings would suggest that the 
efficiency of energy utilisation was lower on the high fat diet than on the low fat diet. 
The excess energy was presumably lost as heat.  
Plantaris and gastrocnemius muscles were significantly lower in the LFR group 
compared to the others which was reflected in the significant decrease in the total hind 
limb muscles (Table 5.1). No other differences were noted in body and organ weights. 
 
Figure 5. 2: Body weights (g) during run-in and over 6 weeks of feeding period in low 
fat reference (LFR), low fat (LF), high fat (HF), high fat DHA (HFDHA) and high 
























Mean value ± SD, 8 animals/group. There is a significant effect of diet on weight gain 
(P<0.001). At day 50, the weight of LFR group is significantly lower than all other 
groups (P<0.01). There are no differences between HF groups. Body weight of HF 
groups at day 50 is 3.6 g (95% CI 0.9, 6.5) greater than LF group. 
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Table 5. 1: Organ weights (mg) soleus:plantaris ratio and total hind limb muscles of mice after 7 weeks of feeding low fat reference diet (LFR), 
low fat (LF) , low fat (LF), high fat (HF), high fat DHA (HFDHA) and high fat EPA (HFEPA) diets.. 













 (815,1027) P<0.001 
Epididymal 











 (591,1215) P<0.001 






















 (110,118) P<0.001 
Soleus:plantaris  0.572 (0.421,0.724) 0.502 (0.453,0.551) 0.507 (0.448,0.565) 0.490
 
(0.425,0.555) 0.502 (0.457,0.547) P=0.455 












 (134,141) P<0.001 
Mean values with 95% CI. Data were analysed by one way analysis of variance (ANOVA) and values with different superscripts indicate significant 
differences (P<0.05) between treatment using Tukey’s multiple range test. 
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5.3.3    Blood biochemistry 
Blood biochemistry in the animals is shown in Table 5.2. Animals in the LF and 
HF group had fasting plasma glucose concentrations in excess of 7.1 mmol/L indicating 
impaired glucose tolerance compared with 5.2 mmol/L in the LFR group. The mean 
plasma glucose concentrations was greater in the LF group (11.9 mmol/L) compared 
with the LFR, HFDHA and HFEPA groups. Fasting insulin values were low (<1 IU/L) 
and partial haemolysis of the sample may have resulted in the low values.  Serum 
cholesterol concentrations tended to be lower in the LFR group compared to the HF 
group but this fell short of statistical significance. Triacylglycerol were greater in the 
HFDHA and HFEPA groups compared to the LF. These findings were opposite to what 
was expected. However, no correction was made for glycerol in the assay and as the 
animals had been fasted overnight there could be a significant contribution from 
glycerol as a result of increased hydrolysis of lipids from adipose tissue.  
Results for the liver enzymes are shown in Table 5.2 Normal values in 
C57BL/6J mice model in the age range of 1 to 2 months were reported by Mazzaccara 
et al, (2008), to ALP 160, AST 105 and ALT 60 IU/L. AST values were higher in the 
present study. ALT values were unremarkable and ALP values were higher in the LFR 
group compared to the HFEPA and HFDHA group. 
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Table 5. 2: Fasting serum insulin, glucose, cholesterol, triacylglycerols (TAG), non-esterified fatty acids (NEFA concentrations and activities of 
alkaline phosphatase (ALP), aspartate transaminase (AST) and alanine transaminase (ALT) in mice fed either low fat reference (LFR), low fat 
(LF), high fat (HF), high fat DHA (HFDHA) or high fat EPA (HFEPA) diets 
Serum analytes 
LFR LF HF HFDHA HFEPA P Anova 











 (3.0,5.7) P = 0.007 











 (0.8,1.7) P = 0.003 











 (52,67) P = 0.037 
AST (IU/L) 433 (195,1060) 246 (61,553) 309 (67,684) 177 (106,249) 173 (63,283) P = 0.646 
ALT (IU/L) 31 (10,73) 19 (0,37) 21  (3,40) 20 (10,30) 19 (8,29) P = 0.812 
Mean values with 95% C, 8 animals/group. Data were analysed by one way analysis of variance (ANOVA) and values with different superscripts 
indicate significant differences (P<0.05) between treatments using Tukey’s multiple range test. 
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5.3.4    Histopathology  
The histopathological findings on the liver are shown in Table 5.3. Steatosis was 
more frequent and severe in the LFR group compared to the HF and HFDHA group. 
Signs of inflammation were less frequent in all HF groups especially, HFDHA, 
compared to LF and LFR groups. Generally, the HFDHA group showed fewer 
histopathological abnormalities compared to the other groups. Examples of sections 
from animals fed the LF and LFR diets are shown in Figure 5.3. The presence of large 
lipid droplets was very evident in the LFR group. 
 
Figure 5. 3: Panel A shows liver section from a mouse fed the hypercaloric low fat 
diet and Panel B shows one from the low fat reference diet stained with haemotoxylin 
and eosin (400x magnification) 
PANEL A     PANEL B 





Table 5. 3: Histopathology scores for steatosis, inflammation and reticulin condensation of mice fed either low fat reference (LFR), low fat 
(LF), high fat (HF), high fat DHA (HFDHA) or high fat EPA (HFEPA) diets 
 
Scores LFR (n=8) LF (n=8) HF (n=8) HFDHA (n=8) HFEPA (n=8) P Anova (Tukey’s) 
Steatosis 
0 (0%) 0 (0%) 1 (13%) 1 (13%) 3 (38%) 0 (0%) 
P=0.001 
1 (5-25%) 2 (25%) 4 (50%) 4 (50%) 5 (63%) 4 (50%) 
2 (25-50%) 0 (0%) 1 (13%) 3 (38%) 0 (0%) 3 (38%) 
3 (50-75%) 2 (25%) 1 (13%) 0 (0%) 0 (0%) 1 (13%) 
4 (>75%) 4 (50%) 1 (13%) 0 (0%) 0 (0%) 0 (0%) 
Mean  3.1 ± 1.3
a
 1.6 ± 1.30
a,b
 1.3 ± 0.7
b
 0.6 ± 0.5
b




0 (Absent) 0 (0%) 4 (50%) 5 (63%) 7 (88%) 6 (75%) 
P=0.004 
1 (Occasional) 3 (38%) 2 (25%) 3 (38%) 1 (13%) 1 (13%) 
2 (Sparse) 1 (13%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
3 (Frequent) 4 (50%) 0 (0%) 0 (0%) 0 (0%) 1 (13%) 
4 (Most) 0 (0%) 2 (25%) 0 (0%) 0 (0%) 0 (0%) 











0 (Absent) 3 (38%) 4 (50%) 4 (50%) 4 (50%) 3 (38%) 
P=0.274 
1 (Occasional) 1 (13%) 2 (25%) 3 (38%) 4 (50%) 4 (50%) 
2 (Sparse) 0 (0%) 0 (0%) 1 (13%) 0 (0%) 0 (0%) 
3 (Frequent) 3 (38%) 0 (0%) 0 (0%) 0 (0%) 1 (13%) 
4 (Most) 1 (13%) 2 (25%) 0 (0%) 0 (0%) 0 (0%) 
Mean 1.8 ± 1.7 1.3 ± 1.8 0.6 ± 0.7 0.5 ± 0.5 0.9 ± 1.0 
Values are expressed in counts (%) or mean score ± SD 
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5.3.5    Fatty acid composition (weight %) of adipose tissue 
The fatty acid composition of the dietary fat was compared with that of adipose 
tissue (Figure 5.4 and Appendix 5.6). It is often assumed that the composition of 
adipose tissue mirrors that of the dietary fat. However, the proportion of palmitic acid 
was lower and that of oleic acid (18:1n-9) in the adipose tissue than in the HF diet 
indicating that a substantial proportion 16:0 had been chain elongated and desaturated to 
form 18:1n-9. In contrast, in the animals fed EPA and DHA, the proportion of palmitic 
acid was similar to that provided in the diet. This would indicate that EPA and DHA 
inhibited the conversion of palmitic acid to oleic acid. DHA accumulated in adipose 
tissue on the DHA diet but there was only a small increased in EPA in adipose tissue on 
the EPA diet.  The proportion of palmitoleic acid (16:1n-7) in epididymal adipose fats 
was greater in the LF and LFR group compared to the HF groups. This fatty acid 
believed to be an indicator of de novo synthesis of lipid from carbohydrate. There were 
statistically significant differences between diets in stearic acid (18:0), linoleic acid 
(18:2n-6), dihomo-gamma linolenic acid (DGLA; 20:3n-6), clupanodonic acid (22:5n-




Figure 5. 4: Fatty acids composition (weight %) derived from adipose tissue and diets 
of mice fed either low fat reference, low fat, high fat, high fat DHA or high fat EPA 
diets. 
























































































































































































































































































































































Mean values ± SD, 8 animals/group. Open bar, dietary fat, filled bar, adipose tissue. 
 
 
5.3.6    Total lipids and the proportions in different lipid fractions 
The concentrations of hepatic lipid fractions are shown in Table 5.4. NEFA 
concentrations were higher in the LFR group compared with the other groups. TAG 
concentrations were higher in the HFEPA group compared to the LF and HFDHA 
group. Cholesteryl ester concentrations were highest in the LF group and greater in the 
HF group compared to the HFDHA and HFEPA group. Phospholipid concentrations 
were high in the HF group compared to the LF and HFDHA group and highest in the 
LFR and HF group. When the results were expressed on a per liver basis (Figure 5.5), 
the differences were smaller because the LF over-feeding caused an increase in liver 
weight compared with the LFR group and the difference between the LF and HF groups 
in total lipids/liver was more marked as overfeeding with HF which increased both liver 
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size and liver fat concentration. It was decided therefore to only make further 
comparisons on a concentration basis rather than a per liver basis.  
 
 
Figure 5. 5: Hepatic lipid concentrations expressed mg fatty acid /liver in mice fed 
either low fat reference (LFR), low fat (LF), high fat (HF), high fat DHA (HFDHA) 
or high fat EPA (HFEPA) diets. 











































Mean values ± SD, 8 animals/group. Open bar, LFR; filled bar, LF; hatched, HF; 
checked, HFDHA; dots, HFEPA.  Data were analysed by one way analysis of variance. 
Bars with different superscripts indicate significant differences (P<0.05) between 





Table 5. 4: Lipid content of non-esterified fatty acids (NEFA), triacylglycerols (TAG), cholesteryl esters (CE) and phospholipids (PL) expressed 











 ± 8.7 27.0
 a,b
 ± 6.7 19.3
 a 
 ± 5.7 29.7
 b
 ± 5.6 P=0.005 
TAG  84.0
 a,b 






 ± 15.2 102.9
 b
 ± 19.6 P=0.014 
CE  41.5
 c
 ± 12.5 9.3
 a
 ± 1.0 22.2
 b
 ± 5.6 11.9
 a
 ± 1.7 13.8
 a,b
 ± 1.2 P<0.001 




 ± 11.9 83.0
 b
 ± 18.3 67.5
 a,b
 ± 2.2 64.7
 a,b















± 22.0 211.5 
b,c 
± 29.4 P<0.001 
Mean values ± SD; 8 animals/group. Data were analysed by one way analysis of variance. Values with different superscripts indicate significant 
differences (P<0.05) between treatments using Tukey’s multiple range test. 
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5.3.7    Fatty acid concentrations by degree of unsaturation in liver lipid fractions 
The concentrations of lipids according to degree of unsaturation by lipid classes 
are shown in Figure 5.6. SFA concentrations in NEFA were lower in LF, HF and 
HFDHA compared to LFR and HFEPA.  In the TAG fraction, SFA concentrations were 
greater in HFEPA and HF when compared to LFR, LF and HFDHA. In the CE fraction, 
SFA concentrations were significantly lower in LF when compared to LFR and HF.  
MUFA concentrations were significantly higher in LFR group in NEFA and CE 
fractions when compared to other groups whereas those in HFDHA and HFEPA 
showed the lowest concentration (Figure 5.6). In TAG fraction, MUFA was lowest in 
HFDHA group when compared to the other groups whereas HF was significantly 
greater when compared to others but showed no statistical difference when compared to 
HFEPA.  In PL, MUFA was significantly lower in HFDHA and HFEPA when 
compared to HF. 
PUFA concentrations in NEFA were greater in the LFR group compared to the 
other groups (Figure 5.6). In the TAG fraction, PUFA concentrations were highest in 
the HFDHA and HFEPA groups compared to the LF group. In the CE fraction, PUFA 
concentrations were highest in the LFR group compared to all other groups but lower in 






Figure 5. 6: Fatty acid concentrations (mg/g) derived from NEFA, TAG, CE and PL 
fractions classified into saturated fats (SFA), monounsaturated fatty acids (MUFA) 
and polyunsaturated fatty acids (PUFA) in mice fed either low fat reference (LFR), 







































































































































































Mean values ± SD, 8 animals/group. Open bar, LFR; filled bar, LF; hatched, HF; 
checked, HFDHA; dots, HFEPA. Saturated fatty acids (SFA), monounsaturated fatty 
acids (MUFA), polyunsaturated fatty acids (PUFA). Data were analysed by one way 
analysis of variance.. Bars with different superscripts indicate significant differences 
(P<0.05) between treatments using Tukey’s multiple range test. 
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5.3.8    Short and long chain PUFA concentrations in different lipid classes  
There were major differences in the concentration of long-chain polyunsaturated 
fatty acids between treatments (Figure 5.7). The addition of EPA and DHA increased n-
3 LCP and decrease n-6 LCP in all fractions. The concentration of n-3 LCP was greater 
in NEFA, TAG, CE and phospholipid in HFPO, HFDHA and HFEPA compared to LFR 
and LF. The lowest concentration on n-3 LCP was found in the LFR and LF group in all 
fractions, which would correspond with the lower level of 18:3n-3, but the 
concentration of n-6 LCP was correspondingly greater. The LFR and LF group led to a 
markedly higher concentration of n-6 LCP in the NEFA, TAG and PL fractions 
compared to HFPO, HFDHA and HFEPA. High fat feeding showed an increase in n-3 
LCP and a decrease in n-6 LCP in all fractions when compared to LFR and LF groups.  
 
Figure 5. 7: Fatty acid concentrations (mg/g) derived from NEFA, TAG, CE and PL 
fractions classified into linolenic acid (18:3n-3), linoleic acid (18:2n-6), n-3 long 
chain PUFA (n-3 LCP) and n-6 long chain PUFA (n-6 LCP) in mice fed either low 
fat reference (LFR), low fat (LF), high fat (HF), high fat DHA (HFDHA) or high fat 
EPA (HFEPA) diets. 























































































































































































Mean values ± SD, 8 animals/group. Open bar, LFR; filled bar, LF; hatched, HF; 
checked, HFDHA; dots, HFEPA.  Linolenic acids (18:3n-3), linoleic acid (18:2n-6), 
long chain polyunsaturated fatty acids (LCP). Data were analysed by one way analysis 
of variance. Bars with different superscripts indicate significant differences (P<0.05) 
between treatments using Tukey’s multiple range test. 
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5.3.9    Major individual fatty acid concentrations in NEFA, TAG, PL and CE 
fractions 
In the NEFA fraction, the concentration of palmitic acid (16:0) was significantly 
higher in HFEPA when compared with LF and HFDHA groups (P<0.001) (Figure 5.8). 
As with adipose tissue, the proportion of palmitic acid (16:0) in the liver was greater in 
the HFDHA than in the HF group whereas the concentration of palmitoleic acid (16:1) 
was lower. Stearic acid concentrations were also higher in the LFR and HFEPA groups 
compared with the other groups.  The concentration of oleic (18:1n-9) and linoleic acid 
(18:2n-6) was significantly higher in LFR compared to LF, HF, HFDHA and HFEPA 
groups.  The HFDHA group had significantly lower concentrations of linoleic acid 
(18:2n-6) when compared to the LF group. In addition, arachidonic acid (AA; 20:4n-6) 
concentrations were significantly higher  in the LFR and LF groups when compared to 
HF and even more so HFDHA and HFEPA groups. As expected, DHA and EPA 
concentrations were highest in mice fed DHA and EPA, respectively. However, there 
was a higher concentration of DHA in the HF compared to the LF group.  
In the TAG fraction, the concentration of palmitic acid was significantly higher 
in the HFEPA group compared to the LF group (Figure 5.8). Palmitoleic acid was 
significantly lower in the HFDHA group compared to the HF group. In accord with the 
findings in the NEFA fraction, stearic acid concentration was higher in HFEPA 
compared to LF, HF and HFDHA. Oleic acid concentrations were significantly higher 
in the HF group compared to the HFDHA group. EPA concentrations were markedly 
higher in HFEPA compared to the other groups. DHA concentrations were greater in 
the order of HFDHA> HFEPA> HF compared to the LF and LFR groups. 
In the cholesteryl ester fraction, cholesteryl oleate and linoleate concentrations 
were both higher in the LFR group compared to the other groups (Figure 5.8). 
Cholesteryl palmitate concentrations were greater in the HF compare to the LF group 
and cholesteryl oleate concentrations were greater in the HF group compared to LF, 
HFDHA and HFEPA groups. Cholesteryl docosahexaenoate concentrations were 
greater in the order HFDHA>HFEPA>HF compared to the LF and LFR groups. The 
concentration of cholesteryl arachidonate was correspondingly lower.  
In the phospholipid fraction, palmitic acid (16:0) concentrations were significantly 
lower in the LF group vs the HF group but were significantly lower in the HFEPA and 
HFDHA group when compared to HF group (Figure 5.8). Arachidonic acid 
concentrations were lower in the HFEPA and HFDHA groups and those of EPA and 
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DHA were higher. The concentration of DHA was notably higher in the HF group 
compared to the LF group.  
 
 
Figure 5. 8: Concentration of different fatty acids (mg/g liver) in major lipid classes 
in mice fed either low fat reference (LFR), low fat (LF), high fat (HF), high fat DHA 











































































































































































































































































Mean values ± SD, 8 animals/group. Open bar, LFR; filled bar, LF; hatched, HF; 
checked, HFDHA; dots, HFEPA. Data were analysed by one way analysis of variance. 
Bars with different superscripts indicate significant differences (P<0.05) between 




The aim of this study was to see if a high fat diet exacerbated NASH in this 
overfeeding model. High fat feeding increased energy intakes (kcal/week) and this was 
a consequence of the higher energy density of the diet. The animals on the high fat diet 
accumulated more epididymal adipose tissue and fattier livers compared to the overfed 
animals on the low fat diet. However, the addition of DHA to the high fat diet decreased 
the fat content of the liver to that similar on the LF diet. The addition of EPA to the high 
fat diet did not decrease liver fat. The findings, therefore, suggest that DHA but not 
EPA reduces fat accumulation in the liver. This finding is also consistent with the 
absence of histological abnormalities in the HFDHA group. 
The expansion of the cholesteryl ester pool was mainly due to increased 
proportions of cholesteryl oleate and linoleate. Unexpectedly, there was no evidence to 
indicate that the HF worsened liver damage as judged by liver enzymes and histology. 
Indeed, the histology indicated more inflammation (P=0.015), steatosis and reticulin 
condensation in mice fed the LFR diet than the LF diets and the least in HF, HFDHA 
and HFEPA groups. 
Adipose tissue composition did not entirely represent the dietary fat in the HF 
group, the proportion of palmitic acid was lower and that of oleic acid was higher. The 
lack of similarity in the fatty acid composition of adipose tissue compared to the dietary 
fat signifies modification of dietary fatty acids in adipose tissue and contribution from 
de novo lipogenesis particularly in the low fat high carbohydrate groups. For example, 
palmitic acid accounted for about 40% of the fatty acids in palm olein but only 25% in 
adipose tissue and oleic acid accounted for 43% in palm olein but 55% in adipose 
tissue. As palmitoleic acid was not provided in the diet it must have been synthesised 
from palmitic acid and the proportion in adipose tissue was about 8%. This still leaves 
about 7% palmitic acid unaccounted and a higher than expected proportion of oleic acid 
in adipose tissue. In the LF group, the linoleic acid accounted from about 57% of the 
dietary fat but about 15% of the adipose tissue. This would suggest that only about a 
quarter of the fat in adipose tissue was derived directly from dietary fat and remaining 
amount would have been synthesised de novo. These findings also lend support to the 
idea that adipose tissue composition is a poor indicator of dietary saturated fat intake 
and that the effect of overfeeding is primarily to increase palmitic and oleic acid 
synthesis, which are the same as the major fatty acids in palm olein. The addition of 
EPA and DHA to the diet results in a higher proportion of 16:0 in adipose fatty acids. 
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This probably was a consequence of decrease chain length and desaturation in oleic acid 
caused by competitive inhibitor by n-3 LCP.  
Hepatic NEFA concentrations were greater in the mice fed the reference diet 
which is low in fat (2 % corn oil) and without condensed milk (CM). This may be due 
to larger amounts of fatty acids being released from adipose tissue to the liver when the 
animals were fasted prior to sacrifice because of their lower energy reserves. Plasma 
NEFA concentration represent the influx of fatty acids from adipose tissue and the spill 
over of fatty acids released during lipolysis which are not trapped by fatty acid binding 
proteins (Sniderman et al, 1998). On the low fat diets, the composition of hepatic NEFA 
was quite similar to that of adipose tissue which is consistent with it being derived 
mainly from the lipolysis of adipose. However, the proportion of oleic acid in this 
fraction was lower than that in adipose tissue. The hepatic NEFA probably reflect the 
composition of the metabolically active pool of fatty acids that feed into esterified lipid 
synthesis and fat oxidation. The lower proportion of oleic acid could indicate a more 
rapid utilisation of this fatty acid for beta-oxidation. Indeed, tracer studies indicate a 
higher rate of beta-oxidation of oleic acid vs palmitic acid (Leyton et al, 1987). 
The regulation of hepatic TAG biosynthesis under various nutritional states has 
been extensively studied in the liver (Mayes & Felts 1967; Menahan et al, 1983; 
Takahashi et al, 2003; Turner et al, 2003). An average mouse liver (1 to 1.5 g) is able to 
incorporate 200 to 300 nmol of glycerol into TAG per min and is dependent on the fatty 
acids present (Greenspan et al, 1982). Results of hepatic TAG suggested a significantly 
rapid desaturation of stearic to oleic acid in all 3 groups that were 3 times lower when 
compared to the NEFA profile. HF group showed a higher desaturation of stearic to 
oleic acid when compared to the LFR and LF respectively. The raised levels of oleic 
acid in TAG liver of HF group may be the reason for the insignificant increase in serum 
cholesterol (Bonanome et al, 1992). A high proportion of stearic acid instead of palmitic 
acid was converted to oleic acid (Bonanome et al, 1992; Emken et al, 1993) or stearic 
acid was synthesised de novo from carbohydrate. Oleic acid is relatively stable to 
oxidation compared with PUFA. On the other hand, a reduced proportion of stearic acid 
(C18:0) and increased proportion of oleic acid (C18:1n-9) increased the proportions of 
long-chain PUFA (AA and DHA) in HF mice. This suggest that high fat palm oil diet 
had the effect of increasing fatty acid desaturation which increases susceptibility to lipid 
oxidation in vivo (Valencak & Ruf 2011).  
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Fatty acids are converted to cholesteryl esters by the action of the enzyme 
acetyl-Coenzyme-A acetyltransferase (ACAT). This enzyme exists in different forms 
but has high specificity for oleic and linoleic acid with linoleic acid being the preferred 
substrate. There was proportionately least cholesteryl linoleate in animals fed the LF 
diet, followed by the HF and then the LFR diet. Previous research has shown that oleic 
acid feeding resulted in the accumulation of cholestryl oleate in the liver whereas 
palmitic acid resulted in a much lower accumulation of cholesteryl oleate (Takeuchi et 
al, 1999). Cholesteryl oleate accounted for 40%, 33% and 16% of cholesteryl esters in 
the LFR, HF and LF mice respectively.  
In hepatic phospholipds, there were marked differences in the balance of n-6/n-3 
long chain polyunsaturated fatty acids The elevated DHA concentrations in the HF fed 
mice is in agreement with the finding in the pilot study and suggests that conversion of 
linolenic acid to DHA may be enhanced on a high fat diet in the presence of a high 
sugar intake, presumably because linolenic acid is spared from oxidation.  
The findings of this study do not support the hypothesis that an increased intake 
of palmitic and oleic acids exacerbates NASH compared with carbohydrate overfeeding. 
The higher proportion of C20-22 polyunsaturated fatty acids in the HF group indicates 
that the high fat and/or high sugar diet promotes their synthesis from linolenic acid and 




Chapter 6:  
The effects of triacylglycerol structure of palmitic 
acid rich fats on liver lipids in mice fed 



























 It has been suggest that animal fats, such as lard, which are high in saturated 
fatty acids, exacerbate fatty liver disease. Palm oil is now the major vegetable oil 
produced globally being produced mainly in Malaysia and Indonesia. Palm oil is high in 
palmitic acid (16:0) but is also high in the oleic acid (18:1n-9) and unlike coconut oil 
contains significant amounts of the essential fatty acid linoleic acid (18:2n-6). Although 
palm oil is regarded as a saturated fat, it may have different properties from animal fats 
because of its triglyceride structure where the palmitic acid is in the sn-1 and sn-3 
positions and the unsaturated fatty acids are present in the sn-2 position mainly as 1,3 
dipalmityl-2 oleoyl-sn-glycerol and 1,2 dioleoyl, 3- palmityl-sn-glycerol. Lard, contains 
a similar proportion of saturated fatty acids and unsaturated fatty acids compared to 
palm olein but is characterised by a high proportion (about 70%) of palmitic acid in the 
sn-2 position of the TAG  mainly as 1,3 dioleoyl-2-palmityl-sn-glucerol.  
Interesterification is a process that does not affect the fatty acid composition but 
redistributes fatty acids in the three positions of TAG. Interesterification can be directed 
to place fatty acids in certain positions using enzymes, for example Betapol™, which is 
an interesterified fat made from palm olein that consists mainly of oleic, palmitic and 
oleic acid  in sn-1, 2 and 3 respectively (OPO) and is used in the manufacture of infant 
formula because of its higher digestibility. More commonly interesterification involves 
randomization of vegetable oils either using a chemical catalyst such as sodium 
methoxide or bacterial derived enzymes. The randomization results in fatty acids being 
equally distributed among the three position of the triacylglycerol. The process is 
widely used by the food industry to make higher melting fats that are favoured for the 
functional characteristics in making margarine and bakery products. This technique is 
now in widespread in Europe when it was decided to avoid using the process of partial 
hydrogenations, which generates trans-fatty acid. 
Palmitic acid in the sn-2 position of TAG as in lard is very well absorbed in rats 
(Kayden et al, 1967) whereas as randomized lard is less well absorbed (Boquillon et al, 
1977). Furthermore, the fatty acids in the sn-2 position are retained in that position upon 
absorption, and TAG synthesis in the intestine retains the same fatty acid as in the sn-2 
MAG (Small et al, 1991). Thus lard which is rich in (oleic, palmitic, oleic acid) OPO 
gives rise to chylomicron TAG that is rich in OPO. Sanders et al, (2011) have recently 
demonstrated differences in postprandial lipaemia between palm olein, interesterificd 
palm olein and lard and confirmed that there are differences in the structural 
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composition of the newly absorbed fat in human volunteers. The effects of altered 
stereospecific TAG structure on liver lipids are uncertain.  
It was hypothesised that the stereospecific location of palmitic acid in TAG may 
result in a different pattern of fat accumulation in the liver. In order to test this 
hypothesis, an experiment was conducted using the high fat overfeeding model 




6.2.1 Dietary fats 
The four test fats compared were: high oleic sunflower oil (HOSO, Archer 
Daniel Mills, Erith, UK), native palm olein (PO, iodine value 56) (Archer Daniel Mills, 
Erith, UK) interesterified palm olein (IPO, made from the same batch of oil as the PO) 
and lard (Sainsbury PLC, UK). The fatty acid composition of the oil and the TAG 
molecular species were determined by high resolution gas chromatography by the 
European laboratories of Archer Daniel Mills (Hamburg, Germany).  The fatty acid 
composition of the experimental fats was confirmed at King’s College London 
following HCl-catalysed methylation to form methyl esters by capillary gas liquid 
chromatography (GLC) using a BP70 column (25 m x 220 µm x 0.25 µm; SGE 
Analytical Science, Victoria, Australia) on an Agilent 6890 (Agilent Technologies, 
Cheshire, United Kingdom).  
Fatty acid methyl standards were obtained from Sigma (Poole, Dorset). The 
proportions of fatty acids in the sn-2 position of the TAG were determined following 
incubation of the TAG with porcine lipase (Type VI-S, from porcine pancreas, EC 
3.1.1.3, 100,000 units, Sigma, Poole, Dorset, UK), separation of the 2-mono-
acylglycerol and analysis of its fatty acid composition were conducted by Androulla 
Filippou (King’s College London). The test fat (50 mg) dissolved in heptane (50 μL) 
was incubated with 0.5 ml sodium cholate and 1 g/L 1 M Tris pH 8.0 at 40°C, 0.2 ml 
CaCl2  (220 g/L water, pre-incubated at 40°C) followed by 200 μl (20,000 units) lipase 
dissolved in TRIS buffer, the tube was immediately vortex mixed following the addition 
of lipase and incubated at 40°C in a shaking water bath for 1 min, removed and vortex 
mixed for 2 min, cooled on ice and 1 ml hydrochloric acid (6 N) and 3 ml diethyl ether 
added. The upper phase was collected and dried under nitrogen and the residue 
dissolved in heptane and applied to a Silica Gel G TLC (0.5 mm) plate and developed in 
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(hexane:diethyl-ether:formic acid glacial (140:60:4 by volume). Following 
development, the plates were sprayed with 5 mg 2’7’-dichlorofluorescein/L methanol 
water (95:5 by volume) and bands visualized under a uv light source.  A standard of 2-
mono-oleoyl-glycerol (Sigma, Poole, Dorset, UK) was used to identify the 
monacylglycerol band. The bands were scraped from the TLC plate and methylated 
with 2 ml methanol: toluene (80:20 by volume) containing 50 g/L HCl by incubation at 
60°C for 2 h. The methyl esters were recovered from the upper phase following the 
addition of 6 ml potassium carbonate for GLC analysis. 
The composition of the experimental fats of both palm olein fractions had a 
similar fatty acid composition but the native PO consisted mainly of 1, 3 dipalmityl-2 
oleoyl-sn-glycerol and 1, 2 dioleoyl, 3- palmityl-sn-glycerol. The proportions of 
palmitic acid at the sn-2 position were 0.6 mol% in HOSO, 9.2 mol% in PO, 39.1 mol% 
in IPO and 70.5 mol% in lard. The lard contained a similar proportion of saturated fatty 
acid (47.0 vs. 47.8 mol %) and oleic acid (39.2 vs. 39.6 mol %) compared to PO and 
IPO but contained more stearic acid (16.2 vs. 4.0 mol %) and less palmitic acid (29.1 vs. 
42.5 mol %) (Table 6.1). 
Differential scanning calorimetry (Reading Scientific Services Ltd; Reading, 
UK) showed lard to have single melting point peak at 32.9°C and the IPO to have two 
melting point peaks at 16.6°C and 38.2°C; measurement of the solid fat content by 
NMR (Reading Scientific Services Ltd; Reading, UK) of lard and IPO gave values of 
7.9% and 9.7% at 32°C, 4.8% and 4.7% at 37°C and 2.7% and 2.2% at 42°C 
respectively. PO had a single melting peak at 13.3°C and was fully melted at that 





Table 6. 1: Proportions of fatty acids in the total fat, in the sn-2 position and the 
triacylglycerol (TAG) composition of the experimental fats 
Taken from Sanders et al, (2011). A, arachidic acid; L, linoleic acid; M, myristic acid; 
O, oleic acid; P, palm olein; S, stearic acid.  
  Mol % 
 
Fatty acids  
 HOSO PO IPO Lard 
14:0 
total 0.1 1.3 1.3 1.7 
sn-2 0.0 0.6 1.2 3.3 
16:0 
total 4.4 42.5 42.5 29.1 
sn-2 0.6 9.2 39.1 70.5 
16:1 
total 0.1 0.2 0.2 2.8 
sn-2 0.0 0.0 0.3 3.2 
18:0 
total 2.8 4.0 4.0 16.2 
sn-2 0.3 1.6 5.6 5.0 
18:1n-9 
total 80.5 39.6 39.6 39.2 
sn-2 87.8 69.1 43.0 14.1 
18:2n-6 
total 10.6 10.8 10.8 8.6 
sn-2 11.3 19.5 10.8 3.9 
      
  Mol % 
Carbon Number TAG species  HOSO PO IPO Lard 
46:0 MPP/PMP 0.0 0.2 0.7 0.2 
46:1 MOM/OMM 0.0 0.1 0.5 0.2 
48:0 PPP 0.0 0.8 7.8 0.8 
48:1 MOP/OPM 0.0 1.6 1.5 1.2 
48:2 MLP/LMP 0.0 0.4 0.6 0.5 
50:0 PPS/PSP 0.0 0.2 2.2 2.8 
50:1 POP/PPO 0.6 29.4 22.6 8.6 
50:2 PLP/LPP 0.2 9.3 6.6 3.3 
52:0 PSS/SPS 0.0 0.0 0.3 4.0 
52:1 POS/PSO/SPO 0.5 5.1 4.2 22.9 
52:2 POO/OPO 10.8 23.0 22.3 23.2 
52:2 PLS/PSL/LPS 0.0 2.0 0.0 8.1 
52:3 PLO/LPO/LOP 1.8 9.9 11.2 11.0 
54:0 SSS 0.0 0.0 0.0 0.4 
54:1 SOS/SSO 0.0 0.6 0.5 1.6 
54:2 SOO/SOP 6.8 2.6 2.1 3.9 
54:2 SLS/LSS 0.0 0.0 0.0 0.5 
54:3 OOO 76.8 3.5 6.2 3.4 
54:3 SLO/OSL/LOS 0.0 1.2 1.1 2.7 
56:2 AOO/OAO 0.0 0.2 0.0 0.0 
 Diacylglycerol 2.4 9.9 9.8 0.7 
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6.2.2 Animal models and materials 
Male C57BL/6J mice were obtained from Charles River, UK and housed singly 
in raised bottom wired cages. Semi-synthetic diets containing 18% by weight fat were 
prepared in a food lab free from contamination: the fat was provided by the test fats, 
high oleic sunflower oil (HOSO), the palm oil (PO), interesterified palm oil (IPO) and 
the lard (see Table 2.3). The dough like consistency diets was formed into pellets by 
hand and frozen for 12 hours in -40°C before transferring to the freeze-drier for 3 days. 
The freeze-dried pellets were then stored in 4°C cold room until experimentation. 
Condensed milk containing 8% (w/w) of the test fat was freshly prepared by mixing 
Carnation Light (contains no fat) in a ratio of 92:8 by volume with the test fat on the 
day of feeding to mice in respective groups. The composition of the test milk is shown 
in Table 2.4. Source of materials and detailed list of ingredients for all diets are 
provided in Chapter 2. 
 
6.2.3 Experimental design 
A parallel design was used to compare 32 animals randomly allocated to 4 
treatments (8/group): HOSO (control), PO, IPO and lard. For 6 weeks, animals were 
allowed ad libitum access to the respective pellets and CM. After 6 weeks on the 
experimental diet, the animals were euthanized.  
Blood samples were collected via cardiac puncture under anaesthesia and whole 
blood was processed to obtain serum after cervical dislocation. Liver, epididymal fat 
pads, soleus, plantaris and gastrocnemius muscles were collected, blotted dry and 
weights were recorded. All tissues were sectioned into separate vials before being 
rapidly frozen in liquid nitrogen and stored in -70°C until analysis. 
 
6.2.4 Analysis of tissue 
 The methods used for analyses are described in detail in Chapter 2, briefly lipids 
were extracted from liver (Folch et al, 1957) and fractionated into non-esterified fatty 
acids (NEFA), triacylglycerols (TAG), cholesteryl esters (CE) and phospholipids (PL) 
by solid phase extraction (Kaluzny et al, 1985). Heptadecanoic acid (C-17) containing 
internal standards were added to quantify the fatty acids present in each fraction. All 4 
fractions were methylated and loaded onto the gas chromatograph to obtain individual 
fatty acid profiles using acid catalysis with HCl (Lepage & Roy 1986). Epididymal fat 
pads (~50 mg) were treated with 2 ml of a 5% solution of HCl in methanol:toluene 
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(80:40 by volume) at 60°C for 2 hours to yield fatty acid methyl esters which were 
collected from the upper phase following the addition of 4 ml 6% potassium carbonate 
solution. The upper phase was diluted with hexane and analysed by gas 
chromatography. The hind limb muscles (soleus, plantaris and gastrocnemius) were 
weighed and recorded to determine if there were signs of muscle loss during the feeding 
period. 
 
6.2.5 Statistical analysis 
Data were analysed using SPSS version 18.0 by analysis of variance (ANOVA). 
Tukey’s multiple range tests was used to make comparisons between diets when the 
overall F value was P<0.05. Chi-squared test was used to compare the differences in the 




6.3.1 Food intake 
Energy intakes during the study are shown in Figure 6.1 and Appendix 6.1. 
Initially there were small differences in energy intakes between groups but by week 5 
these differences had disappeared and the overall energy intake for the 6 week period 
did not differ between groups. Average energy intakes with 95% CI were 104 kcal/week 
(98, 109) in the HOSO group, 109 kcal/week (102, 116) in the PO group, 113 kcal/week 
(108,117) in the IPO group and 109 kcal/week in the lard group. Energy intakes were 
similar in the PO group to that reported in Chapter 5 for the HF diet, which had an 
identical composition. Energy intakes from solid food and condensed milk are shown in 
Appendix 6.2 and 6.3, respectively. In all groups, the contribution to energy intake from 
solid food was less than that from condensed milk in which the condensed milk 




Figure 6. 1: Energy intake (kcal/week) from consumption of all sources over 6 weeks 
of feeding period in mice fed either a high fat high oleic sunflower oil (HOSO), palm 
olein (PO), interesterified palm olein (IPO) or lard diet 




























Mean values ± SD for 8 animals/group. Data were analysed by repeated measures 
ANOVA. No significant differences in energy intake between groups 
 
 
6.3.2 Body and organ weights  
Body weights increased by 2.4, 2.5, 2.6 and 2.3 g in the HOSO, PO, IPO and 
lard groups, respectively but did not differ significantly between groups (Figure 6.2 and 
Appendix 6.4). The animals appeared to be in good health throughout the study and did 
not show significant weight loss in all groups (Appendix 6.5). 
There was a significant difference in liver (P=0.047) with the liver weight being 
highest in the IPO group (Table 6.2). Total limb muscle weights tended to be 
marginally lower in the HOSO but not in adipose tissue and muscle weights or in ratio 
of soleus: plantaris ratio between treatments. However, the liver weights and adipose 





Table 6. 2: Organ weights (g) after 6 weeks of overfeeding either high oleic sunflower oil (HOSO), palm olein (PO), interesterified palm olein 
(IPO) or lard diets. 
 HOSO PO IPO Lard P Anova 
Liver (mg) 771 (706,837) 817 (740,895) 904 (832,976) 825 (736,914) P = 0.047 
Epididymal adipose 
tissue (mg) 
340 (139,541) 414 (185,644) 468 (226,709) 410 (211,609) P = 0.797 
Soleus muscle (mg) 12 (11,13) 12 (10,14) 12 (10,14) 12 (10,15) P = 0.961 
Plantaris muscle (mg) 23 (21,25) 22 (20,24) 24 (22,26) 24 (22,26) P = 0.327 
Gastrocnemius 
muscle(mg) 
174 (165,183) 178 (172,184) 181 (172,190) 174 (159,190) P = 0.635 
Soleus:plantaris ratio 0.513 (0.476,0.550) 0.554 (0.466,0.641) 0.507 (0.438,0.575) 0.508 (0.410,0.606) P = 0.710 










(194,228) P = 0.050 
Values are expressed as mean with 95% CI. Data are analysed by one way analysis of variance. Values with different superscripts indicate 





Figure 6. 2: Body weights (g) over the 6 weeks feeding period in mice fed either a 
high oleic sunflower oil (HOSO), palm olein (PO), interesterified palm olein (IPO) or 
lard diets. 
 




















No significant differences in body weights between groups. Repeated measures ANOVA. 
Mean values ± SD for 8 animals /group. 
 
 
6.3.3 Blood biochemistry  
 There was a tendency for plasma glucose concentrations to be high in all group 
(>7.0 mmol/L) (Table 6.3). However, there were no differences between treatments in 
serum lipids, liver enzymes alkaline phosphatase (ALP), aspartate aminotransferase 




Table 6. 3: Serum analyses of insulin, glucose, cholesterol, triacylglycerols (TAG) 
and non-esterified fatty acids (NEFA) in mice fed either a high fat high oleic 
sunflower oil (HOSO), palm olein (PO), interesterified palm (IPO) or lard diest 
 HOSO PO IPO Lard P Anova 












(mmol/L) 4.4 (3.9,4.8) 5.4 (1.0,9.8) 4.9 (3.8,5.9) 5.1 (4.7,5.5) P=0.808 
Triacylglycerol 
(mmol/L) 0.7 (0.6,0.8) 1.1 (0.2,2.0) 1.3 (0.5,2.1) 1.0 (0.8,1.3) P=0.209 
NEFA 
(mmol/L) 1.5 (1.0,2.0) 2.4 (0.2,4.6) 2.2 (1.4,2.9) 1.6 (1.1,2.0) P=0.368 










ALT (IU/L) 31 (16,46) 31 (7,55) 38 (15,61) 24 (14,33) P=0.429 
Values are expressed as mean with 95% CI. Data are analysed by one way analysis of 
variance. Values with different superscripts indicate significant differences between 




6.3.4 Fatty acids composition of adipose tissue 
The fatty acid composition of the epidydimal adipose tissue compared to the 
dietary fat for the respective diets are showed in Figure 6.3 and Appendix 6.6. The fatty 
acid composition of the HOSO adipose tissue generally mirrored that of the diet except 
that the proportion of palmitic acid was greater than in the diet. In agreement with the 
findings in Chapter 5, the PO diet resulted in a lower proportion of palmitic acid in 
adipose tissue than in the diet and a correspondingly higher proportion of oleic acid.  
IPO results in a higher proportion of palmitic acid compared to PO (23.8 vs 27.3%) and 
lower proportion of linoleic acid (7.9 vs. 9.9%). The proportion of stearic acid was 
greater in the lard fed animals than in the other groups. In contrast to the PO fed 
animals, the proportion of palmitic acid was similar to that provided in the diet on the 
lard diet. Adipose tissue from the PO fed animals contained significantly more 
docosahexaenoic acid (0.3%) compared with the other diets (<0.1%). 
 
Figure 6. 3: Fatty acids composition (weight %) of adipose tissue of C57BL/6J male 
mice fed either a high oleic sunflower oil HOSO), palm olein (PO), interesterified 


























































































































































































































































































6.3.5 Total liver lipids and proportions in different class 
  The lipid concentrations expressed as fatty acids in the different lipid fractions 
did not differ between treatments when expressed per gram tissue (Table 6.4). However, 
when expressed on a per liver basis, the difference between the IPO diet and other diets 
became significant albeit for only PL (Figure 6.4). 
 
Table 6. 4: Liver lipid concentrations as mg fatty acids/g liver in mice fed either a 
high fat high oleic sunflower oil (HOSO), palm olein (PO), interesterified palm olein 
(IPO) or lard diets) 
Fatty 
acids 
HOSO  PO  IPO Lard  
Statistical 
significance 
NEFA 13.6 ± 3.7 11.8 ± 3.6 9.8  ± 3.7 9.5 ± 1.7 P=0.070 
TAG 50.3 ± 7.8 54.5 ± 16.9 36.5 ± 11.8 34.6 ± 6.2 P=0.090 
CE  31.8 ±10.5 31.9 ± 7.5 38.1 ± 10.9 32.6 ± 7.7 P=0.489 
PL 60.4 ± 3.5 60.4 ± 5.8 71.5 ± 12.1 63.4 ± 10.5 P=0.057 
Mean values± SD, 8 animals /group except for PO n=7. Data were analysed by one-
way analysis of variance 
 
Figure 6. 4: Fatty acid concentrations (mg/ liver) in different liver lipid fractions in 
mice overfed high oleic sunflower oil (HOSO) palm oil (PO), interesterified palm oil 
(IPO) or lard. 









































Mean ± SD; n=8 animals/group. Open bar, HOSO; checked, PO; filled bar, IPO; line, 
lard. Data were analysed by one way analysis of variance (ANOVA). Bars with different 
superscripts indicate significant differences (P<0.05) between treatments using Tukey’s 




6.3.6 Fatty acids concentrations by degree of unsaturated in liver lipid fractions  
The concentrations of fatty acid classes in the various lipid fractions are shown 
in Figure 6.5. The concentration of PUFA in the NEFA, TAG and CE fractions were 
greater in the PO compared with IPO and lard diet. In contrast, the concentration of 
MUFA was greater in the cholesteryl esters and phosholipids on the IPO compared to 
PO. The concentration of SFA was lower on the HOSO diet compared with the other 
diets in the phospholipid fraction 
 
Figure 6. 5: Lipid concentrations according to degree of unsaturation in the major 
liver lipid gractions of mice overfed either high oleic sunflower oil (HOSO), palm 
olein, interesterified palm (IPO) or lard diets. 
 













































































































































Mean ± SD; n=8 animals/group. Open bar, HOSO; checked, PO; filled bar, IPO; line, 
lard. Data were analysed by one way analysis of variance (ANOVA). Bars with different 
superscripts indicate significant differences (P<0.05) between treatments using Tukey’s 
multiple range test. 
NEFA= non-esterified fatty acids; TAG= triacylglcyerols; CE=cholesteryl esters; 
PL=phospholipids; SFA=saturated fatty acids; MUFA= monounsaturated fatty acids; 




6.3.7 Fatty acids concentrations in distribution of short and long chain PUFA  
The distribution of short and long chain polyunsaturated (LCP) fatty acids in 
different lipid classes is shown in Figure 6.6. These results indicate substantial 
differences between treatments the palmitate fat rich diet. The proportion of n-3 LCP 
was greater in NEFA, TAG, CE and phospholipid in PO compared to HOSO, IPO and 
lard diets. The lowest proportion on n-3 LCP was found in the HOSO group in all 
fractions but the proportion of n-6 LCP was correspondingly greater. The proportion of 
n-6 LCP in the phospholipid fraction was greater in the IPO group compared to PO and 
lard. 
 
Figure 6. 6 : Fatty acid concentrations (mg/g) of parent and long-chain 
polyunsaturated (LCP) n-3 and n-6 fatty acids in hepatic NEFA, TAG, CE and PL 
fractions in mice overfed either a high oleic sunflower oil (HOSO), palm oil (PO),  
interesterified palm (IPO) or lard diets. 
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Mean ± SD; n=8 animals/group. Open bar, HOSO; checked, PO; filled bar, IPO; line, 
lard. Data were analysed by one way analysis of variance (ANOVA). Bars with different 
superscripts indicate significant differences (P<0.05) between treatments using Tukey’s 





6.3.8 Concentrations of major fatty acids in hepatic NEFA, TAG, PL and CE 
fractions 
The concentrations of the major fatty acids in the liver lipid classes are shown in 
Figure 6.7. The concentration of arachidonic acid (20:4n-6) was significantly greater in 
HOSO in NEFA when compared to the other groups. However, the concentrations of 
EPA and DHA were significantly greater in the PO group compared to the HOSO group 
and the IPO and lard groups. 
For the TAG fraction, the concentration of palmitoleic acid was greater in PO, 
IPO and lard groups when compared to HOSO (Figure 6.7). As expected the 
concentrations of oleic acid was greater in the HOSO group but was also greater in the 
PO group compared to the lard group. The concentation of linoleic acid was highest in 
PO group in comparison to the other groups. Consistent with the finding in NEFA, the 
proportion of DHA were notably higher in the PO group compared with other groups.  
As expected cholesteryl palmitate was significantly lower in the HOSO group 
compared with the other groups (Figure 6.7). However, cholesteryl oleate 
concentrations were higher in the IPO and lard groups compared with the HOSO and 
PO groups. Cholesteryl arachidonate concentrations were greater in the HOSO and PO 
groups compared with the other groups and the concentration of cholesteryl 
docosahexaenoate was notably high in the PO group, a finding that is consistent with 
Chapter 5.  
In the PL fraction, the concentrations of palmitic acid (16:0) were significantly 
lower in the HOSO group compared to the other groups (Figure 6.7). Oleic acid 
concentrations tended to be slightly high in the HOSO group. However, arachidonic 
acid concentrations were lower in the PO group compared to the other groups. The 






Figure 6. 7: Major fatty acid concentration in different hepatic lipid fractions in mice 
overfed either a high oleic sunflower oil (HOSO), palm oil (PO), interesterified palm 

























































































































































































































Mean ± SD; n=8 animals/group. Open bar, HOSO; checked, PO; filled bar, IPO; line, 
lard. Data were analysed by one way analysis of variance (ANOVA). Bars with different 
superscripts indicate significant differences (P<0.05) between treatments using Tukey’s 





6.4  Discussion 
This study set out to determine whether the stereospecific structure of TAG 
influenced its subsequent metabolism in the liver. Overall, there were no differences in 
the proportions of total lipids in the various classes. However, there were significant 
differences in the allocation of various fatty acids to the various fractions notable 
between PO and IPO, which had virtually identical fatty acid composition. This study 
showed clear differences between PO and IPO on the fatty acids species in NEFA 
(palmitic acid and long-chain n-3 polyunsaturated fatty acids), in TAG (palmitic acid, 
oleic and long-chain n-3 polyunsaturated fatty acids) and cholesteryl esters (oleic acid, 
linoleic acid and long-chain n-3 polyunsaturated fatty acids) and phospholipids 
(palmitic acid, arachidonic acid and long-chain n-3 polyunsaturated fatty acids). As the 
fatty acid composition of the PO and IPO was similar and food intakes and growth rates 
were similar between the diets, the only likely explanation is the TAG structure. 
Furthermore, the lard diet showed similar effects on hepatic TAG and cholesteryl esters. 
The findings from this study are original in that they indicate that TAG structure 
influences hepatic lipid metabolism. As far as can be ascertained, this has not previously 
been reported. 
It was hypothesised that there may be differences in adipose tissue fatty acid 
composition between PO and IPO. The proportion of palmitic acid was indeed lower in 
the PO vs the IPO and linoleic acid proportions were higher.  
A consistent finding in this study and in the study reported in Chapter 5 is the 
higher proportion of long-chain n-3 polyunsaturated fatty acids in hepatic lipids after 
palm oil feeding. This diet was devoid of long-chain n-3 polyunsaturated fatty acids and 
so these long-chain n-3 polyunsaturated fatty acids must have been synthesised from 
linolenic acid. There were only trace amounts of linolenic in the test oils and thus the 
main source of linolenic acid would be that associated with the milk or with the casein 
that was used to make the solid diet. The amounts of linolenic acid provided by the 
different diets would be similar. Therefore, the results of this study indicate that the 
capacity to convert linolenic acid to long-chain n-3 polyunsaturated fatty acids is 
favourably influenced by the amount of palmitic acid in the sn-1 and sn-3 position. This 
may be a consequence of competition for beta-oxidation with the higher concentration 
of palmitic acid sparing linolenic acid from oxidation and thus allowing it to be 
converted to longer chain derivatives. Lard, however, did not result in lower 
concentrations of DHA in phospholipids whereas IPO resulted in more arachidonic acid 
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and less DHA than PO. These findings may be of biological significance given the 
importance of arachidonic acid in eicosanoid formation and docosahexaenoic acid as a 




Chapter 7:  
Differential protein expression in low and high 





The accumulation of triacylglycerols (TAGs) from lipids synthesised in the liver 
and influx of non-esterified fatty acids (NEFA) released from adipose tissue resulting in 
hepatic inflammation may cause steatosis and if not treated, may lead to NASH. The 
emerging interest among researchers in investigating the reversible state of NASH, 
which may further lead to the progression of permanent liver cirrhosis, is crucial due to 
the high prevalence of this disease.  
The pathogenesis and the mechanisms of NASH are still being elucidated. 
Proteomic studies show that hepatic steatosis induced by high fat diets leads to the up-
regulation of arginase 1 and down-regulation of endothelial nitric oxide synthase, 
whereby both proteins are involved in nitric oxide metabolism (Eccleston et al, 2011). 
Other proteins are also down-regulated (for example peroxiredoxin, glutathione S-
transferase P1) or up-regulated (for example succinate semialdehyde dehydrogenase, 
glutathione synthetase and selenium binding protein) due to oxidative stress and/or 
induced by high fat feeding (Schmid et al, 2004; Douette et al, 2005; Kirpich et al, 
2011). Some of these alteration in the liver also include perturbations in NEFA uptake 
from adipose tissue to the liver (Srivastava & Chan 2007), hepatic TAG accumulation 
in the liver (Lin et al, 2005) and hepatic liver inflammation (Lieber et al, 2004). Proteins 
associated with lipid metabolism such as fatty acid synthase (Jiang et al, 2009) and 
peroxisome proliferator-activated receptor-α (PPAR-α) (Abdelmegeed et al, 2010) are 
significantly down- and up-regulated, respectively, in response to high fat feeding. 
Furthermore, studies have also shown that insulin resistance is highly correlated with 
hepatic steatosis induced by high fat feeding (de Roos et al, 2009; Fiorentino et al, 
2010). The complexities of hepatic steatosis induced by high fat feeding are multi-
factorial and interrelated between several pathways which are yet to be discovered.  
In studies whereby DHA and EPA are investigated independently, the biological 
effects on the liver have been inconsistent. Selective studies have suggested that EPA 
lowers hepatic epoxide hydrolase, which influences the inflammatory pathways whereas 
DHA affects lipoprotein metabolism (Pan et al, 2004) in relation to oxidative stress 
(Gonzalez-Periz et al, 2006; Mavrommatis et al, 2010; Li et al, 2011). EPA also 
alleviates saturated fat-induced insulin resistance by increasing hepatic fatty acid 
oxidation and decreasing inflammation (Kalupahana et al, 2010; El-Mowafy et al, 
2011). Furthermore, DHA shows a stronger hepatic TAG-lowering effect compared to 
EPA due to a higher suppression of TAG synthesis (Gotoh et al, 2009), exhibited via the 
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reduction of insulin resistance through the increase of plasma adiponectin (Vemuri et al, 
2007). Although both DHA and EPA are essential fatty acids, as individual fatty acids, 
they have differential effects on hepatic metabolism which requires further investigation 
In this study, we addressed the hypothesis that proteomics can determine those 
proteins which change in response to high fat diets and n-3-polyunsaturated fatty acids. 
This will identify key regulatory proteins such as enzymes or structural proteins such as 
those which contribute to the mircroarchitecture.  Protein expression studies do not 
specifically identify if changes occur via transcription (ie alterations in mRNA levels) 
alone but also those affected by perturbations in translation and/or proteolysis. Greater 
insights related to the cause of NASH using proteomics have been performed 
extensively in previous studies (Baranova et al, 2007; Rodriguez-Suarez et al, 2010; 
Burlamaqui et al, 2011).  However, these aforementioned studies have limitations 
whereby none have examined hypercaloric diets in response to liver damage. 
The advancement in proteomics techniques provides pattern recognition of 
biomarkers that are important for the early diagnosis of NASH. The discovery of 
clinically helpful biomarkers also allows for a better understanding of molecular 
mechanisms in the pathogenesis of NASH and its progression from simple steatosis to 
liver cirrhosis (Baranova et al, 2007). However, the underlying mechanisms of NASH 
remains incomplete and no mice model fully shows the clinical features of NASH 
observed in humans (Ariz et al, 2010). To gain a greater mechanistic insight into the 
processes that contribute to the changes in hepatic lipid profile of mice fed low fat (LF) 
and high fat (HF) hypercaloric diets, 2D-DIGE was used to identify proteins that were 
differentially expressed. Another aim of this study was to investigate if dietary EPA and 
DHA ameliorate changes in the expression of proteins in the liver induced by 






Animal work, experimental diets and designs are outlined in Chapter 2. All 
materials and methods for proteomics are described in Chapter 2 and 5. The following 
sections provide information specific to this study. In this present experimental design, 
the 5 groups involved were low fat reference (LFR), low fat hypercaloric (LF), high fat 
hypercaloric (HF), high fat hypercaloric plus DHA (HFDHA) and high fat hypercaloric 
plus EPA (HFEPA) groups. Briefly, the LFR diet contained 2% corn oil whereas LF 
hypercaloric diet contained 2% corn oil plus condensed milk (CM). In addition, the HF 
hypercaloric diet contained 18% palm oil plus condensed milk (CM) and the HFDHA 
diet consisted of 15% palm oil and 3% DHA. Lastly, the HFEPA diet consisted of 15% 
palm oil and 3% EPA. Diets used for this study are described in Table 2.1 and 2.2. Light 
condensed milk has zero fat and was incorporated with 8% of fat (see Table 2.4 for 
composition of light condensed milk and high fat (8% w/w) condensed milk. 
 
7.2.1 DIGE experiment 
 All standard procedures were carried out according to the DIGE protocol 
provided by GE Healthcare. However, optimisation steps were applied to the samples 
accordingly, to obtain results that were shown in this chapter.  
 
7.2.2 Liver preparation and solubilisation for DIGE 
 Protein extraction was carried out on individual mice liver samples and 2x lysis 
buffer containing 7 M urea and 2 M thiourea were used to solubilise proteins in the fatty 
liver because it has been tested to yield high extraction efficiency resulting in 
reproducible protein expression patterns (Zhou et al, 2005). Thiourea allows 
solubilisation of hydrophobic proteins which is essential due to the limited 
concentration of liver proteins. The concentration of proteins in the liver is estimated to 
be 150-250 mg/g liver tissue. 
 After tissue homogenization, proteins were quantified with the 2D-Quant kit 
before the clean-up procedure to ensure that proteins were not degraded during 
homogenization. Then the clean-up procedure was performed, followed by final protein 




7.2.3 Two-dimensional gel electrophoresis and image acquisition 
 The 1
st
 dimension separation was carried out on immobilized pH gradient (IPG) 
strips from pH 3 to 11. After equilibration, the strips were transferred to the slab gels 
(12.1% acrylamide and 0.38% bisacrylamide) for the 2
nd
 dimension separation and run 
with anode (buffer based on piperidinopropionamide) and cathode (0.25 M Tris, 1.92 M 
glycine, 1% w/v SDS) buffer in an Ettan DALTtwelve electrophoresis unit for 5 hours. 
Proteins were detected using silver stain compatible to LC-MS/MS (Yan et al, 2000). 
Gels were scanned using an Ettan DIGE Imager. 
 
7.2.4 Data analysis and statistical test 
Assisted image analysis was performed using the DeCyder software (GE 
Healthcare). The average spot volume is directly related to the protein abundance and 
was thus used for data analysis.  Statistical analysis of one way analysis of variance 
(ANOVA) was carried out and Tukey’s multiple range tests was also carried out among 
the 5 groups. Protein spots were detected using DeCyder and confirmed to be matched 
on Auto level 1 which indicates a strong match across the gels. Protein spots were 
identified as “TRUE” if they were high in abundance and non-overlapping proteins. 
Only proteins that were abundant in volume were selected as proteins of interest 
because proteins spots could be subsequently picked by hand on the silver stained 
preparative gel. Proteins discussed in this study were selected for further identification 
based on its abundance and 3-D images using DeCyder.  
The limitation in using DeCyder for statistical analysis is that P-values were not 
generated when analysis of variance (ANOVA) was used and therefore data was 
analysed using SPSS for multiple groups. Comparisons between (i) LFR vs LF, (ii) LFR 
vs HF, (iii) LF vs HF, (iv) HF vs HFDHA and (v) HF vs HFEPA were also discussed. 
 
7.2.5 Experimental design for DIGE analysis 
To minimize batch variation, the treatment groups with a sample size of 8 
animals per group were subdivided into 2 groups of 4 and randomly assigned to 2 of the 
3 batches. A control group was included in each batch. Therefore, each group of 4 
represented one experimental block.  
After allocating samples into experimental blocks, a symmetrical dye swap was 
applied. First and second dimension separations were run in 2 batches and all samples 
were spread evenly across the 2 batches to reduce biasness resulting from technical 
188 
 
influences. The randomization of Dye labelling and application of controls, treated and 
internal standards on IPG strips for 20 gels are shown in Table 7.1. The internal 
standards consisted of all samples and were run in all gels to minimise gel to gel 
variations (Gorg et al, 2004). 
 
Table 7. 1: The randomization of CyDye labelling and application of controls, treated 






















1 A1 301 2.91 B1 309 1.97 Pool 36058 
2 B2 310 1.99 C1 317 1.69 Pool 36059 
3 C2 318 2.67 D1 325 1.97 Pool 34170 
4 D2 326 2.08 E1 333 2.25 Pool 34171 
5 E2 334 1.98 A2 302 2.75 Pool 36051 
6 A3 303 1.66 C3 319 1.71 Pool 36052 
7 C4 320 1.80 E3 335 2.37 Pool 36053 
8 E4 336 2.24 B3 311 1.30 Pool 36054 
9 B4 312 1.55 D3 327 1.75 Pool 36055 
10 D4 328 1.53 A4 304 2.35 Pool 36056 
11 A5 305 3.09 D5 329 2.18 Pool 96623 
12 D6 330 2.01 B5 313 2.69 Pool 98330 
13 B6 314 1.86 E5 337 2.62 Pool 98331 
14 E6 338 2.49 C5 321 2.70 Pool 98333 
15 C6 322 2.51 A6 306 2.39 Pool 98334 
16 A7 307 1.79 E7 339 2.13 Pool 98335 
17 E8 340 2.78 D7 331 2.18 Pool 98336 
18 D8 332 1.84 C7 323 1.70 Pool 98337 
19 C8 324 2.64 B7 315 1.31 Pool 98338 
20 B8 316 2.98 A8 308 2.11 Pool 98339 
A=LFR,  B=LF, C=HF, D=HFDHA, E=HFEPA; there were 8 animals/group. The 
numberings next to the letter represent the individual mice from respective groups. The 
internal standards are represented by Cy2 (yellow) and the controls and treated 
samples were either dyed in Cy3 (red) or Cy5 (blue).  
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7.3  Results from 2D-DIGE 
7.3.1 Scanned images from 2D-DIGE 




 dimension separation, the protein spots seen on the gel 
images were scanned with the Ettan DIGE Imager. These gel images are presented as an 
overlaid image comprising of the treated, controls and internal standards (Figure 7.1). 
Spot quantitation was carried out on overlaid Cy2 (pooled internal standard)/ Cy5 or 
Cy2 (treated samples) on each gel, followed by gel to gel matching. Every protein spot  
is assigned a volume ratio by DeCyder which is expressed as protein abundance. The 
protein abundance is generated from the volume ratio between the internal standard and 
treated sample from the same gel. Using the relative sample as a reference, the DeCyder 
determines the abundance of specific protein spots (ie. same spot number) (Uwakwe 
2004). By comparing all the protein spots to the same pooled internal standard there is 
no need for normalization (Uwakwe 2004; Marouga et al, 2005). 
 
Figure 7. 1: Overlaid image (top left) of protein spots from all 3 scans comprising of 
controls, either low or high fat hypercaloric sample and internal standards  
 
 
Controls are labelled with Cy5; blue, low or high fat hypercaloric sample  stained with 




7.3.2 Preliminary data analyses  
Of the 3291 protein spots on the master gel, 306 proteins were matched at Auto 
Level 1 among 20 gels by DeCyder (Figure 7.2). Ninety one protein spots were high in 
abundance and structurally the protein peaks were not overlapping. Of these 64 were 
proteins of interest matched on Auto Level 1. The proteins identified at Auto Level 1 
were matched speculatively with the reference gel image of mouse liver in the SWISS-
2D PAGE (Sanchez et al, 2001) before confirming by LC-MS/MS. Seventeen protein 
spots were tentatively identified using SWISS-2D PAGE of mouse liver in Expasy 
Bioinformatics Resource Portal based on its abundance (Table 7.2) and its 3D-peak 
images (Figure 7.3). However, only 6 of the 17 proteins were selected for LC-MS/MS 
because not all the protein spots identified using SWISS-2D PAGE were stained 
abundantly in the preparative gel. The other 8 proteins selected for validation using LC-
MS/MS were based on their abundance on the preparative gel and reference to SWISS 
2D-PAGE gel. A total of 14 proteins were analysed using LC-MS/MS.  
Preparative gels were cast and stained with a silver preparation which is 50 times more 
sensitive compared to the Coomassie Brilliant Blue stain that detects only 
approximately 50 ng of protein (Winkler et al, 2007). In this study, the protein spots 
were picked by hand and therefore only protein spots that were visible and abundant on 
the preparative gels were selected for subsequent verification by LC-MS/MS. Sixty four 
protein spots were identified when scanning the analytical gel using DeCyder (Figure 
7.4) whereas in the preparative gel stained with silver stain only 56 of the 64 protein 
spots of interest were visible (Figure 7.5). The protein spot map was made clearer by 
adding contour lines around the protein spot (Figure 7.6).  
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Figure 7. 2: Flow chart of image analysis and spot selection when comparing LFR vs 











3291 ± 394 spots were detected 
on the master gel  
306 protein spots were matched at Auto Level 1 which indicates the best 
match with a high probability that the match is positive across 20 gels 
17 protein spots were selected based on abundance; but only 6 proteins 
were picked for LC-MS/MS as the others were not stained abundantly in 






Of the 14 proteins, 7 proteins of high abundance on the silver stained gel 
were picked for LC-MS/MS on the basis of average ratio and non-
overlapping peaks; of which 4 were picked by referring to 2D-DIGE 
image of mouse liver showed in SWISS 2D-PAGE to confirm results 
from LC-MS/MS. 
91 protein spots were high in abundance and structurally the protein 
peaks were not overlapping; of which 64 were proteins of interest 
matched on Auto Level 1 
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Figure 7. 3: Proteins of interest which were differentially expressed in mice fed low 
fat reference (LFR), low fat (LF) and high fat (HF) diets 
Spot 1728      Spot 1846 
      
Represenatative images were generated by DeCyder version 6.5 and location of the 
spots on the gels are indicated by the green ring around the peak. Within the box, the 
left peak image represents spots from LFR mice and the right represents either the low 




Figure 7. 4: Protein spots from the analytical gel with annotation on the proteins of 
interest 
 
The  protein spots circled in red are protein of interest (n=64) with non-overlapping 




Figure 7. 5: Post staining of preparative gels used for picking proteins of interest  
 
Protein spots of interest were detected on the preparative gel whereby 14 spots circled 
in blue were picked for LC-MS/MS. The spots circled in red were proteins of interest 
that were not picked. Proteins of interest picked were within the inclusion criteria of 
P<0.05 and at least a 1.5 fold change. Numbers in the box signify the spot identification 
given by DeCyder 
 
 




The 14 proteins selected for picking are annotated in the yellow box with numbers and 
noted by its contour line around the spot. Numbers signify the spot identification given 
by DeCyder. 
 








7.3.3 Protein identification with LC-MS/MS 
 Fourteen selected proteins were digested with trypsin and peptides were 
analysed using LC-MS/MS by Dr. Mike Deery in Cambridge Proteomics Center, 
Cambridge UK. The MASCOT algorithm (Matrix Science) was used and searched 
against the NCBI mouse database. The accesssion number represents the unique 
identification number for the protein identified in the NCBI mouse database.  Data from 
the LC-MS/MS analysis which included molecular weights, isoelectric point, protein 
scores and % coverage are shown in Table 7.3. Data for the relative abundance of 
individual proteins are shown in Table 7.4. 
ANOVA showed that most of those proteins in Table 7.4 were significantly 
altered by the various dietary interventions (P<0.011 to 0.001) except protein spots 
1826 and 2253 (P>0.05).  In the following text we describe first the effects of 
hypercaloric feeding with the LF and HF diets followed by the effects of DHA and 
EPA.  In these descriptions we use the names of the identified proteins as we have every 
confidence in their assignments.  
Ornithine transcarbamylase (OTC), regucalcin and malate dehydrogenase were 
found to be up-regulated between 40 and 130% when comparing LF with LFR (Table 
7.4).  
In the comparison for HF vs LFR, the up-regulated proteins were Isoform 1 of 
epoxide hydrolase 2 (EPHX2), catalase (CAT), ATP synthase subunit alpha (ATP5a1), 
OTC and regucalcin (RGN); changes ranged from 80 to 120% (Table 7.4).  
Carbonic anhydrase 3 (CAR3) was down-regulated by 40% in HF when 
compared with LFR group. In addition, catalase, ATP5a1 and electron transfer 
flavoprotein subunit beta were up-regulated by 30 to 70% when comparing LF vs HF 
groups (Table 7.4).  
Catalase was also found to be up-regulated by 40% in the HFDHA group when 
compared to HF group mice (Table 7.4).   
Malate dehydrogenase (MDH1) and glutathione S-transferase A3 (GSTPA3) 
were picked for LC-MS/MS analyses despite not reaching statistical significance 
because they were found abundant on the preparative gel and were also identified to be 
proteins related to lipid and glucose metabolism when matched with the reference gel 
on SWISS 2D-PAGE.  
The proteins identified with LC-MS/MS (Table 7.3) were compared to the 
protein spots that were matched with the reference gel on SWISS 2D-PAGE (Table 
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7.2). Protein spots matched with the reference gel showed only 64% accuracy. 
Therefore, the tentative protein spots shown in Table 7.2 were deemed unreliable and 
were not used in the analysis to generate pathways in GeneGo. 
 
 





pI MW  Tentative protein 
identification 
611 P17563 5.87 52514 SBP1 Selenium binding protein 1 
618 NF NF NF NF NF 
719 P24270 7.72 59664 CAT Catalase 
902 P26443 6.71 55913 DHE3 Glutamate dehydrogenase 1 
920 NF NF NF NF NF 
992 P26443 6.71 55913 DHE3 Glutamate dehydrogenase 1 
1170 NF NF NF NF NF 
1264 P99023 7.53 42826 THIM 3-ketoacyl-CoA thiolase, 
mitochondrial 
1337 P99016 6.43 41076 IVD Isovaleryl-CoA dehydrogenase 
1521 - - NF NF NF 
1584 NF NF NF NF NF 
1586 NF NF NF NF NF 
1640 P11725 6.66 36123 OTC Ornithine  transcarbamylase, 
mitochondrial 
1696 Q64374 5.16 33407 RGN Regucalcin 
2125 P16015 6.97 29235 CAR3 Carbonic anhydrase 3 
2357 NF NF NF NF NF 
2633 P08228 6.03 15811 SODC Superoxide dismutase 
Statistical test was carried out using Student’s T-test. P-value with <0.05 indicates a 
significant difference between the groups and Average ratios with negative values 
indicate down-regulation of the protein in the experimental group and vice-versa. NF 
indicates that the protein was not found when matched to the reference gel on SWISS 





















Isoform 1 of Epoxide 
hydrolase 2* 
5.85 63045 1762 56.5 
710 P24270 Catalase
& 7.72 60043 1862 58.3 
719 P24270 Catalase* 7.72 60043 1911 59.8 
730 P24270 Catalase 7.72 60043 1803 60.0 
902 Q03265 









8.81 39854 1536 76.3 
1696 Q64374 Regucalcin* 5.15 33899 1092 66.6 



















8.24 27834 1105 63.5 








7.68 23765 738 60.0 
PI stands for Isoelectric point and MW stands for molecular weight of protein. * 
indicates the proteins that were altered in the comparison of LFR vs LF or LFR vs HF 
groups. 
&
 indicates the protein was altered in the comparison of HF vs HFDHA..
 
#
indicates the proteins that were not matched between the SWISSprot and LC-MS/MS. 
Protein score indicates how well the matching regions of polypeptides clusters are 
matched whereas the % coverage indicates how each of the polypeptides clusters match 
the protein. Proteins with the highest scores and % coverage were selected.       
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Table 7. 4 : Protein abundance identified and validated with LC-MS/MS in mice fed either low fat reference (LFR), low fat (LF), high fat (HF), 
high fat DHA (HFDHA) or high fat EPA (HFEPA) diets  
Protein name Spot 
number 
LFR  LF HF HFDHA HFEPA P 
Anova 
Isoform 1 of Epoxide hydrolase 2 611 0.61 
a
 ± 0.06 0.94 
a,b
 ± 0.06 1.33 
b,c
 ± 0.03 1.62 
c 
± 0.03 1.45 
b,c
 ± 0.03 P<0.001 
Catalase 710 0.72 
a,b
 ± 0.02 0.63 
a
 ± 0.03 0.88 
b,c
 ± 0.03 1.23
 d
 ± 0.02 1.12 
c,d
 ± 0.01 P<0.001 
Catalase 719 0.64 
a
 ± 0.03 0.73 
a
 ± 0.03 1.13 
b
 ± 0.04 1.40
 b
 ± 0.01 1.23 
b
 ± 0.02 P<0.001 
Catalase 730 0.83 
a,b 
± 0.04 0.76 
a 
± 0.09 1.16 
a,b,c




± 0.02 P<0.001 
ATP synthase subunit alpha, mitochondrial 902 0.52 
a 
± 0.02 0.63 
a




 ± 0.02 1.23 
b
 ± 0.04 P<0.001 
Ornithine carbamoyltransferase 1640 0.73 
a
 ± 0.02 1.00 
b
 ± 0.04 1.30 
b,c 
± 0.03 1.59 
c
 ± 0.03 1.38 
c
 ± 0.03 P<0.001 
Regucalcin 1696 0.52
 a
 ± 0.09 1.02 
b
 ± 0.06 1.16 
b
 ± 0.02 1.06 
b
 ± 0.02 0.88
 a,b 
± 0.04 P=0.001 
Regucalcin 1728 0.51 
a
 ± 0.12 1.00 
a,b
 ± 0.07 1.19 
b 
± 0.03 1.09 
b
 ± 0.03 1.00 
a,b 
± 0.05 P=0.008 
Malate dehydrogenase, cytoplasmic 1826 0.64 ± 0.12 1.05 ± 0.06 1.02 ± 0.03 1.02 ± 0.05 0.74 ± 0.04 P=0.146 
Malate dehydrogenase, cytoplasmic 1846 0.50 
a
 ± 0.15 1.17
 b
 ± 0.06 1.42 
b
 ± 0.03 1.29 
b
 ± 0.01 0.93 
a,b
 ± 0.05 P=0.004 
Electron transfer flavoprotein subunit beta 2046 0.95 
a,b
 ± 0.03 0.88
 a
 ± 0.03 1.16 
b,c 




± 0.01 P<0.001 
Carbonic anhydrase 3 2125 1.35 
b 
± 0.03 1.12 
a,b
 ± 0.05 0.86
 a
 ± 0.03 0.81 
a
 ± 0.04 0.79 
a
 ± 0.05 P=0.001 
Glutathione S-transferase A3 2253 0.79 ± 0.07 0.98 ± 0.09 1.10 ± 0.06 0.71 ± 0.03 0.74 ± 0.03 P=0.177 
Glutathione S-transferase P1 2360 0.65
 a
 ± 0.11 0.71 
a,b
 ± 0.10 1.18 
a,b
 ± 0.05 1.64 
b
 ± 0.07 1.37 
a,b
 ± 0.08 P=0.011 
 
All data are expressed as standardized protein abundance ± standard errors. One way analysis of variance (ANOVA) and Tukey’s multiple range 
test was used. Values with different superscripts indicate significant differences between treatments. 
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7.3.4 Functional analysis of selected proteins 
 The use of the bioinformatics software tool GeneGo allowed for the analysis of 
protein expression data in the context of regulatory networks, cellular pathways and 
biological functions (Beyer et al, 2007). Together with the statistical analysis obtained 
from the regulatory networks, the biological functions were linked to identify the 
possible pathways related to the effects of LF and HF hypercaloric diets on the liver. In 
this study, GeneGo was used to identify the selected protein networks, only using the 
tentative proteins assigned by LC-MS/MS. It was thought prudent to exclude proteins 
assigned by SWISSprot and these proteins were deemed to be speculative. Thus only 
isoform 1 of epoxide hydrolase, catalase, ornithine transcarbamylase, ATP synthase 
subunit alpha, regucalcin and carbonic anhydrase 3 were input into GeneGo.  The use of 
GeneGo to analyse affected pathways in proteomic studies on the liver has been used 
before (Remily-Wood et al, 2011; Nikolsky et al, 2009).   
 The process networks associated with the selected proteins were identified by 
their P-Value and Ratio. The Ratio indicates the number of selected proteins against the 
number of proteins identified in all other studies involving the selected proteins. There 
were few associations between the selected proteins but a relatively high significance of 
pathways and processes when referred to each individual protein (Table 7.5).  
The main process network associated with the significantly expressed protein 
was related to the response of hypoxia and oxidative stress (P<0.001) (Table 7.6). The 
top 10 diseases associated with the significantly expressed proteins were of high 
significance (P<0.0001) in comparison to other studies available in the GeneGo 
database (Table 7.7). The list of diseases was shown to be related to neuron disease, 
nerve dysfunction and urinary problems. The legend for the nodes used in the network 
clusters are shown in Figure 7.7. The network clusters of the picked proteins and the 
predicted functional proteins are presented in Figure 7.8 to 7.11.  
Briefly, proteins such as ornithine transcarbamylase (OTC) is involved in the 
urea cycle (Figure 7.8) and carbonic anhydrase 3 (CAR3) plays an important role in the 
reversible hydration of carbon dioxide and nitrogen metabolism (Figure 7.9; Kim et al, 
2001). However with only a few proteins identified to have been altered by hypercaloric 
feeding, any in-depth discussion in using pathway analysis would be imprudent.  
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Table 7. 5: Protein networks extracted from GeneGo bioinformatics software 
associated with the selected proteins identified by LC-MS/MS  
Pathway networks P Value Ratio 
Nitrogen metabolism 2.09E-02 *1/35 
Nitrogen metabolism/ Rodent version 2.15E-02 *1/36 
Urea cycle 4.14E-02 *1/70 
Aspartate and asparagines metabolism 4.31E-02 *1/73 
(L)-Arginine metabolism 4.49E-02 *1/76 
HETE and HPETE biosynthesis and metabolism 4.72E-02 *1/80 
Heme metabolism 5.53E-02 *1/94 
Arginine metabolism (Rodent version) 5.70E-02 *1/97 
Oxidative phosphorylation 6.16E-02 *1/105 
ATP/ITP metabolism 7.12E-02 *1/122 
Only 6 proteins were fed into the GeneGo analysis and they were assigned via LC-
MS/MS as SWISSprot was deemed unreliable. The 6 proteins were as follows isoform 1 
of epoxide hydrolase, catalase, ornithine  transcarbamylase, ATP synthase subunit 
alpha, regucalcin and carbonic anhydrase 3 
 
Table 7. 6: Process networks associated with the protein networks (refer to Table 7.5)  
Process networks P Value Ratio 
Response to hypoxia and oxidative stress 2.29E-05 *1/163 
Only 6 proteins were fed into the GeneGo analysis and they were assigned via LC-
MS/MS as SWISSprot was deemed unreliable. The 6 proteins were as follows isoform 1 
of epoxide hydrolase, catalase, ornithine transcarbamylase, ATP synthase subunit 
alpha, regucalcin and carbonic anhydrase 3 
 
Table 7. 7: Diseases associated with the selected proteins and tentative proteins 
extracted from GeneGo bioinformatics software 
Diseases P Value Ratio 
Ornithine  transcarbamylase Deficiency Disease 4. 67E-04 *1/1 
Acatalasia 4. 67E-04 *1/1 
Urea Cycle disorders, Inborn 1.89E-03 *1/4 
Metabolism, Inborn errors 2.40E-03 *3/659 
Hyperammonemia 2.80E-03 *1/6 
Hearing  loss, noise-induced 6.06E-03 *1/13 
Neurma, Acoustic 7.45E-03 *1/16 
Cranial Nerve Neoplasms 7.45E-03 *1/16 
Vestibulocochlear nerve diseases 7.45E-03 *1/16 
Retrocochlear Diseases 7.45E-03 *1/16 
Only 6 proteins were fed into the GeneGo analysis and they were assigned via LC-
MS/MS as SWISSprot was deemed unreliable. The 6 proteins were as follows isoform 1 
of epoxide hydrolase, catalase, ornithine transcarbamylase, ATP synthase subunit 




Figure 7. 7: Legends for the following protein network cluster as constructed by 
GeneGo. Nodes are presented in different colours and shapes to represent the origin 








Figure 7. 8: Ornithine transcarbamylase (OTC) as the picked protein in relation to 
the urea cycle  
 
All legends are presented in Figure 7.7. The hexagons with letter T represents liver 
(tissue), S represents mouse (species), D represents liver (diseases). Source: GeneGo 
202 
 
Figure 7. 9: Carbonic anhydrase 3 (CAR3) in relation to nitrogen metabolism in mice 
All legends are presented in Figure 7.7. The hexagons with letter T represents liver 
(tissue), S represents mouse (species), D represents liver (diseases). Refer to figure 7.7 




Figure 7. 10: Ornithine transcarbamylase (OTC) involved in aspartate and asparagines 
metabolism 
 
All legends are presented in Figure 7.7. The hexagons with letter T represents liver 




Figure 7. 11: Ornithine transcarbamylase (OTC) involved in (L)-Arginine 
metabolism 
 
All legends are presented in Figure 7.7. The hexagons with letter T represents liver 




7.4.1 Methodological considerations 
In these studies both LF and HF mice were fed high hypercaloric diets with 
condensed milk whereas LFR mice was the reference group fed with a low fat pelleted 
diet, without access to the condensed milk. Changes in protein expression in mice liver 
was identified using 2D-DIGE which is the most frequently used gel-based technique in 
clinical proteomics with good reproducibility (Marouga et al, 2005). From the 2D gels, 
proteins of interest were picked for identification by liquid chromatography tandem 
mass spectrometry (LC-MS/MS). Proteins were selected for LC-MS/MS on the basis of 
their average volume ratio and if there was a significant difference of P<0.05 when 
compared to the control group. Only non-overlapping protein spots and only those 
which could be picked by hand manually were considered for further confirmation by 
LC-MS/MS in this study.  
In addition, non-overlapping proteins that were highly matched on Decyder at 
Auto Level 1 in the LF and HF groups when compared to the LFR group were 
tentatively identified using the reference mouse liver gel in SWISS 2D-PAGE. The 
tentative molecular weight (MW) and isoelectric point (PI) of the proteins were 
obtained from the reference gel on SWISS 2D-PAGE. To ensure that the tentative 
proteins were identified accurately, 4 proteins were randomly picked along-side to 
confirm the protein spots on the reference gel. However, the results obtained from LC-
MS/MS showed that the identification of picked protein spots were only 64% accurate 
when compared to those on the reference gel on 2D-image on SWISS 2D-PAGE.  
We assumed that the remaining protein spots that were differentially expressed 
and identified from the SWISS 2D-PAGE database, but not validated by LC-MS/MS, 
were not reliable. They were thus not fed into the GeneGo database for pathway 
analysis.  
Although proteomic methods are considered to be reliable, there is still room for 
optimisation and such advancements in proteomic techniques incur a high cost and 
therefore may not necessarily be used effectively and broadly in clinical practice. A 
more precise and sensitive detection system may be required to identify the majority of 
the proteins affected by LF and HF hypercaloric diets in the liver. The clarification of 
how the protein profiles are modified as a consequence of the LF and HF hypercaloric 
diets on the liver is important in further investigating the progression of steatosis to 
NASH.   
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7.4.2 Biological implications of altered protein in liver due to hypercaloric 
feeding 
The following section is a discussion on the specific proteins that altered in the 
metabolic pathways. To reiterate the points above, proteins were identified by LC-
MS/MS and speculative proteins identified with SWISSprot are not discussed.   
Mice in the LF and HF groups had increased liver size when compared to the 
LFR mice, also known as hepatomegaly (Section 5.3.2). Interestingly, total fats in the 
whole liver of LF and HF mice were not higher when compared to LFR mice but there 
was a significantly higher liver and adipose tissue weight in the HF group mice 
compared to the LF group. In concentration terms, hepatic NEFA was not significantly 
different when comparing LF and HF groups (Section 5.3.9) whereas hepatic TAG was 
significantly higher in HF mice when compared to LF mice (Section 5.3.9). Similarly, 
both hepatic CE and PL were significantly higher in HF fed mice compared to the LF 
fed mice. The significant increase in hepatic NEFA is mainly due to oleic and palmitic 
acid which is also reflected in the hepatic TAG fatty acid profile. The significant 
increase of hepatic CE in HF group is pre-dominantly caused by cholesteryl oleate, 
linoleate and plamitoleate esters. Lastly, in the PL species, there was a significant 
increase in palmitic, stearic acids and DHA in mice fed HF diets compared to the LF 
mice. These findings suggest that a high saturated fat intake does not exacerbate NASH 
(for further details please refer to Chapter 5).  
In the proteomics aspect of this chapter, proteins identified by LC-MS/MS 
shown to alter in response to HF hypercaloric feeding were as follows: isoform 1 of 
epoxide hydrolase 2 (EPHX), catalase, ATP synthase subunit-alpha mitochondrial 
(ATP5α1), ornithine transcarbamylase-mitochondrial (OTC), regucalcin and carbonic 
anhydrase 3 (CAR3). In the comparison between LFR and LF, OTC and regucalcin 
were up-regulated. EPHX, catalase, ATP5α1, OTC and regucalcin were up-regulated 
significantly in the comparison between LFR vs HF groups. CAR3 was significantly 
down-regulated in both HF and LF groups when compared to LFR. Only catalase was 
up-regulated when comparing HFDHA with the HF group. 
 
7.4.3 Proteins involved in urea cycle: ornithine transcarbamylase (OTC) 
Metabolic steps involved in urea excretion occur in the liver through a series of 
reactions between the mitochondria and cytosol.  Ornithine transcarbamylase (OTC) is a 
catalyst responsible for the formation of L-citrulline in the 2
nd
 step of the urea cycle in 
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the mitochondria (Morizono et al, 1997). A mutation in the OTC gene was shown to 
cause disordered urea synthesis (Stratford-Perricaudet et al, 1990; Brusilow & Maestri 
1996). In this study for the thesis, OTC was found to be significantly up-regulated in the 
HF and LF group when compared to the LFR group but there was insufficient time to 
examine plasma ammonia levels. This merits further investigation. The up-regulation of 
OTC in the HF and LF mice may be due to the increase urea cycle activity in the 
mitochondria necessary for muscles to replenish the energy through the glucose-alanine 
cycle during the fasting state.  
 
7.4.4 Protein involved in glucose metabolism: carbonic anhydrase III (CAR3)  
Carbonic anhydrase III (CAR3) is a cytosolic protein found in skeletal muscle 
and liver (Tweedie & Edwards 1989) that catalyzes the interconversion of carbon 
dioxide and carbonic acid to generate hydrogen and bicarbonate ions which maintain pH 
balance (Sanyal 1984). CAR3 plays a role in hepatic de novo lipogenesis by utilizing 
bicarbonate required by acetyl-CoA carboxylase (Lynch et al., 1995) and CAR3 
inhibitors have been demonstrated to reduce de novo lipogenesis in hepatocytes 
(Herbert & Coulson 1984). Besides that, CAR3 functions as an oxygen radical 
scavenger thus protecting cells from oxidative damage (Raisanen et al, 1999).  
Changes in CAR3 together with glutathione S-transferase pi 1 (GSTP1) and 
catalase were found to be markers for pre-cancerous conditions in liver tissue (Kuo et 
al, 2003). Up-regulation of CAR3 is associated with liver fatty acid oxidation and 
down-regulation of this protein may lead to liver damage (Henkel et al, 2006). Changes 
in hepatic CAR3 is also commonly associated with amino acid or protein deprivation. 
For example, the lack of methionine and cysteine in the diet may be result in the up-
regulation of GSTP1 and CAR3 (Ronchi et al, 2004) in the liver. Although CAR3 is 
significantly reduced in hepatocellular carcinoma induced mice, the reduction was 
inconsistent throughout the lobular liver structure when immunohistochemical analysis 
was carried out (Elchuri et al, 2007). Therefore, the mechanism causing the reduction of 
hepatic CAR3 in hepatocellular carcinoma remains unclear (Kim et al, 2004).  
In this study, CAR3 in HF mice was down-regulated when compared with mice 
from the LFR group. This may indicate the decreased activity of de novo lipogenesis 
developed in HF mice due to the HF hypercaloric diet in comparison to LFR mice. 
However, no studies till this date have investigated how the different types of dietary 
fats affect the down- or up-regulation of CAR3. 
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7.4.5 Proteins involved in oxidative stress induced by HF hypercaloric diet: 
catalase (CAT) 
Catalase functions as a catalyst for decomposition of hydrogen peroxide to water 
and oxygen to prevent toxicity of hydrogen peroxide, which may cause cell damage 
(Imlay 2003). Therefore, up-regulation of catalase in both LFR vs HF is correlated with 
low oxidative stress. Mice lacking catalase tended to develop Type II diabetes due to the 
high concentrations of hydrogen peroxide (Goth 2008). Furthermore, mice induced with 
NASH presented decreased levels of catalase activity compared with chow fed mice and 
in the absence of glutathione, detrimental hydroxyl radicals were disposed more slowly 
(Haque et al, 2010). Similar findings were found in ob/ob mice when hepatic steatosis 
was attenuated by feeding green tea extracts causing decreased adipose lipogenesis and 
enhanced hepatic antioxidant defences which resulted in increased hepatic catalase and 
glutathione peroxidase activity (Park et al, 2011). In addition, catalase is up-regulated in 
steatosis, indicating high activity to prevent hepatic oxidative stress (Bujanda et al, 
2008) along with the increments of superoxide dismutase, glutathione peroxidise and 
nitric oxide synthase. In this study for the thesis, there was a significant up-regulation in 
HF group when compared to LFR group. Therefore, the HF group mice may have been 
prevented from hepatic oxidative stress as suggested by Bujanda et al, (2008).  
However, overall antioxidant status was not measured in these studies though this could 
be the focus of future investigations in this area.  
 
7.4.6 Protein involves in maintaining cell homeostatis: regucalcin (RGN) 
 Regucalcin (RGN) plays an important role in maintaining cell homeostasis by 
regulating Ca
2+
 signalling in the liver. For example, the expression of mRNA RGN was 
found to increase 30 minutes after the administration of 5 to 30 mg per 100 g body 
weight of calcium to mice (Murata & Yamaguchi 1997). Furthermore, the inhibitory 
effect of RGN on protein kinase C that is activated by Transcription Factor-2 may 
phosphorylate activators of transcription thus leading to an increased expression in 
cancer cells (Yamasaki et al, 2009). Hepatic RGN is also shown to be stimulated by 
insulin (Nakashima & Yamaguchi 2006) and estrogens (Yamaguchi & Oishi 1995). 
RGN also regulates nuclear function in liver cells (Yamaguchi 2000). 
The increased RGN expression in the HF and LF when compared to LFR group 
may have enhanced glucose utilization, via Ca
2+
 signalling pathway which is regulated 
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by RGN and stimulated by insulin (Yamaguchi et al, 1995). Unfortunately in this study, 
the aspects of calcium ions were not investigated. 
 
7.4.7 Protein involve in transporting ATP: ATP synthase subunit-alpha 
(ATP5α1) 
The ATP synthase subunit alpha (ATP5α1) is a mitochondrial membrane ATP 
synthase that functions as an ion carrier in the electron transport complex (Lee et al, 
1990).  ATP5α1 combines ATP synthesis and/or hydrolysis across the membrane via 
the ATPase proton in the presence of a proton gradient to produce ATP from ADP 
(Tappenden et al, 2011). ATP5α1 in mice liver was up-regulated in the HF group when 
compared with the LFR mice, which implies a higher rate of ATP synthesis indicating 
greater coordination in the regulating mitochondrial proliferating, and gene expression 
related to oxidative phosphorylation (Di Liegro et al, 2000).  However, it is difficult to 
relate these findings to the characteristics changes in the whole liver of LF or HF fed 
mice as the aforementioned studies by Di Liegro et al, (2000) were specifically carried 
out in liver mitochondria. 
 
7.4.8 Biological implications of altered protein in liver due to EPA and/or DHA 
Polyunsaturated n-3 fatty acids such as DHA and EPA are known to be 
protective against high fat hypercaloric diet induced hepatic steatosis and inflammation 
in the liver, but the mechanism of which these individual fatty acids function in the liver 
is still unclear. Work in this thesis tested the hypothesis that the protective effects of 
EPA and DHA would be reflected in the protein profiles and in particular would 
identify proteins which have been previously ascribed to EPA or DHA-induced effects.  
Furthermore in Chapter 5, hepatic NEFA and TAG profiles of mice from the 
HFDHA group were markedly reduced compared to either the HFEPA or HF groups. 
The significant reduction of fats deposited in the liver was mainly due to the reduction 
of oleic acid. Although there were no other detectable alterations besides catalase in the 
protein expression when comparing mice fed the HFDHA hypercaloric diet versus HF 
diet, the effects of DHA in reducing oleic acid concentration in NEFA and TAG 
fractions in the liver may be an important aspect in this study and requires further 
investigation.  
A study by Polozova & Salem (2007) showed that dietary DHA is more likely to 
be metabolised by the liver compared to dietary oleic acid. The uptake of dietary DHA 
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in the liver may be redistributed to the brain and retinal tissues where DHA is the 
predominant n-3 polyunsaturated fatty acid (Sinclair & Crawford 1972). The role of 
DHA in regulating LDL metabolism may mediate via lipoproteins as transporters for n-
3 polyunsaturated fatty acids to the target organs rather than monounsaturated fatty 
acids (Polozova et al, 2006).  
In contrast, one study showed that fish oil, but not pure DHA, significantly 
lowered hepatic epoxide hydrolase levels, an inflammatory response protein in mice fed 
DHA when compared to mice fed high-oleic sunflower oil (Mavrommatis et al, 2010). 
This may explain the role of EPA in lowering expoxide hydrolase more rapidly 
compared to DHA. However, there were no significant differences shown in this protein 
for the studies in the thesis, even though this protein was identifiable in the SWISSprot 
reference gel.  
Catalase was detected to be up-regulated in HFDHA group when compared to 
the HF group. This may indicate a high decomposition rate of hydrogen peroxide to 
water and oxygen to prevent toxicity of hydrogen peroxide in the presence of DHA. 
However, there were no significant changes in the plasma levels of insulin, glucose, 
cholesterol, triacylglycerols (TAG), non-esterified fatty acids (NEFA) and liver 
enzymes (ALP, AST and ALT) when comparing HFDHA and HFEPA with HF group 
mice (Section 5.3.3).  
Mice fed a high-fat fish oil diet for 3 weeks present significant increases in 
peroxisomal beta-oxidation and catalase activity in both liver and myocardium (De 
Craemer et al, 1994). Further investigations were carried out by the aforementioned 
study by De Craemer et al, (1994) whereby 2% of DHA administered to healthy mice 
was shown to induce significant increases in catalase protein of the myocardium after 3 
weeks but there were no changes in catalase protein in the liver. In addition, there were 
no changes in the peroxisomes of myocardium and liver indicating that DHA dosage 
used in the study by De Craemer et al, (1996) did not disrupt fatty acid metabolism in 
the liver. In addition, Demoz et al, (1992) showed that hepatic acyl-CoA oxidase and 
catalase activities increased by 50% and 30% respectively in EPA administered mice. In 
this study for the PhD, catalase was significantly increased in HFDHA when compared 
with HF group. Catalase in the HFDHA group was consistently higher compared to the 
HFEPA group.  
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Consistently in Chapter 5, DHA seem to show a higher effect in lowering TAG 
synthesis in the liver compared to EPA. Further studies are required to target protein 
expressions affecting hepatic fatty oxidation and synthesis. 
 
7.5 Conclusion 
In this study for the thesis, proteins shown to be differentially expressed using 2-
D DIGE were selected for validation by LC-MS/MS. However, the concordance of 
agreement was poor. Nevertheless some proteins identified by LC-MS/MS play an 
important role in cellular respiration, ketone and carboxylic acid metabolism syndrome, 
generation of precursor metabolites and energy generation.  
It is noteworthy that, proteins such as glutathione S-transferases were shown to 
be significantly down-regulated in other studies examining the liver in response to high 
fat feeding and hepatic steatosis (Kirpich et al, 2011).  Moreover, glutathione S-
transferases are known to be up-regulated in the liver due to increased hepatic 
inflammation and oxidative stress (Fernandes et al, 1996; Lee et al, 2009).  Although 
both the proteins were identified by LC-MS/MS in this study for the thesis, they were 
not differentially expressed in the liver in response to feeding hypercaloric low or high 
fat diets. Future work may require a longer period of time to see the differential effects 
of hypercaloric feeding on liver protein profiles.  
However, the precise molecular mechanisms for the effects of the HF 
hypercaloric diet on the liver are still unclear. Future work is required to comprehend 
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8.1  Introduction 
Various studies have shown that hypercaloric diets predispose the liver to both 
the suppression of hepatic fatty acid oxidation and an excessive influx of fatty acids 
from adipose tissue to the liver, causing steatohepatitis also commonly called NASH 
(Dolganiuc et al, 2009; Estep et al, 2010; Stanton et al, 2011). Understanding this 
process is highly relevant particularly when steatohepatitis can lead to the progression 
of other risk factors such as liver fibrosis, cirrhosis and hepatocellular carcinoma with 
corresponding increases in morbidity and mortality (Bugianesi et al, 2002; Bailey et al, 
2002; Pais et al, 2010; Sanyal 2011).  It has been proposed that the development and 
progression of NASH is highly dependent on the different types of fats consumed 
(Hussein et al, 2007; Vallim & Salter et al, 2010) and the degree of hepatic 
inflammation (Harmon et al, 2011). The preceding events that lead to the inflammatory 
response are also poorly defined but are thought to involve cytokines, adipokines, 
PPAR-alpha signalling and a variety of other factors (Czaja 2004). Many of these 
mechanisms are mediated by changes in mRNA expression. 
The n-3 polyunsaturated fatty acids, mainly EPA and DHA, are extremely 
important in down-regulating inflammatory genes and stimulating fatty acid oxidation 
(Yusufi et al, 2003; Shaw et al, 2007; Gorjao et al, 2009). EPA and DHA are both anti-
thrombotic, hypolipidemic and inhibitors of cholesterol and lipoprotein formation in the 
liver (Deckelbaum et al, 2006). The protective effects of EPA and DHA against liver 
inflammation and a reduction in TAG synthesis in the liver are in part mediated by the 
expression of mRNA such as SREBP1-c (Kajikawa et al, 2009).  However, hitherto no 
studies have examined differential effects of EPA or DHA on gene expression in the 
liver. In this regard, it is important to highlight the fact that mRNA levels per se do not 
dictate the subsequent expression of proteins within a cell. Apart from rates of 
translation and post-transcriptional modification of proteins, the microRNAs have a 
pivotal role in modulating mRNA. 
These miRNAs are small (~22 nucleotides) non-coding RNA molecules which 
regulate mRNA expression via post-transcriptional control through poly (A) tail 
removal (Kojima et al, 2010), and binding to un-translated 3’ regions. The miRNAs 
have been proposed to modulate the metabolic pathways related to liver inflammation 
and hepatic fatty acid accumulation (Hand et al, 2009; Padgett et al, 2009). 
Studies have shown the commonly re-occurring miRNAs in liver such as miR-
10 (Zheng et al, 2010), miR-21 (Meng et al, 2007), miR-122 (Xu et al, 2010, Lewis & 
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Jopling 2010), miR-199 (Shen et al, 2010) and miR-200 (Murakami et al, 2011) are 
related to liver fibrosis and hepatocellular carcinoma which are features of chronic 
NASH or its ensuing consequences.  Furthermore hepatocellular inflammation is also 
associated with perturbations in miRNA (Brunt et al, 2001; Dolganiuc et al, 2009). 
Various animal models have shown that NASH related to methionine and choline 
deficient (MCD) (Dolganiuc et al, 2009) and high fat diets (Ahn et al, 2011) cause 
changes in selective miRNAs in the liver. For example, MCD diet regimens resulted in 
either the up-regulation of miR-705 and miR-1224 or down-regulation of miR-182, 
miR-183 and miR-199a-3p (Dolganiuc et al, 2009). However, there are no studies in 
which microRNA arrays have been investigated with respect to hypercaloric feeding of 
low and high fat diets with the inclusion of EPA and DHA. 
We hypothesised that there is differential expression of miRNA in mice fed 
hypercaloric diets with different lipid compositions. In the ensuing studies, all diets had 
adequate protein, carbohydrate and micro-nutrients to minimize factors that may affect 
the accumulation of hepatic fats. The miRNA expression profiles were generated with 
microarray chips and then changes in selected miRNAs were further validated using 
RT-qPCR. We also hypothesised that the mice fed with either supplemental DHA or 
EPA or both will present an improved miRNA profile compared with mice fed a HF 
hypercaloric diet without any n-3 polyunsaturated fats. 
 
8.2 Materials and methods 
Animal work, diets and experimental designs are outlined in Chapter 2. All 
materials and methods including the manufacturer and make of the products for miRNA 
experiments are also listed in Chapter 2. The following sections provide information 
specific to this chapter. There were 5 groups of animals: a single LFR (Low fat 
reference) and 4 hypercaloric groups namely, LF (low fat), HF (high fat), high fat DHA 
(HFDHA) and high fat EPA (HFEPA) groups. In simple terms, the hypercaloric diets 
were supplemented with condensed milk (light fat version) incorporated with either 
corn oil in the LF group, palm oil in the HF group, palm oil with DHA or palm oil with 
EPA (for detailed composition of the diets see Chapter 2). 
 
8.2.1 RNA extraction, hybridization and selection for miRNA microarray 
Total liver RNA was isolated with TRIzol LS Reagent as described in the 
manufacturer’s protocol. The quantity and quality of RNA was assessed using the 
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Nanodrop spectrophotometer and Agilent bioanalyser, respectively. After ensuring the 
quality and quantity of the RNA present in the samples was satisfactory, approx 170 ng 
RNA from each sample (n=6 per group) was pooled to provide an aliquot containing 
1000 ng of sample. Then nuclease-free water was added to each pooled sample to make 
a final volume of 35 µL. Thereafter, 1000 ng of total RNA was labelled with FlashTag 
Biotin HSR kit and hybridized in the Affymetrix Hybridization Oven 640 for 
subsequent analysis by Affymetrix GeneChip miRNA arrays. After 16 hours of 
hybridization, the hybridization cocktail (Section 2.8) was extracted from the array to a 
new tube and filled with array holding buffer and allowed to equilibrate before washing 
and staining. The Affymetrix Fluidics station 450 was used for the washing and staining 
process. 
The hybridization signals on the microarray chips were detected with the 
GeneChip Scanner 3000 7G. Data was summarized, normalized and checked for quality 
control using miRNA QC Tool Software version 1.1.1.0. Statistical analysis was carried 
out between the miRNA probe sets and background probes. The detection are said to be 
“TRUE” when P ≤ 0.06.  
Specifications of the miRNA arrays used in this study were as follow (information was 
obtained from Affymetrix): 
Chip type   : Affymetrix chip for miRNA 
Probe pairs for miRNA  : 4 identical probes 
Probe pairs for sno/scaRNA  : 11 probes 
Oligonucleotide probe length : less than or equals to 25-mer 
Hybridization controls  : bioB, bioC, bioD and cre 
Control sequences  : 22 control probe sets (10 probes/set) 
Background probes   : 95 antigenomic probe sets 
 
8.2.2 Real-time reverse transcriptase-quantitative polymerase chain reaction, 
(real time RT-qPCR)  
The selected miRNAs, namely miR-199a-5p, 200b, 324-5p, 21*, 31*, 345-3p, 
451 and 466f, were normalized against snoRNA-234 (endogenous control). Specific 
primer sequences for each miRNA were ordered from Applied Biosystems which are 
designed to be similar to each independent stem-loop sequence identified in the Sanger 
Institute miRBase (release 10.0) but the primer sequences were not revealed by the 
company. The miRNAs selected for verification was on the basis of the microarray data. 
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MiRNA microarray results were validated using RT-qPCR on independently derived 
RNAs from individual mice. A 2-step RT-qPCR was carried out using TaqMan Small 
RNA assays. In the reverse transcription (RT) step, reagents from TaqMan MicroRNA 
Reverse Transcription (RT) kit were used and cDNAs were reverse transcribed from 
RNA using a small RNA-specific, stem-loop RT primer. Each 15 µL RT reaction was 
combined with RT master mix with total RNA in the ratio of 7µL RT master mix : 5 µL 
total RNA (1 to 10 ng per reaction). Then, 12 µL of total RNA with RT master mix was 
transferred to a 96-well reaction plate and loaded onto a PTC-225 Peltier Thermal 
Cycler set to 4 steps as mentioned in Section 2.9.  
Immediately after the RT run, PCR amplification was continued using TaqMan 
Universal PCR Master Mix II. For this 20 µL per reaction of qPCR reaction mix was 
prepared accordingly (Section 2.9) and transferred into 4 wells of 384-well plate using 
the Biomek FX Beckman Coultier Liquid handling robot. All samples were run in 
quadruplicate. Plates were sealed, centrifuged and loaded onto the 7900 HT Fast RT-
PCR Systems. First-strand cDNA samples were amplified for 40 cycles (95°C for 5 sec, 
60°C for 5sec, 72°C for 22 sec). Quantitative real-time RT-PCR and analysis was 
carried out using the ABI Prism 7000 sequence detection systems.  
The amounts of initial template cDNA for the target miRNA were quantified by 
applying the threshold cycle to the standard curve. The final results for the expression 
levels of target miRNAs were normalized to the expression of snoRNA-234 by referring 
to its standard curve as quantified using real-time RT-qPCR. The 2
-∆∆CT 
method was 
used to calculate the relative quantification (RQ) of intensities indicating fold change 
between the groups. The median Ct of the 4 samples normalized to controls was used 
for comparing Ct values as shown in Appendix 2.1 and 2.2. 
 
8.2.3 Statistical analyses 
 Microarray data was summarized and normalized using the miRNA QC Tool 
Software version 1.1.1.0 which applies Student’s t-test for its P-values. Cycle threshold 
and relative quantification of the selected miRNAs generated from real time RT-qPCR 





8.3.1 Microarray analyses for microRNAs 
One microarray chip was used for each group using pooled good quality RNAs 
from 6 mice per group.  The microarray data in its log form of intensity were then 
normalized against the log intensity of the background probes within the arrays to 
counter technical biasness in order to identify real biological differences between 
groups. An overview of data distribution was represented by the MA plots, with 
intensity ratio (M) plotted against the average intensity (A).  An example of the MA 
plots of HF vs HFEPA is presented in Figure 8.1. The assumption that most miRNAs 
do not change in their expression mean that the clustering of the miRNAs around the 0 
point of the X-axis indicates normalized data.  As seen in the MA plots, there were no 
distinct outliers (Figure 8.1). 
In this chapter there were 4 sets of comparisons of interest (i) LFR vs LF group 
(ii) LFR vs HF group (iii) HF vs HFDHA group (iv) HF vs HFEPA group. After data 
normalization, the intensities of the hybridized probes were filtered according to its 
species and only mouse miRNA were subsequently analysed. There were 609 mouse 
miRNAs and 259 miRNAs were detected as a “TRUE” miRNA with P ≤ 0.06 (Figure 
8.2). Relative intensities were estimated by calculating the difference in log 2 intensities 
between the groups followed by the antilog of the difference obtained.   
For the comparison between LFR and LF groups, a total of 25 miRNAs had fold 
change of >1.5 and 16 miRNAs had a fold change of <0.5 (Table 8.1). For the 
comparison between LFR and HF groups, there were 23 miRNAs with fold change > 
1.5 and 20 miRNAs with fold change <0.5 (Table 8.2). Furthermore, for the comparison 
between HF and HFDHA, a total of 9 miRNAs had fold change of >1.5 and 6 miRNAs 
had fold changes of <0.5 (Table 8.3). For the comparison between HF and HFEPA 
groups, there were 22 miRNAs with fold change > 1.5 and 5 miRNAs with fold changes 
<0.5 (Table 8.4).   
Referring to the Venn diagram (Figure 8.3), there were 25 miRNAs expressed 
in the comparisons between LFR vs LF and LFR vs HF. For the comparison between 
HF vs HFDHA and HF vs HFEEPA, the Venn diagram (Figure 8.4) showed that there 
were 4 miRNAs similarly expressed in both the comparisons. The miRNAs expressed in 
both comparisons are shown in Table 8.5 and 8.6. 
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8.3.2 Quantification of miRNA with RT-qPCR 
 The sequence of the selected miRNAs which were required for the design of 
stem-loop RT and real-time PCR assays for quantitation of mature miRNA expression 
by Applied Biosystems TaqMan (Table 8.7). In this study a small RNA namely 
snoRNA-234 was used as the endogenous control due to its relatively constant 
expression levels in liver tissues (Huang et al, 2005). Furthermore, sno-234 shows 
relatively high abundance and low variation in liver tissues of mice (Chen et al, 2005; 
Chen et al, 2007).  
 
8.3.3 MiRNA expression by RT-qPCR  
MiR-200b, miR-21* and miR-31* were significantly down-regulated in the LF 
group when compared to the LFR group by -76%, -33% and -57% respectively (P<0.01 
to P<0.001; Figure 8.5). In the HF group, miR-199a-5p, miR-200b, miR-324-3p, miR-
21*, miR-31*, miR-345-3p and miR-466f were significantly down-regulated by -86%, -
86%, -51%, -76%, -76%, -72% and -62%, respectively when compared to the LFR 
group (P<0.05 to P<0.001; Figure 8.5).  
In addition, a comparison between LF and HF treated groups (ie, the effects of 
high fat hypercaloric feeding) showed that miR-21* and miR-466f were significantly 
reduced when HF is compared to LF group (P<0.01; Figure 8.5). 
 
8.3.4 MiRNA expression by RT-qPCR in comparison with microarray data  
The comparison between RT-qPCR and the microarray data showed similar 
trends in the expressions for miR-200b, miR-21*, miR-31*, miR-345-3p and miR-466f 
in all comparisons (Figure 8.6). However, opposite effects were seen in miR-324-3p for 
all comparisons and exceptionally miR-200b showed an opposite effect in HF vs 
HFDHA (Figure 8.6). The array and RT-qPCR data for miR-451 appeared to be 
dissimilar in the comparison of LFR vs HF and HF vs HFEPA. There were also a slight 
difference in miR-199a-5p between RT-qPCR and the microarray data when comparing 





Figure 8. 1: MA plot of microarray data from HF and HFEPA groups 
 
M is green intensity ratio on the y-axis; A is average intensities on the x-axis. Formula 
for M=log2R- log2G; A= ½ x (log2R + log2G). 
 
 
Figure 8. 2: Flow chart of miRNA analysis for LFR, LF and HF groups 
  
7624 miRNAs identified in the microarray analysis 
609 miRNAs were derived from mouse  
259 miRNAs were detected as “TRUE” in the LFR group as a control 
Comparison between LFR vs LF: 
- 25 miRNAs up-regulated 
with ≥1.5 fold change 
- 16 miRNAs down-
regulated with fold change 
≤0.5 
Comparison between LFR vs HF: 
- 23 miRNAs up-regulated 
with ≥1.5 fold change 
- 20 miRNAs down-
regulated with fold change 
≤0.5 
 
A total of 8 miRNAs were selected based on previous publications related to hepatic 
steatosis for validation with RT-qPCR  
 
Comparison between HF vs 
HFDHA group: 
- 9 miRNAs up-regulated 
with >1.5 fold change; 
- 6 miRNAs down-regulated 
with fold change <0.5 
 
 
Comparison between HF vs 
HFEPA group: 
- 22 miRNAs up-regulated 
with >1.5 fold change; 
- 5 miRNAs down-regulated 




Table 8. 1: List of mouse miRNAs altered (increased or decreased by at least 50%) 
when comparing LFR vs LF groups 
































mmu-miR-494 7.33 160 2.50E-07 9.56 754 2.10E-08 4.70 
mmu-miR-744 7.59 193 1.00E-06 9.23 600 3.80E-08 3.11 
mmu-miR-762 11.46 2816 4.60E-08 13.03 8346 4.60E-08 2.96 
mmu-miR-714 7.93 245 0.00021 9.45 700 6.50E-07 2.86 
mmu-miR-720 6.64 100 1.30E-06 8.09 272 2.10E-08 2.73 
mmu-miR-203 7.17 144 1.90E-07 8.36 329 7.10E-08 2.29 
mmu-let-7g 8.6 387 2.10E-08 9.79 885 2.10E-08 2.29 
mmu-let-7f 8.32 320 2.10E-08 9.4 677 2.10E-08 2.12 
mmu-miR-455 8.98 505 2.10E-08 10.05 1062 2.10E-08 2.10 
mmu-miR-328 5.72 53 0.00378 6.7 104 0.00037 1.98 
mmu-miR-1195 9.63 790 2.50E-07 10.55 1499 2.10E-08 1.90 
mmu-miR-193 8.02 260 2.10E-08 8.92 485 2.10E-08 1.86 
mmu-miR-101a 4.34 20 0.05493 5.13 35 0.00945 1.72 
mmu-miR-101b 7.04 132 7.10E-08 7.81 224 2.10E-08 1.70 
mmu-miR-193* 7.58 191 2.10E-08 8.33 323 2.10E-08 1.69 
mmu-miR-148b 4.79 28 0.0018 5.52 46 0.00068 1.66 
mmu-miR-139-3p 5.22 37 0.03828 5.92 61 0.00355 1.63 
mmu-miR-712 5.65 50 0.00662 6.35 82 0.00073 1.63 
mmu-miR-188-5p 4.61 24 0.03773 5.3 39 0.00163 1.62 
mmu-miR-467a 4.47 22 0.03977 5.13 35 0.00539 1.58 
mmu-miR-26b 5.46 44 0.00014 6.1 69 5.70E-08 1.56 
mmu-miR-148a 8.17 289 2.10E-08 8.81 448 2.10E-08 1.55 
mmu-miR-324-3p 5.12 35 0.0226 5.74 53 0.00379 1.54 
mmu-miR-139-5p 8.57 380 2.10E-08 9.17 575 2.10E-08 1.51 
mmu-miR-486 8.05 264 1.00E-06 8.63 397 2.50E-07 1.50 
mmu-miR-497 8.18 290 2.10E-08 7.14 141 2.10E-08 0.49 
mmu-miR-199a-3p 9.04 525 2.10E-08 7.97 251 3.50E-07 0.48 
mmu-miR-214 9.38 668 2.10E-08 8.31 317 2.50E-07 0.47 
mmu-miR-181d 5.58 48 7.20E-05 4.51 23 0.07144 0.47 
mmu-miR-379 5.25 38 0.0033 4.12 17 0.11965 0.45 
mmu-miR-18a 7.4 169 1.90E-07 6.2 73 3.30E-05 0.43 
mmu-miR-199b* 5.61 49 6.40E-06 4.35 20 0.23945 0.42 
mmu-miR-183 5.41 42 0.0004 4.14 18 0.33365 0.42 
mmu-miR-708 5.29 39 5.70E-05 3.95 16 0.58027 0.40 
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mmu-miR-200c 7.76 217 2.10E-08 6.42 86 3.30E-06 0.40 
mmu-miR-146b 5.22 37 0.0004 3.83 14 0.27355 0.38 
mmu-miR-199a-5p 9.17 577 2.10E-08 7.76 217 2.10E-08 0.38 
mmu-miR-362-5p 6.8 111 1.00E-06 5.38 42 0.00044 0.37 
mmu-miR-34a 8.79 441 2.10E-08 7.24 152 2.10E-08 0.34 
mmu-miR-214* 5.67 51 0.00025 3.84 14 0.66624 0.28 
mmu-miR-200a 7.73 212 2.10E-08 5.72 53 0.00011 0.25 
*indicates that the miRNA arises from the 3’arm of miRNA; without the star it means 
the miRNA arises from 5’arm of miRNA. Similarly, 5p and 3p indicates that the miRNA 
is derived from the 5’ and 3’ end respectively. miRNA with the same number but 
different letters are derived from the same sequence. Green indicates up-regulated 
miRNAs whereas red indicates down regulated miRNAs. Absolute intensities = 2^ 
Log2Intensities; Relative intensities = Absolute intensities of treated samples/Absolute 
intensities of controls. MiRNAs selected are within the criteria of a “TRUE” detection 




Table 8. 2: List of mouse miRNAs identified when comparing HF with LFR mice 
group  



































mmu-miR-455 8.98 505 2.10E-08 10.49 1438 2.10E-08 2.85 
mmu-let-7g 8.60 387 2.10E-08 10.00 1027 2.10E-08 2.65 
mmu-miR-744 7.59 193 1.00E-06 8.76 434 2.50E-07 2.25 
mmu-let-7f 8.32 320 2.10E-08 9.49 718 2.10E-08 2.24 
mmu-miR-203 7.17 144 1.90E-07 8.27 309 2.10E-08 2.15 
mmu-miR-193 8.02 260 2.10E-08 9.09 547 2.10E-08 2.10 
mmu-miR-148b 4.79 28 0.00180 5.76 54 0.00026 1.95 
mmu-miR-720 6.64 100 1.30E-06 7.55 188 2.10E-08 1.88 
mmu-miR-101b 7.04 132 7.10E-08 7.95 247 2.10E-08 1.87 
mmu-miR-193* 7.58 191 2.10E-08 8.46 352 2.10E-08 1.84 
mmu-miR-705 8.01 258 4.00E-06 8.86 463 6.50E-07 1.80 
mmu-miR-714 7.93 245 0.000210 8.73 423 1.80E-05 1.73 
mmu-miR-291b-5p 4.77 27 0.0328 5.54 47 0.00857 1.70 
mmu-miR-328 5.72 53 0.00378 6.48 89 0.00035 1.70 
mmu-miR-324-3p 5.12 35 0.0226 5.87 59 0.0017 1.69 
mmu-miR-1195 9.63 790 2.50E-07 10.36 1310 2.10E-08 1.66 
mmu-miR-486 8.05 264 1.00E-06 8.74 427 1.30E-07 1.61 
mmu-miR-22* 5.58 48 1.80E-05 6.26 77 7.10E-06 1.60 
mmu-miR-455* 5.00 32 0.00432 5.67 51 0.00036 1.59 
mmu-let-7d* 5.94 62 1.40E-06 6.61 97 4.60E-07 1.58 
mmu-miR-361 8.51 364 2.10E-08 9.16 572 2.10E-08 1.57 
mmu-miR-146a 8.04 263 2.10E-08 8.68 411 2.10E-08 1.56 
mmu-miR-92a 10.02 1037 2.10E-08 10.65 1604 2.10E-08 1.55 
mmu-miR-199b 9.12 557 2.10E-08 8.11 275 2.10E-08 0.49 
mmu-miR-384-5p 4.70 26 0.0178 3.69 13 0.39211 0.49 
mmu-miR-541 5.30 39 0.000250 4.23 19 0.34877 0.48 
mmu-miR-181c 5.24 38 0.00365 4.16 18 0.236 0.47 
mmu-miR-503 6.16 72 0.000360 5.04 33 0.08493 0.46 
mmu-miR-199b* 5.61 49 6.40E-06 4.40 21 0.29115 0.43 
mmu-miR-301a 4.93 31 0.00731 3.70 13 0.58965 0.43 
mmu-miR-764-5p 5.01 32 0.00739 3.78 14 0.51246 0.43 
mmu-miR-200c 7.76 217 2.10E-08 6.53 92 7.70E-06 0.43 
mmu-miR-183 5.41 42 0.000400 4.16 18 0.20933 0.42 
mmu-miR-711 5.51 46 0.00423 4.24 19 0.22206 0.41 
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mmu-miR-214* 5.67 51 0.00025 4.39 21 0.18961 0.41 
mmu-miR-200b 6.25 76 3.50E-07 4.84 29 0.00534 0.38 
mmu-miR-214 9.38 668 2.10E-08 7.96 250 2.20E-06 0.37 
mmu-miR-199a-5p 9.17 577 2.10E-08 7.74 214 2.10E-08 0.37 
mmu-miR-379 5.25 38 0.0033 3.82 14 0.35736 0.37 
mmu-miR-362-3p 5.03 33 0.004 3.50 11 0.92355 0.35 
mmu-miR-146b 5.22 37 0.0004 3.56 12 0.66668 0.32 
mmu-miR-497 8.18 290 2.10E-08 6.24 75 1.40E-06 0.26 
mmu-miR-200a 7.73 212 2.10E-08 5.31 40 0.00263 0.19 
*indicates that the miRNA arises from the 3’arm of miRNA; without the star it means 
the miRNA arises from 5’arm of miRNA. Similarly, 5p and 3p indicates that the miRNA 
is derived from the 5’ and 3’ end respectively. miRNA with the same number but 
different letters are derived from the same sequence. Green indicates up-regulated 
miRNAs whereas red indicates down regulated miRNAs. Absolute intensities = 2^ 
Log2Intensities; Relative intensities = Absolute intensities of treated samples/Absolute 
intensities of controls. MiRNAs selected are within the criteria of a “TRUE” detection 




Table 8. 3: List of mice miRNAs altered (increased or decreased by at least 50%) 



























mmu-miR-689 6.92 121 0.007006 7.83 228 0.002189 1.88 
mmu-miR-483 4.65 25 0.005256 5.54 47 0.007972 1.86 
mmu-miR-719 4.50 23 0.017164 5.28 39 0.000299 1.72 
mmu-miR-501-3p 4.42 21 0.035683 5.20 37 0.00481 1.72 
mmu-miR-872* 4.85 29 0.031088 5.54 47 0.005325 1.61 
mmu-miR-497 6.24 75 1.38E-06 6.89 118 2.33E-07 1.57 
mmu-miR-466f-5p 5.55 47 0.000419 6.19 73 1.44E-05 1.56 
mmu-miR-188-5p 4.96 31 0.021397 5.57 47 0.000908 1.53 
mmu-miR-326 4.88 29 0.038338 5.48 45 0.017652 1.52 
mmu-miR-551b 4.90 30 0.034338 3.87 15 0.621309 0.49 
mmu-miR-297a 4.81 28 0.017439 3.71 13 0.384216 0.47 
mmu-miR-451 6.66 101 5.52E-08 5.32 40 0.00049 0.39 
mmu-miR-10a 6.99 127 2.55E-06 5.48 45 0.000471 0.35 
mmu-miR-149 7.30 157 5.23E-05 5.50 45 0.007379 0.29 
mmu-miR-708* 4.75 27 0.043956 2.93 8 0.570898 0.28 
*indicates that the miRNA arises from the 3’arm of miRNA; without the star it means 
the miRNA arises from 5’arm of miRNA. Similarly, 5p and 3p indicates that the miRNA 
is derived from the 5’ and 3’ end respectively. miRNA with the same number but 
different letters are derived from the same sequence. Green indicates up-regulated 
miRNAs where as red indicates down-regulated miRNAs. Absolute intensities = 2^ 
Log2Intensities; Relative intensities = Absolute intensities of treated samples/Absolute 
intensities of controls. MiRNAs selected are within the criteria of a true detection in HF 
group, and >1.5 fold change or <0.5 fold change between groups  
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Table 8. 4: List of mice miRNAs altered (increased or decreased by at least 50%) 





























mmu-miR-483 4.65 25 0.00526 6.22 75 2.00E-05 2.98 
mmu-miR-466f-5p 5.55 47 0.00042 7.07 134 2.10E-08 2.87 
mmu-miR-494 7.80 223 2.05E-08 9.08 542 2.10E-08 2.43 
mmu-miR-762 11.72 3369 4.59E-08 12.94 7885 4.60E-08 2.34 
mmu-miR-467d* 5.00 32 0.00459 6.07 67 6.20E-06 2.10 
mmu-miR-667 4.73 27 0.05133 5.79 55 0.00258 2.09 
mmu-miR-699 5.23 37 0.03063 6.28 78 0.00119 2.08 
mmu-let-7b* 4.91 30 0.04202 5.89 59 1.10E-06 1.97 
mmu-miR-92a* 5.04 33 0.01369 5.99 64 0.00011 1.94 
mmu-miR-669c 5.99 63 2.60E-05 6.81 112 3.40E-06 1.77 
mmu-miR-574-5p 7.61 195 1.33E-07 8.35 326 2.10E-08 1.67 
mmu-miR-327 5.68 51 0.00118 6.38 83 7.70E-06 1.62 
mmu-miR-21* 4.97 31 0.00684 5.66 51 0.00181 1.62 
mmu-miR-690 13.12 8873 2.05E-08 13.81 14333 2.10E-08 1.62 
mmu-miR-501-3p 4.42 21 0.03568 5.09 34 0.00361 1.59 
mmu-miR-685 7.39 168 2.05E-08 8.04 264 2.10E-08 1.57 
mmu-miR-29b 5.81 56 7.31E-06 6.45 88 1.00E-07 1.56 
mmu-miR-714 8.73 423 1.77E-05 9.37 661 6.50E-07 1.56 
mmu-miR-671-5p 6.44 87 0.00823 7.06 133 0.00113 1.53 
mmu-miR-324-5p 5.82 57 0.00311 6.42 86 0.00161 1.52 
mmu-miR-150 6.78 110 3.86E-06 7.38 166 2.10E-08 1.51 
mmu-miR-31* 6.81 112 9.72E-07 5.79 55 8.70E-05 0.49 
mmu-miR-149 7.30 157 5.23E-05 6.27 77 0.00192 0.49 
mmu-miR-542-5p 4.70 26 0.01869 3.54 12 0.43233 0.45 
mmu-miR-302c* 4.48 22 0.00688 3.17 9 0.12995 0.40 
mmu-miR-345-3p 5.86 58 0.00212 4.44 22 0.06662 0.37 
*indicates that the miRNA arises from the 3’arm of miRNA; without the star it means 
the miRNA arises from 5’arm of miRNA. Similarly, 5p and 3p indicates that the miRNA 
is derived from the 5’ and 3’ end respectively. miRNA with the same number but 
different letters are derived from the same sequence. Green indicates up-regulated 
miRNAs where as red indicates down-regulated miRNAs. Absolute intensities = 2^ 
Log2Intensities; Relative intensities = Absolute intensities of treated samples/Absolute 
intensities of controls. MiRNAs selected are within the criteria of a true detection in HF 





Figure 8. 3: Venn diagram of regulated miRNAs in both HF vs LF  
 
Table 8. 5: List of regulated miRNAs overlapping and expressed individually when 
comparing between (LF vs LFR) and (HF vs LFR) 
miRNAs in LFR vs LF miRNAs in common miRNAs in  LFR vs  HF 
mmu-miR-494 mmu-miR-744 mmu-miR-705 
mmu-miR-762 mmu-miR-714 mmu-miR-291b-5p 
mmu-miR-101a mmu-miR-720 mmu-miR-22* 
mmu-miR-139-3p mmu-miR-203 mmu-miR-455* 
mmu-miR-712 mmu-let-7g mmu-let-7d* 
mmu-miR-188-5p mmu-let-7f mmu-miR-361 
mmu-miR-467a mmu-miR-455 mmu-miR-146a 
mmu-miR-26b mmu-miR-328 mmu-miR-92a 
mmu-miR-148a mmu-miR-1195 mmu-miR-199b 
mmu-miR-139-5p mmu-miR-193 mmu-miR-384-5p 
mmu-miR-199a-3p mmu-miR-101b mmu-miR-541 
mmu-miR-181d mmu-miR-193* mmu-miR-181c 
mmu-miR-18a mmu-miR-148b mmu-miR-503 
mmu-miR-708 mmu-miR-324-3p mmu-miR-301a 
mmu-miR-362-5p mmu-miR-486 mmu-miR-764-5p 
mmu-miR-34a mmu-miR-497 mmu-miR-711 
 mmu-miR-214 mmu-miR-200b 
 mmu-miR-379 mmu-miR-362-3p 
 mmu-miR-199b*  
 mmu-miR-183  
 mmu-miR-200c  
 mmu-miR-146b  
 mmu-miR-199a-5p  
 mmu-miR-214*  
 mmu-miR-200a  




Figure 8. 4: Venn diagram of miRNAs that were overlapping when comparing 
HFDHA vs HF and HFEPA vs HF groups. 
 
Table 8. 6: List of miRNAs overlapping and exprressed individually when comparing 
between (HF vs HFDHA) and (HF vs HFEPA) groups 
miRNAs in HF vs HFDHA miRNAs in common miRNAs in HF vs HFEPA 
mmu-miR-689 mmu-miR-483 mmu-miR-494 
mmu-miR-719 mmu-miR-501-3p mmu-miR-762 
mmu-miR-872* mmu-miR-466f-5p mmu-miR-467d* 
mmu-miR-497 mmu-miR-149 mmu-miR-667 
mmu-miR-188-5p  mmu-miR-699 
mmu-miR-326  mmu-let-7b* 
mmu-miR-551b  mmu-miR-92a* 
mmu-miR-297a  mmu-miR-669c 
mmu-miR-451  mmu-miR-574-5p 
mmu-miR-10a  mmu-miR-327 
mmu-miR-708*  mmu-miR-21* 
  mmu-miR-690 
  mmu-miR-685 
  mmu-miR-29b 
  mmu-miR-714 
  mmu-miR-671-5p 
  mmu-miR-324-5p 
  mmu-miR-150 
  mmu-miR-31* 
  mmu-miR-542-5p 
  mmu-miR-302c* 
  mmu-miR-345-3p 




Table 8. 7: miRNA sequence selected for validation with real-time RT-qPCR for LFR, 
LF and HF groups 









The miRNAs selected for RT-qPCR were related to hepatic steatosis and consequently 






Figure 8. 5: The relative intensities of miR-199a-5p, miR-200b, miR-324-3p and miR-

















































































































































   
 
to be continued 
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Data are mean ± SEM (n=6 per group). Differences between the mean of 5 groups were 
estimated with analysis of variance (ANOVA) followed by Tukey’s test. ANOVA values 
for miR-199a-5p, 200b, 324-3p, miR-21, miR-31, 345-3p, 451 and 466f when 
comparing all 5 groups were P=0.001, <0.001, <0.001, <0.001, <0.001, <0.001, 0.040 
and <0.001 respectively.  
A comparison between LFR vs LF and HF groups was carried out. The significant 
differences between the LFR control group and either the LF or HF group are as 
follows: * = P<0.05, ** = P<0.01 and *** = P<0.001. Differences between the LF and 
HF groups are displayed with a horizontal bar over the two groups where ††= P<0.01.  
There were no significant differences when comparing HF vs HFDHA and HFEPA. 
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Figure 8. 6: Changes in miRNAs in LF and HF groups compared to the LFR group 
and changes in HFDHA and HFEPA groups compared to HF group using either 
















































































































































































































































































8.4.1 Methodological considerations 
 Initial studies with microarrays used one microarray chip per group hence there 
were no statistical analyses between treatments.  Subsequently, specific miRNAs were 
selected for verification by RT-PCR.  Most verification studies are based on a number 
of premises namely (a) the intensity of the signals are “TRUE”; (b) they alter by least a 
defined amount, (c) they are deemed to be of metabolic significance based on existing 
bimolecular information, (d) they have been reported to alter in different diseases or 
conditions. It is tempting just to select those which display the greatest changes, but this 
may not have a firm foundation that relates to the existing knowledge base nor be 
related to hepatic pathology. For example, miR-494 shows a 4.7 fold increase in the HF 
hypercaloric diet but there is very little information on its function. There are only 6 
papers on the pathology of murine miR-494, which are all related to gastric cancer. On 
the other hand, there are 177 papers on miRNA 21*. Whilst miR-494, 200a and 455 
have not been examined in mouse liver, miR-199a-5p (Kanda et al, 2010), 31* (Zhang 
et al, 2011) have.  
The normalization of the data in RT-qPCR is essential in order to obtain relative 
intensities in miRNAs expression which are close to real biological changes. SnoRNA’s 
are commonly used as an endogenous control for normalizing microarray miRNA 
expression data because they are closer in length to miRNAs, expressed abundantly 
across various tissues and most importantly they are unlikely to be related to other 
miRNA regulatory pathways (Kiss 2002). SnoRNA-234 was selected due to its 
consistency of expression (i.e., least variability) across experimental conditions 
compared to snoRNA135, 142, 202 and 251 (Applied 
Biosystems;weblink:http://www3.appliedbiosystems.com/cms/groups/mcb_marketing/d
ocuments/generaldocuments/cms_044972.pdf). These stable small RNAs have been 
used as controls in other studies such as those of Mestdagh et al, (2009) and Meyer et al, 
(2010).   
Although miR-21*, 31*, 345-3p, 451 and 466f were not overtly altered within 
the array studies, comparing LFR vs LF and LFR vs HF, we wanted to confirm the 
results by RT-qPCR. There are numerous studies based on these miRNAs. For example, 
miR-21* was up-regulated in mouse hepatocytes exposed to ionizing radiation which 
led to liver carcinogenesis (Zhu et al, 2010). 
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8.4.2 Comparison between the array and RT-qPCR 
The comparison between the results from the microarray and RT-qPCR studies 
showed that directional changes in miR-200b, miR-21*, miR-31*, miR345-3p and miR-
466f were generally consistent, with the exception of miR-324-3p.  MiR-324-3p showed 
divergent changes when using either the array (up-regulation) or RT-qPCR (down-
regulation). The opposite effect was also seen in miR-200b when comparing HF vs 
HFDHA.  
Overall there is a good concordance of data measured by either the arrays or RT-
qPCR. However, it is difficult to explain why there were divergent results using either 
the array or RT-qPCR for miR-324-3p. One reason could be due to the sensitivity of 
both the methods. This is not unusual since Abruzzo et al, (2005), Bhusari et al, (2006) 
and Ach et al, (2008) showed inconsistencies in results generated by both microarray 
and RT-qPCR. The other explanation is that the primers for the RT-qPCR were not 
correctly provided or were unstable. However, the company which provided the primers 
(Applied Biosystems) was not able to reveal the primer sequence. Moreover, the 
primers were stable as they were manufactured about 1.5 weeks before use. 
Nevertheless, RT-qPCR is considered the gold standard method for quantitative 
analysis.  
There are a number of approaches in which one can analyse the data from either 
the array and/or the RT-qPCR.  For example, one could analyse those miRNAs that 
show common changes within the context of pathway analysis or one could interpret the 
data in terms of individual miRNAs that have been shown to alter in specific 
pathologies related to either lipid oxidation, hepatic steatosis or overfeeding.  Here, the 
latter approach is adopted since several studies have shown that more than 30% of all 
mRNAs can be regulated by a single miRNA (Valencia-Sanchez 2006; Nilsen 2007, 
Tzur et al, 2009). Furthermore, miRNAs regulate translation and mRNA degradation 
which can results in at least a 80% reduction in mRNA levels causing a decrease in 
protein synthesis in selective studies (Guo et al, 2010). MiRNA affects translation by 
preventing the elongation step of protein synthesis or by inhibiting the ability of 
ribosomes to bind targeted mRNAs (Pawlicki et al, 2008).  
In the following section, attention is focused on those miRNAs confirmed to 
have altered by RT-qPCR, though an equally valid approach would be to focus on the 
25 miRNAs differentially expressed in the comparison of LFR vs LF, or others shown 
to alter in the comparison of LFR vs HF or LF vs HF groups. However, the miRNA 
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study was carried out at the end of the thesis so it was not possible to validate all 25 of 
the miRNAs by RT-qPCR due to time constraints.  
 
8.4.3 Influence of hypercaloric diets on miRNA expressions  
The over-expression of miR-199 and miR-200 families have been linked to the 
progression of liver fibrosis by Murakami et al, (2011). The aforementioned study 
determined that 4 out of 11 miR-199 and miR-200 families were significantly elevated 
in liver fibrosis when compared with controls; namely miR-199a, 199a*, 200a and 200b 
(Murakami et al, 2011). The predicted target genes for miR-199 and miR-200 have been 
proposed to include inflammation related genes (FAS, NFKB1), cytokines (IL-6, IL-8, 
TNF-α) and fibrosis related genes (FGFR1, SOCS1) (Murakami et al, 2011). For this 
chapter, miR-199a-5p and miR-200b in the HF group were down-regulated significantly 
when compared to the control LFR group as detected by RT-qPCR. If miRNA can 
down-regulate mRNA, one can speculate that the down-regulated miR-199a-5p and 
200b may be responsible for an up-regulation of inflammatory related genes. However, 
no increase in inflammation was seen in liver of the HF group when compared to the 
LFR group. Rather there was a reduction in inflammation scores. The high fat 
hypercaloric mice may have developed a protective mechanism in overcoming 
suppression of hepatic fatty acid oxidation causing the reduced signs of inflammation in 
the HF group mice as shown in the liver histology presented in Section 5.3.5. For 
example, hepatic inflammatory scores in the HF group revealed 63% of animals with no 
signs of inflammation, whereas in the LFR group 63% of the mice showed 
inflammation at scores 2 and 3.  
In the normal process of liver regeneration, quiescent liver cells enter the cell 
cycle, non-parenchymal and parenchymal cells (hepatocytes) divide and liver restores 
proper formation. The removal of mouse liver by 60% causes the remaining liver to 
grow back to its original mass in approximately 1 week (Zimmermann 2004). During 
liver regeneration, miR-21 was found to be the regulator of hepatocyte proliferation and 
it directly inhibited B-cell translocation gene (Btg2), a cell cycle inhibitor that is 
essential for DNA synthesis in hepatocytes (Song et al, 2010). The over-expression of 
miR-21 inhibited NF-kappaB signalling and miR-21 was up-regulated during early 
stages of liver regeneration (Marquez et al, 2010). In this study chapter, miR-21 was 
significantly down-regulated in the high-fat hypercaloric (HF group) mice compared to 
the high-carbohydrate (LF group) hypercaloric mice. In addition, miR-21 in both the LF 
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and HF group were significantly down-regulated when compared to the LFR group. 
Potentially, the up-regulation of miR-21 may be dependent on the rate of normal liver 
cell proliferation; the more severe the damage in the liver, the higher the degree of miR-
21 expression to regenerate the liver. Therefore, the down-regulation of miR-21 in both 
the LF and HF groups may imply the imposition of less severe liver damage compared 
to the LFR group. This was supported by the histology scores in Section 5.3.4 
A study by Zhang et al, (2011) showed that miR-31 increased in oesophageal 
squamous cell carcinoma tissue compared to normal controls by promoting colony 
formation, migration and invasion. However, there are no other reports on how miR-31 
in the liver responds to high fat diets. Targets of miR-31 include tumour suppressor 
mRNAs such as epithelial membrane protein1 (EMP1), kinase suppressor of ras 2 
(KSR2) and regulator of G-protein signalling 4 (RGS4). Similarly, miR-31 was 
significantly up-regulated in hepatocellular carcinoma cells when compared to non-
tumoral liver cells (Wong et al, 2008; Lee et al, 2008). In contrast, our study showed 
that miR-31 was significantly down-regulated in LF and HF groups when compared to 
the LFR group. Therefore, the lower occurrence of liver inflammation (Section 5.3.4) in 
the LF and HF compared to LFR groups may be reflected in, or be due to, the down-
regulation of miR-31. 
MiR-466f has been found to regulate the expression of collagen genes in 
development, with predicted targets namely, COL1A1, COL19A1, COL1A2, COL4A1, 
COL4A5 and COL3A1 with the latter isoform being the main target (Sterling 2011). 
However, it is difficult to interpret the aforementioned observations in relation to the 
study for this thesis as collagen was not measured. MiR-466f was also found to decrease 
significantly in diabetic mice (Chen et al, 2011). In this study for the thesis, HF groups 
showed a down-regulation of miR-466f in comparison to the LFR group. Interestingly, 
the HF hypercaloric mice showed a significant decrease in miR-466f when compared to 
the LF group mice. However, the serum insulin and glucose from this study did not 
show signs of diabetes in both LF and HF groups (Section 5.3.3). This merits further 
investigation.  
MiR-324-3p and miR-345-3p were significantly down-regulated in the HF group 
when compared with the LFR group. For the comparison between LFR vs LF groups, 
there was a down-regulation in miR-345-3p. Currently, there are no studies on both 
these selected miRNAs in relation to hepatic steatosis in response to different types of 
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hypercaloric diets. Thus, they may be suggested as novel miRNAs that respond to 
hypercaloric diets.  
Our RT-qPCR study in general confirmed the array data.  Thus, an in-depth 
analysis of the arrayed material of the 25 miRNAs expressed in the comparison of LFR 
vs LF and LFR vs HF should ideally be carried out, but time did not allow this. 
However, one needs to consider that some of the aforementioned discussion is 
speculative and further work needs to be carried out to determine the significance of 
these observations. In other words, the present observations are preliminary.  Future 
studies could involve miRNA inhibitors and mimics. In general, an up-regulation of a 
specific miRNA should theoretically show a down-regulation in a particular mRNA 
expression, and vice versa. Such a simple relationship has potential to be used 
therapeutically in the treatment of dietary-related liver disease including the wide 
spectrum of fatty liver disorders. 
 
8.4.4 Influence of EPA and DHA on miRNA expressions  
There was no statistically significant change comparing both HF vs HFDHA and 
HF vs HFEPA using data derived from RT-qPCR. Thus it is difficult to further 
elaborate on mechanisms that may be responsible for the changes described in previous 
sections of the thesis where both DHA and EPA affected the liver lipid and histological 
profiles (Chapter 5). Ideally one needs to do pathway analysis on the collective 
miRNAs expressed in both the comparisons. To this date, there is only 1 paper on the 
effects of miRNA expression in relation to DHA. This shows miRNA profiling in the 
induction of apoptosis in glioma cells and the effects of DHA (Farago et al, 2011). In 
this aforementioned study, down-regulation of miRNAs such as miR-22 and 145 
resulted in the up-regulation of sirtuin 1 and insulin receptor substrate 1, respectively. In 
the presence of DHA, Farago et al, (2011) showed that these changes in miRNAs were 
ameliorated.  However, results in glioma cells are difficult to place within the context of 
the present studies of the thesis which focused almost exclusively on the liver.  On the 
other hand, there are no papers published on miRNAs in relation to the effects of EPA. 
 
8.4.5 Conclusion 
In conclusion, hypercaloric feeding of mice with either low or high fat diets 
resulted in the changes in miRNA expression revealing an interesting approach to 








9.1 General discussion and future studies 
 The aim of this thesis was to examine the role of dietary fat in the development 
of fatty liver and its progression to non-alcoholic steatohepatitis (NASH) and to try to 
identify novel biomarkers using “omics” approaches. Since the term NASH was coined 
by Ludwig et al, (1980), its prevalence has increased and the severity of its effects has 
become apparent, contributing to liver cancer and type 2 diabetes. The prevalence in the 
USA is estimated to be 30% of fatty liver disease cases, which parallels the frequency of 
insulin resistance (Jimba et al, 2005) and obesity (Caldwell et al, 2004).  
Previous studies using mice to study NASH suggested that the accumulation and 
distribution of fat in the liver is promoted by high fat feeding, high cholesterol and/or 
methionine choline-deficient diet (Raubenheimer et al, 2006; Rinella et al, 2008; 
Stanton et al, 2011). More recently, attention has also been drawn to carbohydrates 
particularly fructose as a contributor (Samuel 2011). Some of the experimental models 
used are nutritionally imbalanced (e.g. choline deficient) and not very relevant to human 
dietary intake. For example, Stanton et al. (2011) induced severe inflammation and 
steatohepatitis in mice fed a high fat (45% energy) plus a high cholesterol intake (0.12% 
diet or about 300 mg/1000 kcal) whereas human diets in countries where NASH is 
prevalent provide closer to 35% energy and cholesterol intakes are in the range of 100-
150 mg/1000 kcal. Cholesterol was not included in the diet in this thesis because the 
primary aim was to look at the effect of dietary fats on the liver. Furthermore, in the 
present study care was taken to ensure that the diets were nutritionally balanced.  
The animal model used in this thesis involved feeding a high fat pelleted diet in 
conjunction with ad libitum access to condensed milk. Previous studies refer to such a 
diet as a high fat obesogenic diet (West et al. 1992; Eberhard et al. 1994; Samuelsson et 
al. 2008). Panchal et al. (2011) showed that feeding 8-9 weeks old rats on a similar diet 
increased liver weight, inflammation and fibrosis with elevated liver enzymes. The 
work in this thesis, however, shows that this dietary regimen is not particularly high in 
fat because the animals chose to derive more food energy from the condensed milk than 
from the pelleted diet. However, condensed milk with a low fat content resulted in a 
slightly low energy intake than condensed milk with a higher fat content because of 
differences in energy density. This diet should therefore not be referred to a high fat 
feeding regime. 
The studies reported here in this thesis showed that fasting might exacerbate 
damage to the liver due to rapid mobilization of fat from adipose tissue to the liver. This 
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was also highlighted by Postic & Girard (2008). An improvement to the study design 
might be only to withdraw food from the animals 3-4 hours before sacrifice so as to 
avoid any acute mobilization of fat. A limitation of the present study is the relative short 
duration (6 weeks). While this is adequate to result in fatty liver, a longer period of 
dietary exposure may be needed to observe major inflammatory changes in the liver 
(Pachikian et al, 2011).  A second limitation is that the results in the study are based 
mainly on finding in male animals and there may be difference between gender that are 
worthy of future study. 
This thesis reports some novel finding with regards to the effects of DHA and 
EPA. Both DHA and EPA decreased the amount of cholesteryl oleate and total 
cholesteryl esters in the liver. These findings are in agreement with a report by Du et al, 
(2003). DHA, however, appeared to decrease the amount of fat accumulating in the 
liver. Although hepatic phospholipids showed a greater decrease in DHA fed mice, 
further work is needed to see whether there were changes in the classes of phospholipids 
species. Leflis et al, (2010) reported that mice fed a DHA rich diet for 16 days resulted 
in a significant increase in DHA incorporated in phosphatidylethanolamine and 
phosphatidylcholine in the liver (Leflis et al, 2010). These phospholipid species have 
been suggested as biomarkers of advanced liver disease in both murine and human liver 
tissues (Gorden et al, 2011). An interesting observation was that the synthesis of long-
chain n-3 polyunsaturated fatty acids appeared to be enhanced with this overfeeding 
model. The mechanism for this is uncertain but it is possible that this might be 
promoted by higher levels of insulin that would accompany the overfeeding on 
condensed milk especially as insulin tends to promote the conversion of the parent 
essential fatty acids to their long-chain derivatives. High blood glucose levels, as 
observed in the animals fed the obesogenic diet, would also have the effect of 
suppressing fatty acid oxidation. 
This thesis provides novel data on the effects of triacylglycerol structure of fats 
on liver lipids. The fats used in this study were the same as those used by Sanders et al. 
(2011) in a human study which showed difference in the extent of postprandial lipaemia 
between native palm olein and lard. The data provided in this thesis suggest that the 
metabolic fate on palmitic acid in the sn-2 position is different from that in the sn-1 and 
sn-3 position: notably an effect on hepatic cholesteryl ester concentrations and the 
conversion of linolenic acid to long-chain n-3 polyunsaturated fatty acids. These 
findings need to be independently verified.   
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The proteomics work reported here used 2D-DIGE which has the ability to 
investigate differential protein expression. Kendrick et al, (2011) showed that high fat 
feeding led to the down-regulation of sirtuins 3 which led to liver damage, 
mitochondrial fatty acid oxidative and gluconeogenesis. In this thesis, differential 
expression of the following proteins was found: isoform 1 of epoxide hydrolase 2, 
catalase, ATP synthase subunit-alpha mitochondrial, ornithine carbamoyltransferase-
mitochondrial (OCT), regucalcin and carbonic anhydrase 3. Only carbonic anhydrase 3 
was down-regulated when comparing the high fat hypercaloric with the low fat 
reference group.  
The proteins that were identified to change in response to the high fat diet were 
involved in pathways of nitrogen metabolism, the urea cycle, aspartate and asparagines 
metabolism, arginine and hydroxyeicosatetraenoic acids (HETE) biosynthesis. No 
differences were noted in protein expression between EPA or DHA or with altered TAG 
structure. In addition to issues concerning the sensitivity and specificity of proteomics, 
there are statistical issues because of the number of comparisons being made means that 
some arise by play of chance. The complexity of liver proteomes also implies that the 
functional proteins in the liver related to lipid metabolism are difficult to map with 
DIGE. Studies have reported that the same type of proteins was identified in proteomes 
regardless of species or tissue samples used in DIGE and mass spectrometry (Wilkins et 
al, 1998). The low abundance and hydrophobic proteins were always undetected 
(Wilkins et al, 1998). These adversities are reflected in the current studies whereby 
high-throughput analysis based on proteomics still lack accurate sensitive tests toward 
the identification of novel biomarkers to assess NASH (Ariz et al, 2010). The results 
presented here do not suggest that proteomics is likely to yield information regarding 
biomarkers of NASH.  
The findings with regard to miRNAs were more promising. It has been proposed 
that miRNAs regulate the metabolic pathways related to liver inflammation and hepatic 
fatty acid accumulation (Hand et al, 2009). The significant role of miRNAs in binding 
to complementary site of target messenger RNA causing either transcript degradation or 
translational repression (Wiklund et al, 2010) has been proposed to be useful as a 
potential diagnostic tool in the pathogenesis of non-alcoholic fatty liver disease (Jin et 
al, 2009). For instance, down-regulated miR-122 led to increased hepatic fatty-acid 
oxidation and decrease fatty acid synthesis rates in the liver (Esau et al, 2006). 
Therefore, this implies that miR-122 is a key regulator of lipid metabolism which may 
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act as a therapeutic target. In addition, the inhibition of miR-122 led to the activation of 
5’ AMP-activated protein kinase which stimulated hepatic fatty acid oxidation (Esau et 
al, 2006). The present study used microarrays and then confirmed candidate miRNAs of 
interest with RT-qPCR.  
The RT-qPCR results showed that miR-199a-5p, miR-200b, miR-324-3p, miR-
21*, miR-31* and miR-451 were down regulated in the animals fed a hypercaloric diet 
low in fat when compared to the animals fed a eucaloric diet. Animals overfed a high fat 
diet showed down-regulation of miR-199a-5p, miR-200b, miR-324-3p, miR-21*, miR-
31*, miR-345-3p, miR-451 and miR-466f compared to the mice fed a eucaloric diet. 
Interestingly, there was a significant difference in miRNA expression between high fat 
and low fat hypercaloric feeding with miR-21* and miR-466f having lower values 
following the high fat regimen. However, none of these miRNAs were altered in 
response to either dietary EPA or DHA in comparison to HF diet.  
There is limited information published on miRNAs, for example, there is only 
one study on miR-466f by Chen et al, (2011) who reported an increase in miR-466f 
expression in diabetic induced mice. This aforementioned study showed that there were 
8 other miRNAs which were up-regulated such as miR-34a, 744 and 1937b. One needs 
to be aware that by comparing an individual miRNA with other studies, one may not 
obtain the true reflection on the pathological changes. In other words, miRNAs should 
be analysed collectively, for instance in this study, the miR-483, 501-3p, 466f-5p and 
149 which were altered when comparing between both HF vs HFDHA and HF vs 
HFEPA may give an indication of true effects of EPA and/or DHA in relation to 
miRNA expression. 
The selected miRNAs were not associated with the protein networks identified 
in this study for the thesis. In future work, a different approach may be taken by 
selecting miRNAs of interest before investigating protein expression. For example, Li et 
al, (2011) examined liver in ageing mice and identified that miR-34a and 93 increased.  
They then used 3 data mining tools namely miRBase, Targetscan and RNA22. These 
bioinformatic techniques indentified putative target mRNAs, namely those encoding the 
proteins Sirt1 and Mgst1. Both these protein are hepatoprotective (Li et al, 2011).  The 
aforementioned authors then confirmed their findings by quantifying Sirt1 and Mgst1 
by immunoassay and indeed the levels of these proteins were markedly reduced in livers 
of ageing mice.  The role of miR-34a and 93 in suppressing their target proteins Sirt1 
and Mgst1were subsequently confirmed by transfection studies (Li et al, 2011).  
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Although elegant in approach, it was not possible to carry out similar studies for this 
thesis due to time constraints.  
 
 
9.2 Final remarks and conclusions 
The work in this thesis indicates that overfeeding results in fatty liver and that 
this is not specifically made worse by a high fat diet. In the case of DHA, it appears to 
have favourable effects on fatty liver. However, further work on miRNAs is warranted. 
The increased prevalence of NASH globally is strongly related to the obesity epidemic 
and the increased prevalence of type 2 diabetes. Obesity results from an imbalance 
between energy intake and energy expenditure and there is a lack of consistent evidence 
to show that diets with different ratios of fat/carbohydrate differ in their respect to cause 
obesity. Restriction of energy intake is essential in order to prevent obesity and NASH. 
Increased physical activity may help maintain energy balance but is not an effective 
means of promoting weight loss. However, it is uncertain whether increased physical 
activity reduces liver fat and this would be worth of future study. In the meantime, the 
prevention of NASH will continue to depend on controlling the body mass index of the 
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Appendix 2.1: Cycle threshold (Ct) values and relative quantification (RQ) of the selected miRNAs in response to low fat hypercaloric diet (LF 
group) and HF hypercaloric diet (HF group) to the controls (LFR group) 
Sample mmu-miR-199a-5p mmu-miR-200b mmu-miR-324-3p 
  ∆Ct ∆∆Ct RQ ∆ Ct ∆∆Ct RQ ∆ Ct ∆∆Ct RQ 
A2 3.38 -0.71 1.64 1.06 -1.20 2.30 5.21 0.19 0.88 
A3 3.61 -0.49 1.40 1.13 -1.13 2.19 5.34 0.31 0.80 
A5 4.56 0.46 0.73 1.25 -1.01 2.02 4.12 -0.90 1.87 
A6 5.38 1.29 0.41 4.46 2.20 0.22 5.32 0.29 0.82 
A7 2.44 -1.66 3.16 1.00 -1.26 2.39 4.4 -0.62 1.53 








B10 5.22 1.13 0.46 4.01 1.75 0.30 5.22 0.19 0.87 
B12 5.39 1.29 0.41 4.58 2.32 0.20 5.50 0.48 0.72 
B13 4.98 0.89 0.54 3.09 0.83 0.56 5.87 0.84 0.56 
B14 4.93 0.84 0.56 3.75 1.49 0.36 5.32 0.29 0.82 
B16 5.43 1.34 0.40 3.28 1.02 0.49 5.89 0.87 0.55 








C17 8.11 4.02 0.06 5.32 3.06 0.12 6.47 1.45 0.37 
C20 6.61 2.52 0.17 6.05 3.79 0.07 6.46 1.44 0.37 
C21 7.58 3.48 0.09 5.06 2.80 0.14 6.12 1.10 0.47 
C22 6.93 2.83 0.14 3.72 1.46 0.36 5.59 0.57 0.67 
C23 5.20 1.10 0.47 3.33 1.07 0.48 5.05 0.02 0.98 








∆Ct = normalized Ct values = (Ct miRNA – Ct of endogenous control). Ct values for selected miRNA and endogenous control are in Appendices 




Appendix 2.2: Continuation of Appendix 2.1. Cycle threshold (Ct) values and relative quantification (RQ) of the selected miRNAs in response to 
low fat diet (LF group) and obesogenic diets (HF group) to the controls (LFR group) generated from real time RT-qPCR run 
Sample mmu-miR-21* mmu-miR-31* mmu-miR-345-3p mmu-miR-451 mmu-miR-466f 
  ∆ Ct ∆∆Ct RQ ∆ Ct ∆∆Ct RQ ∆ Ct ∆∆Ct RQ ∆ Ct ∆∆Ct RQ ∆ Ct ∆∆Ct RQ 
A2 3.66 -0.48 1.40 2.62 0.15 0.90 4.94 -0.38 1.30 0.83 -0.21 1.16 4.64 -0.26 1.19 
A3 4.76 0.61 0.65 2.46 0.00 1.00 5.66 0.34 0.79 2.35 1.30 0.40 5.71 0.82 0.57 
A5 3.72 -0.42 1.34 1.82 -0.65 1.56 4.71 -0.61 1.53 -0.71 -1.76 3.38 4.87 -0.03 1.02 
A6 3.73 -0.41 1.33 2.76 0.29 0.82 5.37 0.04 0.97 1.02 -0.02 1.02 4.44 -0.46 1.38 
A7 4.04 -0.10 1.07 1.60 -0.86 1.82 5.23 -0.09 1.06 2.10 1.06 0.48 4.53 -0.37 1.29 















B10 4.76 0.62 0.65 3.46 1.00 0.50 5.98 0.65 0.64 -0.07 -1.11 2.16 4.89 -0.01 1.01 
B12 4.66 0.51 0.70 4.58 2.12 0.23 6.17 0.85 0.56 1.20 0.15 0.90 4.52 -0.38 1.30 
B13 4.86 0.71 0.61 3.97 1.51 0.35 5.78 0.46 0.73 1.25 0.21 0.87 5.51 0.62 0.65 
B14 3.84 -0.31 1.24 3.90 -0.14 1.10 5.86 0.54 0.69 1.15 0.11 0.93 - - - 
B16 6.02 1.87 0.27 3.98 1.52 0.35 6.91 1.58 0.33 1.11 0.06 0.96 - - - 















C17 6.77 2.62 0.16 5.22 2.76 0.15 7.66 2.33 0.20 2.30 1.26 0.42 6.58 1.69 0.31 
C20 6.12 1.98 0.25 5.30 2.83 0.14 7.20 1.88 0.27 2.10 1.06 0.48 6.22 1.32 0.40 
C21 7.95 3.80 0.07 4.71 2.24 0.21 7.19 1.87 0.27 1.80 0.76 0.59 6.11 1.22 0.43 
C22 5.97 1.83 0.28 4.02 1.55 0.34 7.93 2.61 0.16 1.95 0.91 0.53 5.59 0.69 0.62 
C23 4.76 0.62 0.65 3.29 0.83 0.56 6.16 0.84 0.56 1.11 0.07 0.95 6.25 1.36 0.39 















∆Ct = normalized Ct values = (Ct miRNA – Ct of endogenous control). Ct values for selected miRNA and endogenous control are in Appendices 
XX. ∆∆ Ct = (∆Ct – Average of ∆Ct of control group). Relative quantification (RQ) = 2^-∆∆Ct. Average of RQ values are expressed in Mean ± SE.
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Appendix 2.3: Cycle threshold (Ct) values and relative quantification (RQ) of intensities of the selected miRNAs in response to DHA (HFDHA 
group) and EPA (HFEPA group) to the controls (HF group) generated from RT-qPCR run 
 
 
mmu-miR-21* mmu-miR-31* mmu-miR-345-3p mmu-miR-451 mmu-miR-466f-5p 
 
 
∆Ct ∆∆Ct RQ ∆ Ct ∆∆Ct RQ ∆ Ct ∆∆Ct RQ ∆ Ct ∆∆Ct RQ ∆Ct ∆∆Ct RQ 
HF 
C17 6.77 0.13 0.91 5.22 0.65 0.64 7.66 0.44 0.74 2.30 0.45 0.73 6.58 0.26 0.83 
C20 6.12 -0.51 1.43 5.30 0.72 0.61 7.20 -0.01 1.01 2.10 0.25 0.84 6.22 -0.10 1.07 
C21 7.95 1.31 0.40 4.71 0.13 0.92 7.19 -0.03 1.02 1.80 -0.05 1.03 6.11 -0.21 1.15 
C22 5.97 -0.66 1.58 4.02 -0.56 1.48 7.93 0.72 0.61 1.95 0.10 0.93 5.59 -0.73 1.66 
C23 4.76 -1.88 3.67 3.29 -1.29 2.44 6.16 -1.06 2.08 1.11 -0.74 1.67 6.25 -0.07 1.05 














D26 6.84 0.20 0.87 4.84 0.26 0.84 8.48 1.27 0.42 2.95 1.10 0.47 7.15 0.83 0.56 
D27 5.48 -1.16 2.23 4.53 -0.05 1.04 7.71 0.49 0.71 3.18 1.32 0.40 6.45 0.13 0.91 
D28 6.06 -0.58 1.50 4.51 -0.07 1.05 6.80 -0.42 1.34 1.74 -0.11 1.08 6.66 0.34 0.79 
D30 8.65 2.01 0.25 6.83 2.26 0.21 9.76 2.55 0.17 4.83 2.97 0.13 7.88 1.56 0.34 
D31 7.40 0.77 0.59 5.51 0.93 0.52 7.62 0.40 0.76 3.57 1.71 0.30 7.96 1.64 0.32 













E33 4.68 -1.95 3.88 4.21 -0.37 1.29 6.25 -0.96 1.95 0.64 -1.21 2.31 - - - 
E34 7.04 0.40 0.76 4.69 0.11 0.93 7.41 0.19 0.88 1.59 -0.26 1.20 5.28 -1.04 2.06 
E35 6.35 -0.29 1.22 5.23 0.65 0.64 7.19 -0.03 1.02 1.43 -0.42 1.34 7.01 0.69 0.62 
E37 7.08 0.44 0.74 6.11 1.53 0.35 7.98 0.76 0.59 2.10 0.25 0.84 7.21 0.89 0.54 
E38 7.94 1.30 0.41 5.99 1.41 0.38 8.80 1.59 0.33 3.53 1.68 0.31 6.85 0.53 0.69 














Legend for Table XX: ∆Ct = normalized Ct values = (Ct miRNA – Ct of endogenous control). Ct values for selected miRNA and endogenous control 
are in Appendices XX. ∆∆ Ct = (∆Ct – Average of ∆Ct of control group). Relative quantification (RQ) = 2^-∆∆Ct. Average of RQ values are 
expressed in Mean ± SE. 
 
Appendix 2.4: Continuation of Appendix 2.5. Cycle threshold (Ct) values and relative quantification (RQ) of intensities of the selected miRNAs 
in response to DHA (HFDHA group) and EPA (HFEPA group) to the controls (HF group) generated from RT-qPCR run 
  mmu-miR-199a-5p mmu-miR-200b mmu-miR-324-3p 
  ∆ Ct ∆∆Ct RQ ∆Ct ∆∆Ct RQ ∆Ct ∆∆Ct RQ 
C17 8.11 1.19 0.44 5.32 0.58 0.67 6.47 0.39 0.76 
C20 6.61 -0.31 1.24 6.05 1.31 0.40 6.46 0.38 0.77 
C21 7.58 0.65 0.64 5.06 0.32 0.80 6.12 0.04 0.97 
C22 6.93 0.00 1.00 3.72 -1.02 2.02 5.59 -0.49 1.41 
C23 5.20 -1.72 3.30 3.33 -1.41 2.65 5.05 -1.04 2.05 








D26 8.55 1.63 0.32 5.31 0.57 0.67 7.09 1.01 0.50 
D27 6.59 -0.33 1.25 5.45 0.71 0.61 7.15 1.06 0.48 
D28 6.06 -0.86 1.82 4.29 -0.45 1.36 6.01 -0.08 1.06 
D30 9.29 2.36 0.19 6.59 1.85 0.28 8.34 2.26 0.21 
D31 7.24 0.32 0.80 5.85 1.12 0.46 8.07 1.99 0.25 
D32 6.26 -0.66 1.59 3.86 -0.87 1.83 5.55 -0.54 1.45 







E33 5.99 -0.93 1.91 4.25 -0.49 1.40 5.97 -0.11 1.08 
E34 6.95 0.03 0.98 4.80 0.06 0.96 7.08 1.00 0.50 
E35 6.79 -0.14 1.10 4.64 -0.10 1.07 7.51 1.42 0.37 
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E37 11.34 4.42 0.05 5.24 0.50 0.70 6.75 0.66 0.63 
E38 8.74 1.81 0.28 5.14 0.40 0.76 7.24 1.16 0.45 
E40 7.30 0.38 0.77 4.85 0.11 0.93 6.66 0.58 0.67 









Appendix 5.1: Total energy intake (kcal/week) from the consumption of all sources during run-in and over 6 weeks of feeding period in mice fed 
either low fat reference (LFR), low fat (LF), high fat (HF), high fat DHA (HFDHA) or high fat EPA (HFEPA) diets 
 













































































 (110,125)   P<0.001 
Values are expressed as mean with 95% CI. One way analysis of variance (ANOVA) and Tukey’s multiple range test was used for data from run-in 
to week 6. Repeated measure was used to analyse energy intake of mice from Week 1 to 6. Values with different superscripts indicate significant 





Appendix 5.2: Energy intake (kcal/week) from solid food intake during run-in and over 6 weeks of feeding period in mice fed either low fat 
reference (LFR), low fat (LF), high fat (HF), high fat DHA (HFDHA) or high fat EPA (HFEPA) diets 
 
LFR LF HF HFDHA HFEPA P Anova 












































































 (0,11) P<0.001 
Values are expressed as mean with 95% CI. One way analysis of variance (ANOVA) and Tukey’s multiple range test was used for data from run-in 
to week 6. Repeated measure was used to analyse solid food intake of mice from Week 1 to 6. Values with different superscripts indicate significant 





Appendix 5.3: Energy intake (kcal/week) from milk intakes over 6 weeks of feeding period in mice fed either low fat reference (LFR), low fat 
(LF), high fat (HF), high fat DHA (HFDHA) or high fat EPA (HFEPA) diets. No milk was administered to mice from low fat reference group 
 


































































 (106,118) P<0.001 




Appendix 5.4: Body weights (g) during run-in and over 6 weeks of feeding period in low fat reference (LFR), low fat (LF), high fat (HF), high 
fat DHA (HFDHA) and high fat EPA (HFEPA) groups 
 













































































 (26.3,30.9) P<0.001 
Values are expressed as mean with 95% CI. One way analysis of variance (ANOVA) and Tukey’s multiple range test was used. Values with different 




Appendix 5.5: Weight gain (g) of mice before and after fasting  
 











 (27.5,32.3) P<0.001 
After fasting 17.9(16.4,19.4) 22.8(21.8,23.8) 26.6(23.6,29.5) 27.7(25.0,30.5) 27.4(25.0,29.7) P<0.001 






















Values are expressed as mean with 95% CI. One way analysis of variance (ANOVA) and Tukey’s multiple range test was used. Values with different 
superscripts indicate significant differences between treatments. 
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Appendix 5.6: Fatty acids composition (weight %) derived from adipose tissue of C57BL/6J mice fed either low fat reference (LFR), low fat 
(LF), high fat (HF), high fat DHA (HFDHA) or high fat EPA (HFEPA) diets 
 



















16:0 11.3 24.8 1.3 11.3 22.2 2.9 40.3 25.1 1.2 33.7 33.8 1.5 33.6 32.7 1.6 P=0.914 
16:1 0.0 10.9 2.6 0.0 13.1 6.6 0.2 7.9 2.0 0.2 6.0 1.0 0.2 7.7 3.4 P=0.728 
18:0 1.7 4.5 1.0 1.7 1.9 0.4 4.4 1.9 0.5 3.8 2.8 0.2 3.7 2.6 0.5 P=0.474 
18:1n-9 28.7 45.8 1.7 28.7 47.3 8.5 42.7 54.7 2.3 36.1 39.1 1.3 35.8 42.3 1.0 P=0.978 
18:2n-6 56.8 13.1 2.9 56.8 14.9 1.6 11.3 9.7 0.2 9.7 9.7 0.8 9.9 10.8 1.7 P=0.907 
18:3n-3 1.2 0.1 0.0 1.2 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.3 0.1 0.1 P=0.581 
20:3n-6 0.0 0.1 0.0 0.0 0.2 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 P=0.715 





 0.0 0.0 0.1
 a,b
 0.0 2.5 0.2
 a,b
 0.0 12.2 0.4
 b
 0.1 P=0.033 
22:4n-6 0.2 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.3 0.0 0.0 P=0.367 
22:5n-6 0.0 0.2
 a,b
 0.1 0.0 0.1
 a,b
 0.1 0.0 0.0
 a
 0.0 0.6 0.3
 b
 0.0 0.1 0.1
 a,b
 0.0 P=0.053 
22:5n-3 0.0 0.0
 a
 0.0 0.0 0.0
 a
 0.0 0.0 0.1
 a
 0.0 0.6 0.5
 a,b
 0.1 0.4 1.1
 b
 0.3 P=0.004 
22:6n-3 0.0 0.1
 a
 0.1 0.0 0.0
 a
 0.0 0.0 0.2
 a
 0.1 10.9 6.8
 b
 0.2 1.9 1.7
 a
 0.4 P=0.001 
Values of fatty acids in adipose tissue are expressed as mean ± standard deviation. One way analysis of variance (ANOVA) and Tukey’s multiple 





Appendix 6.1: Energy intake (kcal/week) from consumption of all sources over 6 
weeks of feeding period in mice fed either a high fat high oleic sunflower oil 
(HFHOSO), HF palm oil (HFPO), HF interesterified palm (HFIPO) or HF lard 
(HFL) diet 
Period Diets N Mean 




Lower  Upper  
Week 1 
High fat HOSO 8 107
a
  101 114 
P=0.013 
High fat PO 7 125
 b
  115 134 
High fat IPO 8 112
 a,b
  102 123 
High fat Lard 8 110
 a
  103 117 
Week 2 
High fat HOSO 8 112
 a,b
  106 120 
P=0.001 
High fat PO 7 103
 a
  94 112 
High fat IPO 8 112
 a,b
  107 116 
High fat Lard 8 120
 b
  115 126 
Week 3 
High fat HOSO 8 101
 a
  96 106 
P=0.002 
High fat PO 7 111
 b
  104 118 
High fat IPO 8 112
 b
  106 117 
High fat Lard 8 101
 a
  96 106 
Week 4 
High fat HOSO 8 98
 a
  91 105 
P=0.050 
High fat PO 7 101
 a.b
  92 111 
High fat IPO 8 110
 b
  105 115 
High fat Lard 8 104 
a,b
  98 111 
Week 5 
High fat HOSO 8 98
 a
  90 108 
P=0.028 
High fat PO 7 107
 a,b
  99 114 
High fat IPO 8 116 
b
  109 124 
High fat Lard 8 109
 a,b
  97 121 
Week 6 
High fat HOSO 8 102
 
 92 113 
P=0.204 
High fat PO 7 107
 
 99 115 
High fat IPO 8 114
 
 105 122 
High fat Lard 8 108
 
 101 115 
Week 1-
6 
High fat HOSO 8 104  98 109 
P=0.067 
High fat PO 7 109
 
 102 116 
High fat IPO 8 113
 
 108 117 
High fat Lard 8 109
 
 104 113 
Values are expressed as mean ± SD with 95% CI. One way analysis of variance 
(ANOVA) and Tukey’s multiple range test was used for data week 1to 6. Repeated 
measure was used to analyse energy intake of mice from Week 1 to 6. Values with 
different superscripts indicate significant differences between treatments 
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Appendix 6.2: Energy intake (kcal/week) from solid food intake over 6 weeks of 
feeding period in mice fed either a high fat high oleic sunflower oil (HFHOSO), HF 
palm oil (HFPO), HF interesterified palm (HFIPO) or HF lard (HFL) diet 
Period Diets n Mean 
95% Confidence Interval 
Bounds P Anova 
Lower  Upper  
Week 1 
High fat HOSO 8 40 
b
  28 53 
P=0.399 
High fat PO 7 47
 a
  37 56 
High fat IPO 8 53
 a
  39 66 
High fat Lard 8 55 
a
  32 77 
Week 2 
High fat HOSO 8 36
 b
  21 51 
P<0.001 
High fat PO 7 14
 a
  2 26 
High fat IPO 8 47 
b
  34 60 
High fat Lard 8 53
 b
  40 66 
Week 3 
High fat HOSO 8 16
 c
  2 30 
P=0.105 
High fat PO 7 9
 a
  3 15 
High fat IPO 8 28
 b
  14 43 
High fat Lard 8 20
 a,b
  7 33 
Week 4 
High fat HOSO 8 19
 c
  6 31 
P=0.041 
High fat PO 7 8
 a
  5 10 
High fat IPO 8 29
 b
  15 42 
High fat Lard 8 29 
b
  12 45 
Week 5 
High fat HOSO 8 18
 a
  7 28 
P=0.200 
High fat PO 7 12
 b
 8 16 
High fat IPO 8 29
 b
  13 46 
High fat Lard 8 22 
b
  6 38 
Week 6 
High fat HOSO 8 20
 a,b
  11 29 
P=0.005 
High fat PO 7 11
 a
  8 15 
High fat IPO 8 28 
b
  17 40 
High fat Lard 8 13
 a
  9 18 
Week 1-
6 
High fat HOSO 8 24
 
  16 32 
P=0.317 
High fat PO 7 11
 
  2 20 
High fat IPO 8 31
 
  23 40 
High fat Lard 8 26
 
  17 34 
Values are expressed as mean ± SD with 95% CI. One way analysis of variance 
(ANOVA) and Tukey’s multiple range test was used for data week 1to 6. Repeated 
measure was used to analyse energy intake of mice from Week 1 to 6. Values with 
different superscripts indicate significant differences between treatments 
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Appendix 6.3: Energy intake (kcal/week) from condensed milk intake over 6 weeks of 
feeding period in mice fed either a high fat high oleic sunflower oil (HFHOSO), HF 
palm oil (HFPO), HF interesterified palm (HFIPO) or HF lard (HFL) diet 
Period Diets n Mean 
95% Confidence interval 
Bounds P Value 
Lower  Upper  
Week 1 
High fat HOSO 8 67 
a,b
  58 76 
P=0.019 
High fat PO 7 78
 b
  65 91 
High fat IPO 8 60
 a,b
  52 67 
High fat Lard 8 55
 a
  39 71 
Week 2 
High fat HOSO 8 77
 a,b
  64 91 
P=0.032 
High fat PO 7 89
 b
  72 106 
High fat IPO 8 64
 a
  54 75 
High fat Lard 8 67
 a,b
  51 83 
Week 3 
High fat HOSO 8 85  68 101 
P=0.058 
High fat PO 7 102  96 108 
High fat IPO 8 83  71 95 
High fat Lard 8 81  66 96 
Week 4 
High fat HOSO 8 80  66 93 
P=0.188 
High fat PO 7 94  85 102 
High fat IPO 8 81  68 95 
High fat Lard 8 76  59 92 
Week 5 
High fat HOSO 8 81  67 96 
P=0.423 
High fat PO 7 94  90 99 
High fat IPO 8 87  71 103 
High fat Lard 8 87  77 98 
Week 6 
High fat HOSO 8 82  69 95 
P=0.150 
High fat PO 7 96  87 105 
High fat IPO 8 85  71 99 
High fat Lard 8 94  86 102 
Week 1-
6 
High fat HOSO 8 80  71 89 
P=0.067 
High fat PO 7 91 80 102 
High fat IPO 8 82 72 91 
High fat Lard 8 84 74 94 
Values are expressed as mean ± SD with 95% CI. One way analysis of variance 
(ANOVA) and Tukey’s multiple range test was used for data week 1to 6. Repeated 
measure was used to analyse energy intake of mice from Week 1 to 6. Values with 




Appendix 6.4: Body weights (g) over 6 weeks of feeding period in mice fed either a 
high fat high oleic sunflower oil (HFHOSO), HF palm oil (HFPO), HF 
interesterified palm (HFIPO) or HF lard (HFL) diet 
Period Diets n Mean 
95% Confidence Interval 
Bounds 
P Anova 
Lower  Upper   
Week 1 
High fat HOSO 8 16.1  15.2 17.0 
P=0.126 
High fat PO 7 16.6  15.6 17.5 
High fat IPO 8 16.6  15.8 17.4 
High fat Lard 8 15.5  14.6 16.3 
Week 2 
High fat HOSO 8 17.9 
a,b
  16.7 19.0 
P=0.011 
High fat PO 7 18.9
 a,b
  17.7 20.1 
High fat IPO 8 19.3
 b
  18.4 20.3 
High fat Lard 8 17.5
 a
  17.0 18.0 
Week 3 
High fat HOSO 8 19.3
 a,b
  18.1 20.5 
P=0.012 
High fat PO 7 20.7
 a,b
  19.6 21.9 
High fat IPO 8 20.9
 b
  19.7 22.0 
High fat Lard 8 19.1
 a
  18.5 19.7 
Week 4 
High fat HOSO 8 20.4
 a,b
  19.1 21.7 
P=0.028 
High fat PO 7 21.2
 a,b
  19.7 22.7 
High fat IPO 8 22.2
 b
  20.9 23.6 
High fat Lard 8 20.1
 a
  19.2 20.9 
Week 5 
High fat HOSO 8 21.2  19.7 22.7 
P=0.075 
High fat PO 7 22.1  20.4 23.9 
High fat IPO 8 23.2  21.3 25.0 
High fat Lard 8 20.9  19.9 21.9 
Week 6 
High fat HOSO 8 21.9  20.3 23.6 
P=0.086 
High fat PO 7 22.8  20.8 24.7 
High fat IPO 8 24.4  22.3 26.6 






High fat HOSO 8 10.1  8.0 12.1 
P=0.161 
High fat PO 7 11.0 8.5 13.4 
High fat IPO 8 12.8  10.4 15.1 
High fat Lard 8 10.8 9.6 12.1 
Values are expressed as mean ± SD with 95% CI. One way analysis of variance 
(ANOVA) and Tukey’s multiple range test was used for data week 1to 6. Repeated 
measure was used to analyse milk intake of mice from Week 1 to 6. Values with different 




Appendix 6.5: Mean weight loss before and after fasting in mice fed either a high fat 
high oleic sunflower oil (HFHOSO), HF palm oil (HFPO), HF interesterified palm 
(HFIPO) or HF lard (HFL) diet 
Period Diets n Mean 
95% Confidence 
Interval Bounds P Anova 










High fat PO 7 22.8±2.1 20.8 24.7 
High fat IPO 8 24.4±2.6 22.3 26.6 






High fat HOSO 8 19.6±2.0 17.9 21.3 
P=0.262 
High fat PO 7 20.2±2.4 18.0 22.4 
High fat IPO 8 21.8±3.1 19.2 24.4 




High fat HOSO 8 2.3±0.5 1.9 2.8 
P=0.630 
High fat PO 7 2.6±0.4 2.2 2.9 
High fat IPO 8 2.6±0.8 1.9 3.3 
High fat lard 8 2.3±0.5 1.9 2.7 
Values are expressed as mean ± SD with 95% CI. One way analysis of variance 
(ANOVA) and Tukey’s multiple range test was used. Values with different superscripts 




Appendix 6.6: Fatty acids composition (weight %) derived from adipose tissue of C57BL/6J male mice fed either a high fat high oleic sunflower 


























16:0 4.0 11.6 
a 
± 1.1 40.3 23.8
 b 
± 0.7 40.5 27.3
 c
 ± 1.0 27.8 24.6
 b 
± 1.0 P<0.001 
16:1          0.1 3.0
 a
 ± .9 0.2 7.5
 b
 ± 1.3 0.2 9.3
 b
 ± 1.1 2.5 8.0
 b
 ± 1.3 P<0.001 
18:0 2.9 1.6
 b
 ± 0.3 4.4 2.2
 a
 ± 0.4 4.4 2.0
 a
 ± 0.1 17.9 3.6
 a
 ± 0.9 P<0.001 
18:1n-9 81.7 74.1
b 
± 2.9 42.7 55.6
 a
 ± 1.8 42.5 53.1
 a
 ± 1.9 39.7 54.8
 a
 ± 1.8 P<0.001 
18:2n-6 10.7 8.9
 a,b 
± 1.1 11.3 9.9
 b
 ± 0.9 11.0 7.9
 a
 ± 1.0 9.3 8.3
 a
 ± 0.9 P=0.003 
18:3n-3 - 0.1 ± 0.1 - 0.0 ± 0.0 - 0.1 ± 0.0 - 0.1 ± 0.1 P=0.085 
20:3n-6 - 0.1 ± 0.0 - 0.1 ± 0.0 - 0.1 ± 0.0 - 0.1 ± 0.0 P=0.548 
20:4n-6 - 0.2 ± 0.1 - 0.3 ± 0.1 - 0.2 ± 0.1 - 0.2 ± 0.1 P=0.453 
20:5n-3 - 0.0
 a
 ± 0.0 - 0.1
 b
 ± 0.0 - 0.1
 a
 ± 0.1 - 0.1
 a
 ± 0.1 P<0.001 
22:4n-6 - 0.0 ± 0.1 - 0.0 ± 0.0 - 0.0 ± 0.0 - 0.0 ± 0.0 P=0.354 
22:5n-6 - 0.0 ± 0.1 - 0.0 ± 0.0 - 0.0 ± 0.0 - 0.0 ± 0.0 P=0.652 
22:5n-3 - 0.0
 a
 ± 0.0 - 0.1
 b
 ± 0.0 - 0.0
 a
 ± 0.0 - 0.0
 a
 ± 0.0 P<0.001 
22:6n-3 - 0.0
 a
 ± 0.0 - 0.3
 b
 ± 0.1 - 0.0
 a
 ± 0.1 - 0.1
 a
 ± 0.1 P<0.001 
Values are expressed as mean with 95% CI. One way analysis of variance (ANOVA) and Tukey’s multiple range test was used. Values with different 





Appendix 8.1: Snapshot of the amplification plot of miR-200b generated from real 
time RT-qPCR  
 
The amplification plot shows the fluorescence signal (in log scale) against cycle 
number. Baseline of graph shows there’s little change in fluorescence in initial cycles of 
PCR. The fixed threshold is represented by green line parallel to x-axis. Ct values are 
determined at the exponential phase of the curve whereby the fluorescence signal 








Appendix 8.2: Changes in miRNAs in LF and HF groups compared to the LFR group 
using either microarrays or RT-qPCR. 
 
Changes from Microarray Changes from RT- qPCR 
% change in  
LF 
% change in 
HF 
% change in  
LF 
% change in 
HF 
miR-199a-5p -62% -62% -66% -86% 
miR-200b -46% -63% -76% -86% 
miR-324-3p +54% +69% -36% -51% 
miR-21* -11% -24% -33% -76% 
miR-31* -36% -31% -57% -76% 
miR-345-3p -38% -16% 0% -72% 
miR-451 0% +5% -9% -54% 
miR-466f -49% -6% -44% -62% 
The % changes in miRNA expression of treated samples in comparison to LFR controls 
are tabulated according to data generated via the microarray (using pooled samples) or 
RT-qPCR (using individual samples). The table is compiled from data contained within 
the information sets in Tables 10.1 & 10.2 and Figure 10.6 & 10.7; -x% means down 
regulation in treated sample and vice versa.  
 
 
Appendix 8.3: Changes in miRNAs in HFDHA and HFEPA groups compared to HF 
group using either microarrays or RT-qPCR  
 
Changes from microarray Changes from RT-qPCR 










miR-199a-5p +3% +4% -20% -32% 
miR-200b +35% -27% -30% -21% 
miR-324-3p -39% -45% -40% -43% 
miR-21* -29% +62% -22% -15% 
miR-31* -15% -51% -31% -36% 
miR-345-3p +12% -63% -34% -18% 
miR-451 -61% -15% -43% +8% 
mir-466f -34% -36% -29% -26% 
Data were analysed using independent t-test; P-value < 0.05 indicates significant 
difference between groups. x% represents percentage difference in miRNA expression of 
treated samples in comparison to control; -x% means down regulation in treated 
sample and vice versa.  
 
 
